Advertisement

Therapiekonzepte

  • H.-J. Schmoll
  • U. Fink

Zusammenfassung

Der wesentliche Leitgedanke bei der Abfassung der Therapiekapitel war, die Grundvoraussetzung für die therapeutischen Überlegungen wie Histologie, Grading, Stadieneinteilung und diagnostische Maßnahmen, ebenso wie die Therapiestrategie mit Stellung und Indikation von Chirurgie, Strahlentherapie und Chemotherapie möglichst „gebrauchsfertig“, komprimiert und präzisiert wiederzugeben.

Literatur

  1. Abrams RA et al (1986) Phase II study of combination chemotherapy with etoposide and amsacrine in the relapsed adult leukemia. Cancer Treat Rep 70: 535ff.PubMedGoogle Scholar
  2. Appelbaum FR et al (1984) Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. Ann Intern Med 101: 581–588PubMedGoogle Scholar
  3. Baccarani M, Tura S (1979) Differentiation of myeloid leukaemia cells: new possibilities for therapy. Br J Haematol 42: 485–490PubMedGoogle Scholar
  4. Baccarani M et al (1983) Low dose arabinosyl cytosine for treatment of myelodysplastic syndromes and subacute myeloid leukemia. Leukemia Res 7: 539–545Google Scholar
  5. Begg CB et al (1984) A critical comparison of allogeneic bone marrow transplantation and conventional chemotherapy as treatment for acute nonlymphocyctic leukemia. J Clin Oncol 2: 369–378PubMedGoogle Scholar
  6. Bennett JM et al (1976) Proposals for the classification of the acute leukemias French-American-British (FAB) Cooperative group. Brit J Heamatol 33: 451–458Google Scholar
  7. Bennett JM et al (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51: 189–199PubMedGoogle Scholar
  8. Bennett JM et al (1985) Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M 7). A report of the French-American-British Cooperative group. Ann Intern Med 103: 460–462PubMedGoogle Scholar
  9. Bennett JM et al (1985) Proposed revised criteria for the classification of acute myeloid leukemia: A report of the French-American-British Cooperative group. Ann Intern Med 103: 626–629Google Scholar
  10. Bloomfield CD, Brunning RD (1985) The revised French-American-British classification of acute myeloid leukemia: is new better? (Editorial), Ann Intern Med 103: 614–615PubMedGoogle Scholar
  11. Bodey GP et al (1978) Prolonged remissions in adults with acute leukemia following late intensification chemotherapy and immunotherapy. Cancer 47: 1937–1945Google Scholar
  12. Büchner T et al, for the AML Cooperative Group (1982) Multicenter study on intensified remission induction therapy for acute myeloid leukemia. Leukemia Res 6: 827–831Google Scholar
  13. Büchner T et al (1984) Long-term remission in acute myelogenous leukaemia. Lancet 1: 571PubMedGoogle Scholar
  14. Büchner T et al (1984) Aktuelle Konzepte der Therapie akuter Leukämien. In: Büchner, Urbanitz, van de Loo (Hrsg) Therapie der akuten Leukämien. Springer, Berlin Heidelberg New York, pp 107–115Google Scholar
  15. Büchner T et al (1985) Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol 3: 1583–1589PubMedGoogle Scholar
  16. Büchner T et al (1986) Akute myeloische Leukämie des Erwachsenen. Weiterentwicklung der Therapie auf der Basis klinischer Phase-II- und Phase-III-Studien. Onkologie 9: 83–91PubMedGoogle Scholar
  17. Capizzi R et al (1983) Sequential high dose Ara-C and asparaginase in the treatment of poor risk and previously untreated patients with ANLL. Proc 13th Int Congr Chemother 216: 23–28Google Scholar
  18. Capizzi R et al (1984) Treatment of poor risk acute leukemia with sequential high-dose Ara-C and asparaginase. Blood 63: 694–700PubMedGoogle Scholar
  19. Capizzi R et al (1986) Asparaginase potentiates high dose Ara-C (HiDAC) in relapsed and refractory ANNL patient. (Abstr C 637) Proc ASCO 5: 163Google Scholar
  20. Cheson BD et al (1986) Is the use of low dose Ara-C (LoA) warranted in acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS)? (Abstr 582) Proc ASCO 5: 149Google Scholar
  21. Dicke KA et al (1986) Current status of bone marrow transplantation (BMT) for acute myelogenous leukemia (AML). (Abstr 655) Proc ASCO 5: 167Google Scholar
  22. Dutcher JP et al (1986) Intensive maintenance therapy (IMT) in acute non-lymphocytic leukemia (ANLL). (Abstr 592) Proc ASCO 5: 152Google Scholar
  23. Foon KA (1981) Intensive chemotherapy as the treatment of choice for elderly patients with acute myelogeneous leukemia. Blood 58: 467–470PubMedGoogle Scholar
  24. Herzig RH et al (1983) High-dose cytosine arabinoside therapy for refractory leukemia. Blood 62: 361–369PubMedGoogle Scholar
  25. Hiddemann W et al (1985) AMSA/Etoposid (VP 16–213). Eine Phase I/II-Studie bei refraktärer akuter myeloischer Leukämie. Onkologie 8: 181–184PubMedGoogle Scholar
  26. Hiddemann W et al (1986) High-dose cytosine-arabinoside and mitoxantrone: a highly effective regimen in refractory adult acute myeloid leukemia. (Abstr 618) Proc ASCO 5: 158Google Scholar
  27. Hines JD et al (1984) High-dose cytosine-arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia. J Clin Oncol 2: 545–549PubMedGoogle Scholar
  28. Hoelzer D et al (1984) Low-dose Ara-C in the treatment of acute leukemia. Cytotoxicity or differentiation induction? Blut 48: 233–238PubMedGoogle Scholar
  29. Hossfeld DK et al (1985) Low-dose cytarabine: Chromosomal findings suggesting its cytostatic as well as differentiating effect. Leukemia Res 9: 329–330Google Scholar
  30. Housset M et al (1982) Small doses of cytosine arabinoside in the treatment of acute myeloid leukemia: Differentiation of myeloid leukaemic cells? Br J Haematol 51: 125–129PubMedGoogle Scholar
  31. Jehn U et al (1984) Clinical trial of low-dose Ara-C in the treatment of acute leukemia and myelodysplasia. Blut 48: 255–261PubMedGoogle Scholar
  32. Jehn U et al für die EORTC Leukemia-Lymphoma Study Group (1985) AML-6 und AML-7 Studie zur Behandlung der akuten myeloischen Leukämie. Zyklisch alternierende Chemotherapie während der Remission bzw. Remissionsinduktion und Überlebenszeit bei alten Menschen. Onkologie 8: 160–164PubMedGoogle Scholar
  33. Kahn SB et al (1984) Full dose versus attenuated dose daunorubicin, cytosinearabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 2: 865–870PubMedGoogle Scholar
  34. Kantarjian HM et al (1986) Acute promyelocytic leukemia. MD Anderson Hospital experience. Am J Med 80: 789–797PubMedGoogle Scholar
  35. Keating JM et al (1981) A four-year experience with anthracycline, cytosine-arabinoside, vincristine and prednisone combination chemotherapy in 325 adults with acute leukemia. Cancer 194: 2779–2788Google Scholar
  36. Kolb HJ (1984) Allogeneic bone marrow transplantation in leukemia. In: Leukemia, Thiel E, Thierfelder S (eds) Recent results in cancer research. Springer, Berlin Heidelberg New York, pp 269–289Google Scholar
  37. Link H et al (1985) Therapy for acute myeloid leukemia in 119 adults. Comparison of 2 treatment protocols. Blut 51: 49–57PubMedGoogle Scholar
  38. Link H et al (1986) TAD-induction therapy for 175 adults with acute myeloid leukaemia followed by consolidation and maintenance therapy — the joint study of Ulm and Tübingen. Onkologie 9: 135–138PubMedGoogle Scholar
  39. Mayer RJ et al (1982) The role of intensive post-induction chemotherapy in the management of patients with acute myelogenous leukemia. Cancer Treat Rep 66: 1455–1462PubMedGoogle Scholar
  40. Mittermüller J et al (1985) Cytotoxic action of low dose Ara-C. Investigations in a marrow grafted patient with relapse. Onkologie 8: 168–171PubMedGoogle Scholar
  41. MRC Report (1978) Immunotherapy of acute myeloid leukaemia. Br J Cancer 37: 1–7Google Scholar
  42. Murray C et al (1983) Remission of acute myelogenous leukemia in elderly patients with prior refractory dysmyelopoietic anemia. Cancer 52: 967–970PubMedGoogle Scholar
  43. Overkamp F, Meusers P, Brittinger G (1985) COAP Regimen: Successful treatment approach in patients with acute myeloid leukaemia with partial remission after TAD induction therapy. Blut 51: 208 Abstr 194Google Scholar
  44. Pfreundschuh M, Huhnstein W (1981) Therapie der akuten Leukämien. Krankenhausarzt 54: 206ff.Google Scholar
  45. Preisler HD (1982) Therapy for patients with acute myelocytic leukemia who enter remission: Bone marrow transplantation or chemotherapy? Cancer Treat Rep 66: 1467–1473PubMedGoogle Scholar
  46. Preisler HD et al (1983) Therapy of secondary acute nonlymphocytic leukemia with cytarabine. N Engl J Med 308: 21–23PubMedGoogle Scholar
  47. Preisler HD et al (1984) Prediction of response of acute nonlymphocytic leukaemia to therapy with „high-dose“ cytosine arabinoside. Br J Haematol 58: 19–32PubMedGoogle Scholar
  48. Prentice HG et al (1984) Mitoxantrone in relapsed and refractory acute leukemia. Semin Oncol (Suppl 1) 11: 32–35PubMedGoogle Scholar
  49. Rai KR et al (1981) Treatment of acute myelocytic leukemia: A study by Cancer and Leukemia Group B. Blood: 1203–1212Google Scholar
  50. Rees JKH (1984) The treatment of acute myeloid leukaemia (AML). Report of a large multi-center trial. In: Büchner, Urbanitz, van de Loo(Hrsg) Therapie der akuten Leukämien. Springer, Berlin Heidelberg New York pp 101–105Google Scholar
  51. Rudnick SA et al (1979) High dose cytosine arabinoside (HDARAC) in refractory acute leukemia. Cancer 44: 1189–1193PubMedGoogle Scholar
  52. Sauter C et al (1982) Acute myelogenous leukemia: Successful treatment of relapse with cytosine arabinoside, VP-16–213, vincristine and vinblastine (A-triple-V). Eur J Cancer Clin Oncol 18: 733 ffPubMedGoogle Scholar
  53. Sauter C et al (1984) Acute myelogenous leukaemia: Maintenance chemotherapy after early consolidation treatment does not prolong survival. Lancet I: 379–382Google Scholar
  54. Schiff RD et al (1984) Low-dose arabinosyl cytosine (LD ARA-C) in hematologic malignancies and myelodysplastic syndromes (MDS). Proc ASCO 3: 206Google Scholar
  55. Tschopp L et al (1986) Efficacy and clinical cross-resistance of a new combination therapy (AMSA/VP 16) in previously treated patients with acute nonlymphocytic leukemia J. Clin Oncol 4: 318–324PubMedGoogle Scholar
  56. Vogler R et al (1984) A randomized comparison of postremission therapy in acute myelogenous leukemia. A Southeastern Cancer Study Group trial. Blood 63: 1039–1045PubMedGoogle Scholar
  57. Vogler WR et al (1986) Randomized trial of high-dose cytarabine versus amsacrine in acute myelogenous leukemia in relapse: a Leukemia Intergroup study. Cancer Treatm Rep 70: 455–459Google Scholar
  58. Weh JH et al (1984) Low-dose cytosine-arabinoside in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Blut 48: 239–242PubMedGoogle Scholar
  59. Weiss R et al (1984) Low-dose Ara-C in treatment of refractory anemia with excess of blasts (RAEB) and acute non-lymphocytic leukemia (ANLL). Proc ASCO 3: 203Google Scholar
  60. Whitecar JP, Bodey GP, Freireich EJ et al (1972) Cyclophosphamide, Vincristine, Cytosine Arabinoside and Prednisone (COAP) combination chemotherapy for acute leukemia in adults. Cancer Chemother Rep 56: 543–550PubMedGoogle Scholar
  61. Willemze R et al (1983) Experience with intermediate and high dose cytosine arabinoside in refractory acute leukaemia. Onkologie 6: 200–204PubMedGoogle Scholar
  62. Wisch JS et al (1983) Response of preleukemic syndromes to continuous infusion of low-dose cytarabine. N Engl J Med 309: 1599–1602PubMedGoogle Scholar
  63. Wolff SN et al (1984) High-dose (HD) cytosine arabinoside (ARA-C) and daunorubicin (D) for acute non-lymphocytic leukemia (ANLL) in first remission (Abstr). Proc Am Soc Clin Oncol 3.C-752Google Scholar
  64. Worsley AM, Galton DHG (1984) Acute myeloid leukaemia: Is „consolidation“ therapy necessary? Br J Haematol 56: 361–364PubMedGoogle Scholar
  65. Yates JW et al (1982) Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: A CALGB-Study. Blood 60: 454ffPubMedGoogle Scholar
  66. Zittoun R et al (1983) High-dose cytosine-arabinoside (Ara-C) alone or combined with m-AMSA for induction or consolidation-maintenance in acute myelogenous leukemia (AML). Proc 13th Int Congr Chemother 216: 62–66Google Scholar
  67. Abromowitch M et al (1985) Etoposide (VP-16) with prednisone and vincristine for the treatment of refractory acute lymphoblastic leukemia. J Clin Oncol 3: 789–792PubMedGoogle Scholar
  68. Baccarani M et al (1982) Adolescent and adult acute lymphoblastic leukemia: prognostic features and outcome of therapy: A study of 293 patients. Blood 60: 677–684PubMedGoogle Scholar
  69. Bennett JM et al (1976) Proposals for the classification of the acute leukaemias. Br J Haematol 33: 451–458PubMedGoogle Scholar
  70. Bennet JM et al (1981) The morphological classification of acute lymphoblastic leukaemia: Concordance among observers and clinical correlations. Br J Haematol 47: 553–561Google Scholar
  71. Bleyer WA, Poplack DG (1985) Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries. Semin Oncol 12: 131–148PubMedGoogle Scholar
  72. Bloomfield CD (1985) Acute lymphoblastic leukemia: clinical and biological features. In: Goldman JM, Preisler HD (eds) Leukemias. Butterworths London, pp 163–189Google Scholar
  73. Carella AM et al (1981) Induction and consolidation combination chemotherapy with 8 drugs (L-10 protocol) for acute lymphoblastic leukemia. Haematologica (Pavia) 66: 311–326Google Scholar
  74. Clarkson B et al (1985) Acute lymphoblastic leukemia in adults. Semin Oncol 12: 160–179PubMedGoogle Scholar
  75. Early AP et al (1981) Treatment of refractory adult acute lymphocytic leukaemia and acute undifferentiated leukaemia with an anthracycline antibiotic and cytosine arabinoside. Br J Haematol 48: 369–375PubMedGoogle Scholar
  76. Early AP et al (1982) A pilot study of high dose cytosine arabinoside for acute leukemia and refractory lymphoma — clinical response and pharmacology. Cancer Res 42: 1587–1594PubMedGoogle Scholar
  77. Ellison RR et al (1986) Prognostic values affecting response and survival in adults with acute lymphocytic leukemia (ALL) on CALGB 8011 (Abstr 609). Proc ASCO 5: 156Google Scholar
  78. Frick J et al (1984) Successful treatment of meningeal leukemia using systemic high-dose cytosine arabinoside. J Clin Oncol 2: 365–368PubMedGoogle Scholar
  79. Gottlieb AJ et al (1984) Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: A prospective randomized trial by cancer and leukemia group B. Blood 64: 267–274PubMedGoogle Scholar
  80. Henderson ES (1983) Acute lymphocytic leukemia. In: Gunz FW, Henderson ES (eds) Leukemia, 4th edn. Grune & Stratton, New York, pp 575–625Google Scholar
  81. Henderson DS et al (1979) Combination chemotherapy and radiotherapy for acute lymphocytic leukemia in adults: Results of CALGB protocol 7113. Leuk Res 3: 395–407PubMedGoogle Scholar
  82. Hoelzer D (1984) Current status of ALL/AUL therapy in adults. In: Thiel E, Thierfelder S (eds) Leukemia, Recent developments in diagnosis and therapy. Recent results in cancer research, Springer, Berlin Heidelberg New York Tokyo, vol 93, pp 184–203Google Scholar
  83. Hoelzer D et al (1984) Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults. Blood 64: 38–47PubMedGoogle Scholar
  84. Jacobs AD, Gale RP (1984) Recent advances in the biology and treatment of acute lymphoblastic leukemia in adults. N Engl J Med 311: 1219–1231PubMedGoogle Scholar
  85. Linker CA et al (1986) Adult acute lymphoblastic leukemia: intensive therapy with improved results (Abstr 636). Proc ASCO 5: 163Google Scholar
  86. Lister TE et al (1978) Combination chemotherapy for acute lymphoblastic leukemia in adults. Br Med J 7: 199–203Google Scholar
  87. Lister TA et al (1983) The treatment of adult acute lymphoblastic leukaemia (ALL). (Abstr. C-661) Proc Am Soc Clin Oncol 2: 170Google Scholar
  88. Lobel JS et al (1979) Methotrexate and asparaginase combination chemotherapy in refractory acute lymphoblastic leukemia of childhood. Cancer 43: 1089–1094PubMedGoogle Scholar
  89. Maurer AM (1986) New directions in the treatment of acute lymphoblastic leukemia in children. N Engl J Med 315: 316–317Google Scholar
  90. Omura GA et al (1980) Combination chemotherapy of adult acute lymphoblastic leukemia with randomized central nervous system prophylaxis. Blood 55: 199–204PubMedGoogle Scholar
  91. Pfreundschuh M, Hunstein W (1981) Therapie der akuten Leukämien. Krankenhausarzt 54: 206 ffGoogle Scholar
  92. Prentice HG (1983) A review of the current status and technique of allogenic bone marrow transplantation for treatment of leukaemia. J Clin Pathol 36: 1207–1215PubMedGoogle Scholar
  93. Rivera G et al (1980) Combined VM-26 and cytosine arabinoside in treatment of refractory childhood lymphocytic leukemia. Cancer 45: 1284–1288PubMedGoogle Scholar
  94. Rivera G et al (1982) VM-26 therapy in children with drug-refractory lymphocytic leukemia. Cancer Chem Pharmacol 7: 169–172Google Scholar
  95. Rivera GK et al (1986) Intensive retreatment of childhood acute lymphoblastic leukemia in first bone marrow relapse: a Pediatric Oncology Group Study. N Engl J Med 315: 273–279PubMedGoogle Scholar
  96. Rudnick SA et al (1979) High dose cytosine arabinoside in refractory acute leukemia. Cancer 44: 1189–1193PubMedGoogle Scholar
  97. Sobol RE et al (1986) Clinical significance of mixed lymphoid and myeloid characteristics in adult acute lymphoblastic leukemia (Abstr 623) Proc ASCO 5: 159Google Scholar
  98. Thiel E (1984) Biological and clinical significance of immunological cell markers in leukemia. In: Thiel E, Thierfelder S (eds). Leukemia. Recent developments in diagnosis and therapy. Recent results in cancer research, Springer, Berlin Heidelberg New York Tokyo, vol 93, pp 102–158Google Scholar
  99. Thiel E (1986) Leukämiezell-Analyse bei der Diagnose der ALL/AUL: Klinische Wertigkeit heute verfügbarer Methoden. Onkologie 9: 60–65PubMedGoogle Scholar
  100. Thomas ED et al (1979) Marrow transplantation for patients with acute lymphoblastic leukemia in remission. Blood 54: 468–476PubMedGoogle Scholar
  101. Walters R et al (1986) VAD: Effective, low morbidity, outpatient induction therapy for adult acute lymphocytic leukemia (ALL). Proc ASCO 5: 167 (Abstr 654)Google Scholar
  102. Willemze R et al (1980) Treatment of acute lymphoblastic leukaemia in adolescents and adults: comparison of two schedules for CNS leukaemia prophylaxis. Scand J Haematol 24: 421–426Google Scholar
  103. Woodruff R (1978) The management of adult lymphoblastic leukaemia. Cancer Treat Rev 5: 95–113PubMedGoogle Scholar
  104. Allan NC et al (1978) Combination chemotherapy for chronic granulocytic leukaemia. Lancet II: 523 ffGoogle Scholar
  105. Arlin ZA et al (1986) Treatment of blastic transformation of chronic myelogenous leukemia with mitoxantrone. Cancer Chemother Pharmacol 17: 189–190PubMedGoogle Scholar
  106. Baccarani M and the Italian Cooperative Study Group on Chronic Myeloid Leukemia (1981) Early splenectomy and polychemotherapy versus polychemotherapy alone in chronic myeloid leukemia. Leuk Res 5: 149–157PubMedGoogle Scholar
  107. Brodsky I et al (1979) Myeloproliferative disorders: II CML: Clonal evolution and its role in management. Leuk Res 3: 379–393PubMedGoogle Scholar
  108. Champlin R et al (1983) Allogenic bone marrow transplantation for chronic myelogenous leukemia in chronic or accelerated phase. Transplant Proc 15: 1401–1404Google Scholar
  109. Clarkson B (1985) Chronic myelogenous leukemia: Is aggressive treatment indicated? J Clin Oncol 3: 135–139PubMedGoogle Scholar
  110. Coleman M et al (1980) Combination chemotherapy for terminal phase chronic granulocytic leukemia. Cancer and Leukemia Group B Studies. Blood 55: 29–36PubMedGoogle Scholar
  111. Cunningham I et al (1979) Results of treatment of Ph1 + chronic myelogenous leukemia with an intensive treatment regimen (L-5 protocol). Blood 53: 375–395PubMedGoogle Scholar
  112. Douglas ID, Whiltshaw E (1978) Remission induction in chronic granulocytic leukaemia using intermittent high-dose busulphan. Br J Haematol 40: 59–64PubMedGoogle Scholar
  113. Fefer A et al (1982) Treatment of chronic granulocytic leukemia with chemoradiotherapy and transplantation of marrow from identical twins. N Engl J Med 306: 63PubMedGoogle Scholar
  114. Georgii A et al (1980) Chronic megakaryocytic granulocytic myelosis — CMGM. A subtype of chronic myeloid leukemia. Virchows Arch [A] 389: 253–268Google Scholar
  115. Goldman JM et al (1982) Treatment of chronic granulocytic leukemia (CGL) by bone marrow transplantation (BMT). Proceedings of the 3rd International Symposium on Therapy for Acute Leukemia, p 360Google Scholar
  116. Goldman JM et al (1986) Bone marrow transplantation for patients with chronic myeloid leukemia. New Engl J Med 314: 202–205PubMedGoogle Scholar
  117. Gomez GA et al (1976) Splenectomy for palliation of chronic myelocytic leukemia. Am J Med 61: 14–22PubMedGoogle Scholar
  118. Hellriegel KP (1981) Therapie der Blastenkrise der chronischen myeloischen Leukämie. Ergebnisse einer Phase II-Studie mit Vindesin. Folia Haematol (Leipzig) 108: 699–704Google Scholar
  119. Hossfeld KD (1986) Die chronischen Leukämien. Dtsch Ärztebl 83: 963–966Google Scholar
  120. Italian Cooperative Study Group on Chronic Myeloid Leukemia (1984) Results of a prospective randomized trial of early splenectomy in chronic myeloid leukemia. Cancer 54: 333–338Google Scholar
  121. Jehn U, Metzger J (1984) Phase II-Studie zur Behandlung der CML-Blastenkrise mit Vindesin und Prednison. Onkologie 7: 342–345PubMedGoogle Scholar
  122. Kantarjian HM et al (1985) Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemia. J Clin Oncol 3: 192–200PubMedGoogle Scholar
  123. Karanas A, Silver RT (1968) Characteristics of the terminal phase of chronic granulocytic leukemia. Blood 32: 445–450PubMedGoogle Scholar
  124. Kennedy BJ (1972) Hydroxyurea therapy in chronic myelogenous leukemia. Cancer 29: 1052–1056PubMedGoogle Scholar
  125. Kyle RA et al (1961) A syndrome resembling adrenal cortical insufficiency associated with long term busulfan (myleran) therapy. Blood 18: 497–510Google Scholar
  126. Lahnerter-Palacios J et al (1986) Rapid control of myeloid compartment with vindesine in chronic phase of chronic myelogenous leukemia (letter). Cancer Treatm Rep 70: 315–316Google Scholar
  127. Lemoine F, Najman I (1985) Vindesine and prednisone in the treatment of blast crisis of chronic myeloid leukemia. Cancer Treat Rep 69: 203–204PubMedGoogle Scholar
  128. Lowenthal RM et al (1975) Intensive leukapheresis as initial therapy for chronic granulocytic leukemia. Blood 46: 835–844PubMedGoogle Scholar
  129. Mahmoud HK et al (1985) Bone marrow transplantation for chronic granulocytic leukaemia. Klin Wschr 63: 560–564PubMedGoogle Scholar
  130. Mandelli F et al (1982) Vindesine in the treatment of refractory hematologic malignancies: A phase II study. Leuk Res 6: 649–652PubMedGoogle Scholar
  131. Marks SM et al (1978) Terminal transferase as a predictor of initial responsiveness to vincristine and prednisone in blastic chronic myelogenous leukemia. N Engl J Med 298: 812 ffPubMedGoogle Scholar
  132. McCaffrey R et al (1973) Terminal deoxynucleotidyl transferase in a case of childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA 70: 521PubMedGoogle Scholar
  133. Medical Research Council’s Working Party for Therapeutic Trials in Leukemia (1968) Chronic granulocytic leukaemia: Comparison of radiotherapie and busulfan therapy. Br Med J I: 201–208Google Scholar
  134. Murphy ML, Chaube S (1964) Preliminary survey of hydroxyurea (NSC-3 20 65) as a teratogen. Cancer Chemother Rep 40: 1–7PubMedGoogle Scholar
  135. Musshoff K et al (1969) Die Lebenserwartung der chronischen myeloischen Leukämie in Abhängigkeit von individuellen und krankheitsspezifischen Faktoren und der Therapie. Klin Wochenschr 47: 179–183PubMedGoogle Scholar
  136. Niederle N et al (1985) Investigation of recombinant human interferon alpha 2 (r IFN-Alpha2) in chronic myelogenous leukemia (CML) Blut 53: 232 (Abstr. 268)Google Scholar
  137. Niederle N et al (1986) α2-Interferon: erste Behandlungsergebnisse bei der chronischen myeloischen Leukämie. Dtsch med Wschr 111: 767–772PubMedGoogle Scholar
  138. Phillips GL, Herzig GP (1984) Intensive chemotherapy, total body irradiation, and autologous marrow transplantation for chronic granulocytic leukemia-blast phase: Report of four additional cases. J Clin Oncol 2: 379–384PubMedGoogle Scholar
  139. Schiffer CA et al (1982) Treatment of the blast crisis of chronic myelogenous leukemia with 5-azacytidine and VP 16–213. Cancer Treat Rep 66: 267–271PubMedGoogle Scholar
  140. Sharp JC et al (1979) Karyotypic conversion in Ph1 positive myeloid leukaemia with combination chemotherapy. Lancet 1: 1370–1372PubMedGoogle Scholar
  141. Sokal JE et al (1984) Prognostic discrimination in „good-risk“ chronic granulocytic leukemia. Blood 63: 789–799PubMedGoogle Scholar
  142. Speck B et al (1982) Allogenic marrow transplantation for chronic granulocytic leukemia. Blut 45: 237–242PubMedGoogle Scholar
  143. Spiers ASD (1979) Metamorphosis of chronic granulocytic leukemia: Diagnosis, classification and management. Br J Haematol 41, 1–7PubMedGoogle Scholar
  144. Spiers ASD et al (1974) Chronic granulocytic leukemia: Multiple-drug chemotherapy for acute transformation. Br Med J 3: 77ff.PubMedGoogle Scholar
  145. Talpaz M et al (1983) Concise report. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 62: 689–692PubMedGoogle Scholar
  146. Talpaz M et al (1986) Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha2 in chronic myelogenous leukemia. New Engl J Med 334: 1065–1069Google Scholar
  147. Thomas ED et al (1986) Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 104: 155–163PubMedGoogle Scholar
  148. Uzuka Y, Saito Y (1985) Treatment of chronic myelogenous leukemia in blastic crisis with chemotherapy incorporating vindesine-prednisolone. Cancer Treatm Rep 69: 1297–1299Google Scholar
  149. Wiernik PH (1984) The current status of therapy for and prevention of blast crisis of chronic myelocytic leukemia. J Clin Oncol 2: 329–335PubMedGoogle Scholar
  150. Winton EF et al (1981) Intensive chemotherapy with daunorubicin, 5-azacytidine, 6-thioguanine and cytarabine (DATA) for the blastic transformation of chronic granulocytic leukemia. Cancer Treat Rep 65: 389–392PubMedGoogle Scholar
  151. Appelbaum FR et al (1985): Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin’s disease. J Clin Oncol 3: 1490–1494PubMedGoogle Scholar
  152. Bakemeier RF et al (1984): BCVPP chemotherapy for advanced Hodgkin’s disease: evidence for greater duration of complete remission, greater survival and less toxicity than with a MOPP regimen. Results of the ECOG study. Ann Intern Med 101: 447–456PubMedGoogle Scholar
  153. Bennett MH et al (1983): The prognostic significance of cellular subtypes in nodular sclerosing Hodgkin’s disease: An analysis of 271 non-laparotomized cases (BNLI-report 22). Clin Radiol 34: 497–501PubMedGoogle Scholar
  154. Beretta G et al (1984): Comparative evaluation of ABVD vs. ABV as induction treatment for malignant lymphomas. 2nd International Conference on malignant lymphomas, Lugano, Switzerland. June 1984 (Abstr. T110)Google Scholar
  155. Bonadonna G et al (1975): Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastin, and imidazole carboxamide versus MOPP. Cancer 36: 252–259PubMedGoogle Scholar
  156. Bonadonna G et al (1978): MOPP vs MOPP plus ABVD in stage IV Hodgkin’s disease. Proc. Am. Assoc. Cancer Res. Clin. Oncol. 19: 363Google Scholar
  157. Bonadonna G et al (1982 a): ABVD chemotherapy in the treatment of Hodgkin’s disease. Cancer Treat Rev 9: 21–35PubMedGoogle Scholar
  158. Bonadonna G et al (1982 b): Cyclic delivery of MOPP and ABVD combinations in stage IV Hodgkin’s disease: Rationale, background studies and recent results. Cancer Treat Rep 66: 881–887PubMedGoogle Scholar
  159. Bonadonna G et al (1985): Third-line salvage chemotherapy in Hodgkin’s disease. Sem Oncol 12 (Suppl 2): 23–25Google Scholar
  160. Bonadonna G et al (1986) Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin’s disease. A report of 8-year results. Ann Intern Med 104: 739–746PubMedGoogle Scholar
  161. British National Lymphoma Investigation Report No. 1 (1975): Value of prednisone in combination chemotherapy of stage IV Hodgkin’s disease. Br Med J II: 413–414Google Scholar
  162. Carbone PP et al (1971): Report of the committee on Hodgkin’s disease staging classification. Cancer Res 31: 1860–1861PubMedGoogle Scholar
  163. Carella AM et al (1985): Massive chemotherapy with non-frozen autologous bone marrow transplantation in 13 cases of refractory Hodgkin’s disease. Eur J Cancer Clin Oncol 21: 607–613PubMedGoogle Scholar
  164. Chapman RM et al (1981 a): Male gonadal dysfunction in Hodgkin’s disease. JAMA 245:1323–1328PubMedGoogle Scholar
  165. Chapman RM et al (1981 b): Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin’s disease. Blood 58:849–851PubMedGoogle Scholar
  166. Coleman CN (1986) Secondary malignancy after treatment of Hodgkin’s disease: an evolving picture. J Clin Oncol 4:821–824PubMedGoogle Scholar
  167. Connors JM (1984): Is it an E lesion or stage IV? An unsettled issue in Hodgkin’s disease staging. J Clin Oncol 2:1421–1423PubMedGoogle Scholar
  168. Cooper MR et al (1984): The effects of prior radiation therapy and age on the frequency and duration of complete remission among various four drug treatments for advanced Hodgkin’s disease. J Clin Oncol 2:748–755PubMedGoogle Scholar
  169. Cornbleet MA et al (1985): Pathologic stages IA and IIA Hodgkin’s disease: results of treatment with radiotherapy alone (1968–1980). J Clin Oncol 3:758–768PubMedGoogle Scholar
  170. Cosset JM et al (1984): The prognostic significance of large mediastinal masses in the treatment of Hodgkin’s disease. The experience of the Institute Gustave-Roussy. Hematol Oncol 2:33–43PubMedGoogle Scholar
  171. Cramer PH (1985): Secondary acute non lymphoblastic leukemias (SANLL) after MOPP-chemotherapy (CT) plus radiotherapy (RT) for Hodgkin’s disease (HD). Role of infradiaphragmatic (ID) RT. Proc. ASCO 4:213 (Abstr C-832)Google Scholar
  172. Crowther D et al (1984): A randomized study comparing chemotherapy alone with chemotherapy followed by radiotherapy in patients with pathologically staged IIIA Hodgkin’s disease. J Clin Oncol 2:892–897PubMedGoogle Scholar
  173. Crukovich MJ et al (1986): Stage IIB Hodgkin’s disease: the Stanford experience. J Clin Oncol 4:472–479Google Scholar
  174. Desser RK et al (1977): Prognostic classification of Hodgkin’s disease in pathologie stage III, based on anatomic considerations. Blood 49:883–893PubMedGoogle Scholar
  175. De Vita VT et al (1970): Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med 73:881–895Google Scholar
  176. De Vita VT et al (1980): Curability of advanced Hodgkin’s disease with chemotherapy. Ann Intern Med 92:587–595Google Scholar
  177. De Vita VT (1982): Consequences of the chemotherapy of Hodgkin’s disease. Cancer 47:1–13Google Scholar
  178. De Vita VT (1986): Chemotherapy of the lymphomas: “Looking back — moving forward” (Richard and Hinda Rosenthal Foundation Award Lecture). AACR 27, Los Angeles, 7. Mai 1986Google Scholar
  179. Diehl L et al (1985): Computed tomography (CT) of the chest in the initial staging of Hodgkin’s disease (HD-patients). Proc ASCO 4:210 (Abstr C-819)Google Scholar
  180. Diehl V et al (1986): Zwischenergebnisse der Therapiestudien HD 1, HD 2 und HD 3 der deutschen Hodgkin-Studiengruppe. Med Klinik 81:1–6Google Scholar
  181. Dmitrowsky E et al (1986): Lymph node aspiration in the management of Hodgkin’s diseasee. J Clin Oncol 4:306–310Google Scholar
  182. Dument J et al (1984): High-dose chemotherapy and bone marrow transplantation in poor prognosis Hodgkin’s disease. 2nd International Conference on Malignant Lymphomas. Lugano, Switzerland 1984 (Abstr 69)Google Scholar
  183. Fabian C et al (1984): Lack of correlation of Ann Arbor clinical parameters and biopsy determination of liver involvement in stage III and IV Hodgkin’s disease. A Southwest Oncology Group (SWOG) Study, 2nd Internat Conference on Malignant Lymphomas. Lugano, Switzerland (Abstr N 24)Google Scholar
  184. Ferme C et al (1984): Combined modality in Hodgkin’s disease. Comparison of six versus three courses of MOPP with clinical and surgical restaging. Cancer 54:2324–2329PubMedGoogle Scholar
  185. Ferrant A et al (1985): Combined modality therapy for mediastinal Hodgkin’s disease. Prognostic significance of constitutional symptoms and size of disease. Cancer 55:317–322PubMedGoogle Scholar
  186. Fisher RJ et al (1979): Prolonged disease free survival in Hodgkin’s disease with MOPP reinduction after first relapse. Ann Intern Med 90:761–763PubMedGoogle Scholar
  187. Fuks Z et al (1976): Long-term effects of external radiation of the pituitary and thyroid glands. Cancer 37:1152–1161PubMedGoogle Scholar
  188. Gaetini A et al (1984): Preservation of ovarian function after inverted Y radiotherapy in Hodgkin’s disease. A new surgical method of transposition, 2nd Internat Conference on Malignant Lymphomas, Lugano (Abstr T 110)Google Scholar
  189. Gassmann W et al (1985): Radiotherapy of Hodgkin’s disease after primary failure of chemotherapy and recurrence after chemotherapy. Blut 51:206 (Abstr 188)Google Scholar
  190. Glatstein E et al (1969): The value of laparotomy and splenectomy in the staging of Hodgkin’s disease. Cancer 24:709 ffPubMedGoogle Scholar
  191. Glick JH, Tsiatis A (1986) MOPP/ABVD chemotherapy for advanced Hodgkin’s disease (Editorial). Ann Intern Med 104:876–878PubMedGoogle Scholar
  192. Gobbi PG et al (1985): Reevaluation of prognostic significance of symptoms in Hodgkin’s disease. Cancer 56:2874–2880PubMedGoogle Scholar
  193. Goffinet DR et al (1976): Abdominal irradiation in Non-Hodgkin’s lymphoma. Cancer 37:2797–2805PubMedGoogle Scholar
  194. Goldman JM (1981): Combination chemotherapy for stage IV Hodgkin’s disease (Report No 14). Clin Radiol 31:531–536Google Scholar
  195. Gomez GA et al (1984): Staging laparotomy and splenectomy in early Hodgkin’s disease. No therapeutic benefit. Am J Med 77:205–210PubMedGoogle Scholar
  196. Harker WG et al (1984): Combination chemotherapy for advanced Hodgkin’s disease after failure of MOPP; ABVD and B-CAVe. Ann Intern Med 101:440–446PubMedGoogle Scholar
  197. Haybittle JL et al (1985): Review of British National Lymphoma Investigation studies of Hodgkin’s disease and development of prognostic index. Lancet 1:967–972PubMedGoogle Scholar
  198. Herman TS et al (1985): Late relapse among patients treated for Hodgkin’s disease. Ann Intern Med 102:292–297PubMedGoogle Scholar
  199. Hoppe RT et al (1980): Prognostic factors in pathological stage IIIA Hodgkin’s disease. Cancer 46:1240–1246PubMedGoogle Scholar
  200. Hoppe RT (1985): The management of stage II Hodgkin’s disease with a large mediastinal mass: A prospective program emphasizing irradiation. Int J Radiat Oncol Biol Phys 11:349–353PubMedGoogle Scholar
  201. Horning SJ et al (1981): Female reproductive potential after treatment for Hodgkin’s disease. N Engl J Med 304:1377–1382PubMedGoogle Scholar
  202. Jagannath S et al (1984): High dose chemotherapy and autologous bone marrow transplant (ABMT) in relapsed Hodgkin’s disease (HD). Proc Am Soc Clin Oncol 3:255 (Abstr C-988)Google Scholar
  203. Jochelson M et al (1985): The significance of the residual mediastinal mass in treated Hodgkin’s disease. J Clin Oncol 3:637–634PubMedGoogle Scholar
  204. Jones SE (1980): Importance of staging in Hodgkin’s disease. Semin Oncol 7:126–135PubMedGoogle Scholar
  205. Kant AJ et al (1986): The pathologic and clinical heterogeneity of lymphocyte-depleted Hodgkin’s disease. J Clin Oncol 4:284–294PubMedGoogle Scholar
  206. Kaplan HS (1966): Role of intensive radiotherapy in the management of Hodgkin’s disease. Cancer 19:356–367Google Scholar
  207. Kaplan HS et al (1975): The management of Hodgkin’s disease. Cancer 36:796–803PubMedGoogle Scholar
  208. Kaplan HS (1980): Hodgkin’s disease. Harvard University Press, CambridgeGoogle Scholar
  209. Kinsella TJ et al (1982): Late effects of radiation therapy in the treatment of Hodgkin’s disease. Cancer Treat Rep 66:991–1002PubMedGoogle Scholar
  210. Klimo P, Connors JM (1985): MOPP/ABV Hybrid program: Combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin’s disease. J Clin Oncol 3:1174–1182PubMedGoogle Scholar
  211. Krikorian JG et al (1979 a): Appearance of non-Hodgkin’s lymphoma after therapy for Hodgkin’s disease. N Engl J Med 300:452–458PubMedGoogle Scholar
  212. Krikorian JG et al (1979 b): Hodgkin’s disease, stages I and II occuring below the diaphragm. Cancer 43:1866–1871PubMedGoogle Scholar
  213. Lee CKK et al (1980): Prognostic significance of mediastinal involvement in Hodgkin’s disease treated with curative radiotherapy. Cancer 46:2403–2409PubMedGoogle Scholar
  214. Levi JA et al (1977): Limited extranodal Hodgkin’s disease-unfavorable prognosis and therapeutic implications. Am J Med 63:365–372PubMedGoogle Scholar
  215. Lister TA (1985): Hodgkin’s-disease in adults: the challenge. Post Grad Med J 61:103–107Google Scholar
  216. Lister TA et al (1983): The treatment of stage IIIA Hodgkin’s disease. J Clin Oncol 1:745–749PubMedGoogle Scholar
  217. Lukes R et al (1966): Report of the nomenclature committee. Cancer Res 26 (Part I): 1311 ffGoogle Scholar
  218. Marks JE et al (1974): Extended mantle radiotherapy in Hodgkin’s disease and malignant lymphoma. AJR 121:772–778Google Scholar
  219. Mauch P et al (1978): The significance of mediastinal involvement in early stage Hodgkin’s disease. Cancer 42:1039–1045PubMedGoogle Scholar
  220. Mauch P et al (1979): An evaluation of total nodal irradiation as treatment for stage IIIA Hodgkin’s disease. Cancer 43:1255–1261PubMedGoogle Scholar
  221. Mauch P et al (1985): Treatment of patients with „minimal“stage IIIA Hodgkin’s disease with mantle and paraaortic irradiation. Int J Radiat Oncol Biol Phys 11 (Suppl 1): 155–156Google Scholar
  222. Mauch P et al (1985): Reduction of fatal complications from combined modality therapy in Hodgkin’s disease. J Clin Oncol 3:501–505PubMedGoogle Scholar
  223. Mauch P et al (1985): Stage III Hodgkin’s disease: improved survival with combined modality as compared with radiation therapy alone. J Clin Oncol 3:1166–1173PubMedGoogle Scholar
  224. McElwain TJ et al (1977): A combination of chlorambucil, vinblastine, procarbazine and prednisone for treatment of Hodgkin’s disease. Br J Cancer 36:276 ffPubMedGoogle Scholar
  225. Mead GM et al (1982): Single agent palliative chemotherapy for end-stage Hodgkin’s disease. Cancer 50:829–835PubMedGoogle Scholar
  226. Morgan GW et al (1985): Late cardiac, thyroid, and pulmonary sequelae of mantle radiotherapy for Hodgkin’s disease. Int J Rad Oncol Biol Phys 11:1925–1931Google Scholar
  227. Morgenfeld M et al (1972): Treatment of malignant lymphoma with cyclophosphamide, vincristine, procarbazine and prednisone combination. XIV Internat Congr Hematolog Sao Paulo (abstract No 578), Brasil 1972Google Scholar
  228. Morris SW et al (1985): Low dose irradiation: its value in stage IV Hodgkin’s disease (HD). Proc ASCO 4:208 (Abstr C-811)Google Scholar
  229. Musshoff K (1971): Prognostic and therapeutic implications of staging in extranodal Hodgkin’s disease. Cancer Res 31:1814–1828PubMedGoogle Scholar
  230. Page V et al (1970 a): Physical and dosimetric aspects of radiotherapy of malignant lymphomas. I. The mantle technique. Radiology 96:609–618PubMedGoogle Scholar
  231. Page V et al (1970 b): Physical and dosimetric aspects of the radiotherapy of malignant lymphomas. II. The inverted Y-technique. Radiology 96:619–627PubMedGoogle Scholar
  232. Phillips GL et al (1986): High-dose chemotherapy, fractionated total-body irradiation, and allogeneic marrow transplantation for malignant lymphoma. J Clin Oncol 4:480–488PubMedGoogle Scholar
  233. Pillai GN et al (1985): Prognostic factors for stage IV Hodgkin’s disease treated with MOPP, with or without bleomycin. Cancer 55:691–697PubMedGoogle Scholar
  234. Propert KJ et al (1986): Combination chemotherapy with vinca-alkaloids and alkylating agents for stage III and IV Hodgkin’s disease (HD): Ten years of follow-up (CALGB 7251). Proc ASCO 5:192 (Abstr 755)Google Scholar
  235. Prosnitz LR (1976): Long-term remissions with combined modality therapy for advanced Hodgkin’s disease. Cancer 37:2826–2833PubMedGoogle Scholar
  236. Prosnitz LR (1977): Ann Arbor staging system for Hodgkin’s disease:,E’ stands for error! Int J Radiat Oncol Biol Phys 2:1039PubMedGoogle Scholar
  237. Prosnitz LR et al (1980): Supradiaphragmatic Hodgkin’s disease: Significance of large mediastinal masses. Int J Radiat Oncol Biol Phys 6:809–813PubMedGoogle Scholar
  238. Prosnitz LR et al (1982): Combined modality therapy for advanced Hodgkin’s disease: Long term follow up data. Cancer Treat Rep 66:871–879PubMedGoogle Scholar
  239. Prosnitz LR et al (1985): Treatment selection for stage IIIA Hodgkin’s disease patients. Int J Radiation Oncol Biol Phys 11:1431–1437Google Scholar
  240. Radiotherapy of stage I and II Hodgkin’s disease — a collaborative study (1984). Cancer 54:1928–1942Google Scholar
  241. Ray GR et al (1970): A means of preserving ovarian function following pelvic megavoltage radiotherapy for Hodgkin’s disease. Radiology 96:175–180PubMedGoogle Scholar
  242. Rosenberg SA (1971): Hodgkin’s disease of the bone marrow. Cancer Res 31:1733–1736PubMedGoogle Scholar
  243. Rosenberg SA et al (1985): The evolution and summary results of the Stanford randomized clinical trial of the management of Hodgkin’s disease: 1962–1984. Int J Radiat Oncol Biol Phys 11:5–22PubMedGoogle Scholar
  244. Santoro A et al (1982 a): Salvage chemotherapy with ABVD in MOPP resistant Hodgkin’s disease. Ann Intern Med 96:139–143PubMedGoogle Scholar
  245. Santoro A et al (1982 b): Alternating drug combinations in advanced Hodgkin’s disease. N Engl J Med 306:770–775PubMedGoogle Scholar
  246. Santoro A et al (1982 c): Thirdline chemotherapy with CCNU, etoposide and prednimustine (CEP) in Hodgkin’s disease resistant to MOPP and ABVD. Proc ASCO 1:C-165Google Scholar
  247. Santoro A et al (1985): Long term therapeutic and toxicologic results of MOPP-RT-MOPP vs. ABVD-RT-ABVD. Proc ASCO 4:199 (Abstr C-777)Google Scholar
  248. Saß W et al (1984): Splenektomie bei Erwachsenen und das OPSI-Syndrom. Dtsch med Wschr 109:1249–1254PubMedGoogle Scholar
  249. Schomberg PJ et al (1984): Prognostic significance of mediastinal mass in adult Hodgkin’s disease. Cancer 53:324–328PubMedGoogle Scholar
  250. Schreiber DP et al (1985): The potential benefits of therapeutic splenectomy for patients with Hodgkin’s disease and Non-Hodgkin’s lymphomas. Int J Radiat Oncol Biol Phys 11:31–36PubMedGoogle Scholar
  251. Schultz HP et al (1975): Management of presumptive or proven Hodgkin’s disease of the liver. A new radiotherapy technique. Int J Radiat Oncol Biol Phys 1:1–8PubMedGoogle Scholar
  252. Seymour-Austin MM et al (1984): Hodgkin’s disease in patients over sixty years old. Ann Intern Med 100:13–18Google Scholar
  253. Slamina J et al (1977): Long-term side effects in irradiated patients with Hodgkin’s disease. Int J Radiat Oncol Biol Phys 2:1–19Google Scholar
  254. Stein RS et al (1980): Anatomic substages in stage III Hodgkin’s disease. A collaborative study. Ann Intern Med 92:159–165PubMedGoogle Scholar
  255. Strauss DJ et al (1984): Treatment of advanced Hodgkin’s disease with chemotherapy and irradiation. Amer J Med 76:270–278Google Scholar
  256. Strickland P (1981): Radiotherapy or chemotherapy as the initial treatment for stage IIIA Hodgkin’s disease (Report No 13). Clin Radiol 32:527–530PubMedGoogle Scholar
  257. Sutcliffe S et al (1978): MVPP chemotherapy regimen for advanced Hodgkin’s disease. Br Med J 1:683Google Scholar
  258. Sutcliffe SB et al (1985): Prognostic groups for management of localized Hodgkin’s disease. J Clin Oncol 3:393–401PubMedGoogle Scholar
  259. Tubiana M et al (1984): Prognostic significance of erythrocyte sedimentation rate in clinical stages I–II of Hodgkin’s disease. J Clin Oncol 2:194–200PubMedGoogle Scholar
  260. Tubiana M et al (1985): A multivariate analysis of prognostic factors in early stage Hodgkin’s disease. Int J Radiation Oncol Biol Phys 11:25–30Google Scholar
  261. Valagussa P et al (1982): Absence of treatment-induced second neoplasms after ABVD in Hodgkin’s disease. Blood 59:488–494PubMedGoogle Scholar
  262. Valagussa P et al (1986) Second acute leukemia and other malignancies following treatment for Hodgkin’s disease. J Clin Oncol 4:830–837PubMedGoogle Scholar
  263. Vinciguerra V et al (1986) Alternating cycles of combination chemotherapy for patients with recurrent Hodgkin’s disease following radiotherapy: a prospective randomized study by the Cancer and Leukemia Group B. J. Clin Oncol 4: 847–858Google Scholar
  264. Young CW et al (1982): Multidisciplinary treatment of Hodgkin’s disease by an alternating chemotherapeutic regimen of MOPP/ABVD and low-dose radiation therapy restricted to originally bulky disease. Cancer Treat Rep 66:907–914PubMedGoogle Scholar
  265. Zagars G, Rubin R (1985): Laparotomy-staged IA versus IIA Hodgkin’s disease. A comparative study with evaluation of prognostic factors for stage IIA disease. Cancer 56:864–873PubMedGoogle Scholar
  266. Zittoun R et al (1985): Extended versus involved field irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin’s disease. J Clin Oncol 2:207–214Google Scholar
  267. Adelstein DJ et al (1985) High-dose cytosine arabinoside in previously treated patients with poor-prognosis Non-Hodgkin’s lymphoma. Cancer 56:1493–1496PubMedGoogle Scholar
  268. Anderson CC et al (1986) Very high dose chemotherapy with autologous bone marrow rescue in adult patients with resistant relapsed lymphoma. Cancer Chemother Pharmacol 16:170–175PubMedGoogle Scholar
  269. Appelbaum FR et al (1978) Prolonged complete remission following high dose chemotherapy of Burkitt’s lymphoma in relapse. Cancer 41:1059–1063PubMedGoogle Scholar
  270. Armitage JO et al (1986) Chemotherapy of diffuse large-cell lymphoma — rapidly responding patients have more durable remissions. J Clin Oncol 4:160–164PubMedGoogle Scholar
  271. Bagley CM et al (1972) Advanced lymphosarcoma: Intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisone. Ann Intern Med 76:227–234PubMedGoogle Scholar
  272. Bajetta E et al (1985) Phase II study with amsacrines (m-AMSA and m-AMSA lactate) in refractory lymphomas. Cancer Treat Rep 69:965–969PubMedGoogle Scholar
  273. Binet JL et al (1981) Chronic lymphocytic leukaemia: Proposal for a revised prognostic staging system. Br J Haematol 48:365–367Google Scholar
  274. Biron P et al (1985) Massive therapy and autologous bone marrow transplantation (ABMT) in very bad prognosis Burkitt lymphoma (BL) (28 cases, 30 ABMT). Proc ASCO 4:207 (Abstr C-807)Google Scholar
  275. Bitran JD et al (1977) Survival of patients with localized histiocytic lymphoma. Cancer 39:342–346PubMedGoogle Scholar
  276. Bonadonna G et al (1976) Recent trends in the treatment of Non-Hodgkin’s lymphomas. Eur J Cancer 12:661–637PubMedGoogle Scholar
  277. Bonadonna G et al (1977) Non-cross-resistant combinations in stage IV Non Hodgkin’s lymphomas. Cancer Treat Rep 61:1117–1123PubMedGoogle Scholar
  278. Bonadonna G (1985) Chemotherapy of malignant lymphomas. Semin Oncol 12[Suppl. 6]:1–14PubMedGoogle Scholar
  279. Brady LW, Asbell SO (1980) Malignant lymphoma of the gastrointestinal tract. Radiology 137:291–298PubMedGoogle Scholar
  280. Bremer K et al (1980) Chemotherapie der Non-Hodgkin-Lymphome. Internist 21:512–528PubMedGoogle Scholar
  281. Brittinger G et al (1980) Grundlagen und allgemeine Probleme der Therapie der Non-Hodgkin-Lymphome. Internist 21:493–501PubMedGoogle Scholar
  282. Brittinger G et al (1984) Clinical and prognostic relevance of the Kiel classification of Non-Hodgkin-lymphomas. Results of a prospective multi-center study by the Kiel lymphoma study group. Hematol Oncol 2:269–306PubMedGoogle Scholar
  283. Brittinger G et al (1985) Non-Hodgkin-Lymphome und Plasmozytom. Klinische Onkologie (R. Gross u. C. G. Schmidt, Hrsg.) Thieme Stuttgart-New York 41.1–41.71Google Scholar
  284. Brittinger G et al (1986) Klinische und prognostische Relevanz der Kiel-Klassifikation der Non-Hodgkin-Lymphome. Onkologie 9:118–125PubMedGoogle Scholar
  285. Brittinger G, Meusers P, Engelhard M (1986) Strategien der Behandlung von Non-Hodgkin-Lymphomen. Internist 27:485–497PubMedGoogle Scholar
  286. Bunn PA, Jr, Foon KA (1985) Therapeutic options in advanced cutaneous T cell lymphomas: A role for interferon alfa-2a (RoferonR-A). Semin Oncol 12:18–24PubMedGoogle Scholar
  287. Bunn PA Jr et al (1984) Recombinant leukocyte A interferon: An active agent in advanced cutaneous T-cell lymphomas. Ann Intern Med 101:484–487PubMedGoogle Scholar
  288. Bunn PA Jr et al (1984) Treatment of cutaneous T-cell lymphomas (CTCL) with biologic response modifiers: Recombinant leukocyte A interferon (IFL-rA) and T101 monoclonal antibody. Second International Conference on Malignant Lymphoma, Lugano, June 13–16Google Scholar
  289. Bunn PA Jr, Lamberg SI (1979) Report of the committee on staging and classification of cutaneous T-cell lymphomas. Cancer Treatm Rep 63:725–728Google Scholar
  290. Burg G (1979) Moderne Diagnostik und stadiengerechte Therapie kutaner Lymphome. Fortschr Prakt Dermatol Venerol 9:215–227Google Scholar
  291. Burg G et al (1980) Therapie der Mycosis fungoides. Ther Gegenw 119:2–16Google Scholar
  292. Burg G, Braun-Falco O (1983) Cutaneous lymphomas, pseudolymphomas, and related disorders. Springer Verlag New York-Tokyo 1983Google Scholar
  293. Bush RS et al (1977) Radiation therapy of localized Non-Hodgkin’s lymphoma. Cancer Treatm Rep 61:1129–1136Google Scholar
  294. Cabanillas F et al (1980) IMVP16: An effective regimen for patients with lymphoma who relapsed after initial combination chemotherapy. Blood 60:693–697Google Scholar
  295. Cabanillas F et al (1984) Results of ifosfamide — VP-16 salvage combination for patients with recurrent or refractory aggressive lymphoma. Vortrag 85, 2nd Int. Conf. on Malignant Lymphoma, Lugano, June 13–16Google Scholar
  296. Calvo F et al (1985) Intensive chemotherapy of hairy cell leukemia in patients with aggressive disease. Blood 65:115–119PubMedGoogle Scholar
  297. Canellos GP (1985) Interferon in the treatment of malignant lymphoma. Sem Oncol 12:25–29Google Scholar
  298. Cavalli F (1985) VP-16 in the treatment of malignant lymphomas: A report from the Swiss Group for Clinical Cancer Research (SAKK). Semin Oncol 12 (Suppl 2):33–36PubMedGoogle Scholar
  299. Cheever MA et al (1982) Treatment of hairy cell leukemia with chemo-radio-therapy and identical twin bone-marrow transplantation. N Engl J Med 307:479–481PubMedGoogle Scholar
  300. Claudy AL et al (1982) Treatment of cutaneous T-cell lymphoma with a new aromatic retinoid (RO 10–9359). Arch Dermatol Res 273:37–42PubMedGoogle Scholar
  301. Coleman M (1985) Chemotherapy for large-cell lymphoma: Optimism and caution. Ann Intern Med 103:140–142PubMedGoogle Scholar
  302. Coltman CA et al (1984) Mitoxantrone in refractory non Hodgkin’s lymphoma. A Southwest Oncology Group Study. Semin Oncol [Suppl 1] 11:50–53Google Scholar
  303. Coltman Ca et al (1986) CHOP is curative in thirty percent of patients with diffuse large-cell lymphoma: A twelve year SWOG follow up. Proc ASCO 5:197 (Abstr 774)Google Scholar
  304. Connors JM et al (1985) Treatment of low stage aggressive histology Non-Hodgkin’s lymphoma with 3 cycles of CHOP and involved field radiation (IFRT). Proc ASCO 4:199 (Abstr C-775)Google Scholar
  305. Connors JM, Klimo P (1986) MACOP-B 12 week chemotherapy for lymphoma: update and additional observations. Proc ASCO 5:192 (Abstr 753)Google Scholar
  306. Doberauer C et al (1985) Systemical chemotherapy with etoposide, methotrexate, bleomycin, prednisone and prednimustine in advanced mycosis fun-goides. Blut 51:145 (Abstr 239)Google Scholar
  307. Dragosics B et al (1985) Primary gastrointestinal Non-Hodgkin’s lymphomas. A retrospective clinico-pathologic study of 150 cases. Cancer 55:1060–1073PubMedGoogle Scholar
  308. Ezdinli EZ et al (1980) Nodular mixed lymphocytic-histiocytic lymphoma (NM). Response and survival. Cancer 45:261–267PubMedGoogle Scholar
  309. Ezdinli EZ et al (1980) Moderate versus intensive chemotherapy of prognostically favorable Non-Hodgkin’s lymphoma. A progress report. Cancer 46:29–33PubMedGoogle Scholar
  310. Fisher RI et al (1978) Regression of a T-cell lymphoma after administration of antithymocyte globulin. Ann Intern Med 88:799–800PubMedGoogle Scholar
  311. Fisher RI et al (1983) Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of ProMACE and MOPP chemotherapy. Ann Intern Med 98:304PubMedGoogle Scholar
  312. Fisher RJ et al (1984) Randomized trial of ProMACE-MOPP vs ProMACE-CytaBOM in previously untreated advanced stage, diffuse aggressive lymphomas. Proc ASCO 3:242, C-945Google Scholar
  313. Foon KA et al (1984) Treatment of advanced Non-Hodgkin’s lymphoma with recombinant leucocyte A interferon. New Engl J Med 311:1148–1152PubMedGoogle Scholar
  314. Foon KA et al (1985) Phase II trial of recombinant leukocyte A interferon in patients with advanced chronic lymphocytic leukemia. Am J Med 78:216–220PubMedGoogle Scholar
  315. Foon KA et al (1986) Recombinant leukocyte a interferon therapy for advanced hairy cell leukemia. Therapeutic and immunologic results. Americ J Med 80:351–356Google Scholar
  316. Freeman CR et al (1986) Primary malignant lymphoma of the central nervous system. Cancer 58:1106–1111PubMedGoogle Scholar
  317. French cooperative group on chronic lymphocytic leukaemia (1986) Effectiveness of „CHOP“regimen in advanced untreated chronic lymphocytic leukaemia. Lancet 1:1346–1349Google Scholar
  318. Freund M et al (1983) CNS manifestations in Non-Hodgkin’s lymphomas (NHL). Klin Wschr 61:903–909PubMedGoogle Scholar
  319. Gale RP, Foon KA (1985) Chronic lymphocytic leukemia. Recent advances in biology and treatment. Ann Intern Med 103:101–120PubMedGoogle Scholar
  320. Gastl G et al (1985) Treatment with low dose human recombinant interferon-alpha-2-ARG induces complete remission in patients with hairy cell leukemia. Onkologie 8:143–144PubMedGoogle Scholar
  321. Gastl G et al (1985) Clinical results and mode of action of interferon-alpha in the treatment of hairy cell leukemia. Blut 51:231Google Scholar
  322. Gastl G et al (1986) Minimal and atoxic doses of interferon alpha are clinically effective for the treatment of hairy cell leukemia. Blood (in press)Google Scholar
  323. Gaynor ER, Ultmann JE (1984) Non-Hodgkin’s lymphoma: Management strategies. N Engl J Med 311:1506–1508PubMedGoogle Scholar
  324. Gaynor ER et al (1985) Treatment of diffuse histiocytic lymphoma (DHL) with COMLA (cyclophosphamide, Oncovin, methotrexate, leucovorin, cytosine arabinoside): A 10-year experience in a single institution. J Clin Oncol 3:1596–1604PubMedGoogle Scholar
  325. Glatstein E (1982) Radiation therapy in the treatment of advanced non-Hodgkin’s lymphomas. In Rosenberg SA, HS Kaplan: Malignant lymphomas: Etiology, immunology, pathology, treatment. Academic Press New York, pp 503–512Google Scholar
  326. Glatstein E et al (1977) Combined modality therapy in malignant lymphomas. Cancer Treatm Rep 61:1199–1207Google Scholar
  327. Goldstone AH (1985) Autologous bone marrow transplantation for non-Hodgkin’s lymphomas: The preliminary European experience. In: Autologous bone marrow transplantation (Dicke KA, Spitzer G, Zander AR, eds.), University of Texas, MD Anderson Hospital. pp. 67–74Google Scholar
  328. Golomb HM (1983) Hairy cell leukemia, lessons learned in 25 years. J Clin Oncol 1:652–656PubMedGoogle Scholar
  329. Golomb HM, Ratain MJ, Vardiman JW (1986) Sequential treatment of hairy cell leukemia: A new role for interferon. In: Important advances in oncology (De Vita VD, Hellman S, Rosenberg S, eds) L. B. Lippincott Philadelphia pp. 311–321Google Scholar
  330. Gospodarowicz MK et al (1983) Curability of gastrointestinal lymphoma with combined surgery and radiation. Int J Radiat Oncol Biol Phys 9:3–9PubMedGoogle Scholar
  331. Gospodarowicz MK et al (1984) Prognostic factors in nodular lymphomas: A multivariate analysis based on the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys 10:489–497PubMedGoogle Scholar
  332. Grever MR et al (1983) An investigation of 2’-desoxycoformycin in the treatment of cutaneous T-cell lymphoma. Blood 61:279–282PubMedGoogle Scholar
  333. Grever MR et al (1985) Low-dose desoxycoformycin in lymphoid malignancy. J Clin Oncol 3:1196–1201PubMedGoogle Scholar
  334. Groopman JE (1985) Therapeutic options in hairy-cell leukemia. Semin Oncol 12:30–34PubMedGoogle Scholar
  335. Grouls V (1983) Die Haarzell-Leukämie. Dtsch Ärztebl 80:25–32Google Scholar
  336. Gulati S et al (1985) Update of autologous stem cell transplantation (ASCT) for poor prognosis lymphoma. Proc ASCO 4:209 (Abstr C-814)Google Scholar
  337. Hagberg H et al (1982) Radiation therapy of non-Hodgkin’s lymphoma stages I and II. Acta radiol 21:145–150Google Scholar
  338. Hallahan D et al (1986) Combined modality treatment for tumor stage mycosis fungoides (MF). Proc ASCO 5:198 (Abstr 778)Google Scholar
  339. Hancock BW (1985) Vindesine, Etoposide (VP-16), and Prednisolone (VEP) in relapsed patients with grade II non-Hodgkin’s lymphoma. Semin Oncol [Suppl 2] 12:26–28PubMedGoogle Scholar
  340. Herrmann R et al (1980) Gastrointestinal involvement in Non-Hodgkin’s lymphoma. Cancer 46:215–222PubMedGoogle Scholar
  341. Höffken K et al (1985) Zur Prognose von Non-Hodgkin-Lymphomen. Retrospektive Untersuchung zum Wert der Kiel-Klassifikation und der New Working Formulation an 634 Patienten des Westdeutschen Tumorzentrums Essen. Tumor Diagnostik & Therapie 6:14–19Google Scholar
  342. Hoelzer D et al (1984) Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults. Blood 64:38–47PubMedGoogle Scholar
  343. Honegger HP, Cavalli F (1984) Current status and perspectives in the treatment of non-Hodgkin’s lymphomas. Eur J Cancer Clin Oncol 20:305–314PubMedGoogle Scholar
  344. Horning SJ, Rosenberg SA (1984) The natural history of initially untreated low-grade non-Hodgkin’s lymphomas. N Engl J Med 311:1471–1475PubMedGoogle Scholar
  345. Horning S et al (1985) Human interferon alpha in malignant lymphoma and Hodgkin’s disease. Results of the American Cancer Society trial. Cancer 56:1305–1310PubMedGoogle Scholar
  346. Horwich A, Peckham M (1983) „Bad Risk“ Non-Hodgkin-Lymphomas. Semin Hematol 20:35–56PubMedGoogle Scholar
  347. Jones SE et al (SWOG) (1981) Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma. Cancer 43:417–425Google Scholar
  348. Judson JR, Wiltshaw E (1985) Cis-chlorodiammine platinum (Cisplatinum) and etoposide (VP-16) in malignant lymphoma — an effective salvage regimen. Cancer Chemother Pharmacol 14:258–261PubMedGoogle Scholar
  349. Jungi WF, Kroner Th, Obrecht JP, Burki K, Berchtold W, Cavalli F (1984) Chemotherapy with vindesine, iphosphamide and prednisone (VIP) as treatment for refractory non-Hodgkin’s Lymphoma. 2nd Int. Conference on Malignant Lymphoma. Lugano, June 13–16 (Abstr P91)Google Scholar
  350. Kaminski MS et al (1986) Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy. Ann Intern Med 104:747–756PubMedGoogle Scholar
  351. Kaye F et al (1986) A randomized trial comparing conservative and aggressive therapy in mycosis fungoides. Proc ASCO 5:195 (Abstr 765)Google Scholar
  352. Kehoc JE et al (1985) Value of splenectomy in non-Hodgkin’s lymphoma. Cancer 55:1256–1264Google Scholar
  353. Klimo P, Connors J (1985) MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 102:596–602PubMedGoogle Scholar
  354. Knospe WH (1974) Bi-weekly chlorambucil treatment of CLL. Cancer 33:555–562PubMedGoogle Scholar
  355. König E et al (1979) Efficacy of doxorubicin in prolymphocytic leukaemia. Br J Haematol 42:487–488PubMedGoogle Scholar
  356. Krüger G, Fischer R (1980) Das maligne Non-Hodgkin-Lymphom. Internist 21:483–492PubMedGoogle Scholar
  357. Laurence J et al (1982) Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six drug COP-BLAM regimen. Ann Intern Med 97:190–195PubMedGoogle Scholar
  358. Lennert K (1978) Malignant lymphomas other than Hodgkin’s disease. Springer, Berlin Heidelberg New York. In: Uehlinger E (Hrsg) Handbuch der speziellen pathologischen Anatomie und Histologie, Bd 1, T3BGoogle Scholar
  359. Lennert K, Stein H (1981) Histopathologic der Non-Hodgkin-Lymphome (nach der Kiel-Klassifikation). Springer, BerlinGoogle Scholar
  360. List AF et al (1986) Gastrointestinal (Gl) non-Hodgkin’s lymphoma (NHL). Proc ASCO 5:195 (Abstr 767)Google Scholar
  361. Loeffler JS et al (1985) Primary lymphomas of the central nervous system: Patterns of failure and factors that influence survival. J Clin Oncol 3:490–494PubMedGoogle Scholar
  362. Luce JK et al (1973) Remission induction chemotherapy of malignant lymphoma with bleomycin, cyclophosphamide, vincristin, and prednison. Proc Am Assoc Cancer Res 14:66Google Scholar
  363. Magee MJ et al (1985) Hairy cell leukemia. Durability of response to splenectomy in 26 patients and treatment of relapse with androgens in six patients. Cancer 56:2557–2562PubMedGoogle Scholar
  364. Mahmoud HK et al (1985) Treatment of hairy-cell leukemia with recombinant leukocyte A interferon. Onkologie 8:141–142PubMedGoogle Scholar
  365. Mahrle G et al (1983) Chemotherapie kutaner T-Zell-Lymphome mit Aroti-noid. Dtsch med Wschr 108:1753–1757PubMedGoogle Scholar
  366. Maor MH et al (1984) Non-Hodgkin’s lymphoma. Stages IE and IIE gastric lymphoma. Cancer 54:2330–2337PubMedGoogle Scholar
  367. Mascret B et al (1986) Treatment of malignant lymphomas with high dose of chemo- or chemoradiotherapy and bone marrow transplantation. Eur J Cancer Clin Oncol 22:461–471PubMedGoogle Scholar
  368. McKelvey et al (SWOG) (1976) Hydroxyldaunomycin (ADM) combination chemotherapy in malignant lymphoma. Cancer 38:1484–1493PubMedGoogle Scholar
  369. Meusers P et al (1985) Die Therapie des refraktären Non-Hodgkin-Lym-phoms. Tumor Diagnostik & Therapie 6:87–91Google Scholar
  370. Meusers P et al (1985) Clinical features and therapeutic aspects of a non-Hodgkin lymphoma of intermediate-grade prognosis. Blut 51:147Google Scholar
  371. Meusers P, Zou P, Brittinger G (1986) Non-Hodgkin-Lymphome. Empfehlungen zur standardisierten Tumortherapie. Dtsch Ärztebl 83:2449–2454Google Scholar
  372. Miller RA et al (1983) Monoclonal antibody therapeutic trials in 7 patients with T-cell lymphoma. Blood 62:988–995PubMedGoogle Scholar
  373. Miller RA et al (1982) Treatment of B-cell lymphoma with monoclonal antiidiotype antibody. New Engl J Med 306:517–522PubMedGoogle Scholar
  374. Minna JD et al (1979) Report of the committee on therapy for mycosis fungoides and Sézary syndrome. Cancer Treatm Rep 63:729–736Google Scholar
  375. Montserrat E et al (1985) Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone. Cancer 56:2369–2375PubMedGoogle Scholar
  376. Moxley JH (1974) Intensive combination chemotherapy and x-irradiation in Hodgkin’s disease. Cancer Res 27:1258–1263Google Scholar
  377. Müller-Weihrich S et al (1984) BFM-Studie 1981/83 zur Behandlung hochmaligner Non-Hodgkin-Lymphome bei Kindern: Ergebnisse einer nach histologisch-immunologischem Typ und Ausbreitungsstadium stratifizierten Therapie. Klin Pädiat 196:135–142Google Scholar
  378. Musshoff K (1980) Strahlentherapie der Non-Hodgkin-Lymphome. Internist 21:502–511PubMedGoogle Scholar
  379. Musshoff K, Schmidt-Vollmer H (1975) Prognostic significance of primary site after radiotherapy of non-Hodgkin’s lymphoma. Br J Cancer [Suppl 11] 31:425–434Google Scholar
  380. Musshoff K et al (1975) Prognosis of non-Hodgkin’s lymphomas with special emphasis on the staging classification. Z Krebsforsch 83:323–341Google Scholar
  381. Nakada H et al (1984) A phase II clinical trial of oral VP-16–123 in non-Hodgkin’s lymphoma. 2nd Intern Conference on malignant Lymphoma. Lugano, Switzerland, Juni 1984 (Abstr T93)Google Scholar
  382. Nkrumah FK, Neequaye JE, Biggar R (1985) Intrathecal chemoprophylaxis in the prevention of central nervous system relapse in Burkitt’s lymphoma. Cancer 56:239–242PubMedGoogle Scholar
  383. Norman van AS (1986) Splenectomy for hairy cell leukemia. Cancer 57:644–648PubMedGoogle Scholar
  384. O’Connell MJ et al (1986) Clinical trial of recombinant leukocyte alpha interferon as initial therapy for favorable histology non-Hodgkin’s lymphomas and chronic lymphocytic leukemia. An ECOG pilot study. J Clin Oncol 4:128–136PubMedGoogle Scholar
  385. O’Connell MJ et al (1986) Chemotherapy (CT) followed by consolidation radiation (RT) for stage II non-Hodgkin’s lymphoma (NHL). An ECOG combined modality trial. Proc ASCO 5:191 (Abstr 748)Google Scholar
  386. Paulson S et al (1983) Large cell lymphomas of the stomach: improved prognosis with complete resection of all intrinsic gastrointestinal disease. J Clin Oncol 1:263–269PubMedGoogle Scholar
  387. Pfreundschuh M, Schaadt M, Diehl V (1986) Chemotherapie der Non-Hodgkin-Lymphome (NHL). Internist 27:506–524PubMedGoogle Scholar
  388. Phillips GL et al (1984) Treatment of resistant malignant lymphoma with cyclophosphamide, total body irradiation, and transplantation of cryopre-served autologous marrow. N Engl J Med 310:1557–1561PubMedGoogle Scholar
  389. Phillips GL et al (1986) High dose chemotherapy, fractioned total-body irradiation, and allogeneic marrow transplantation for malignant lymphoma. J Clin Oncol 4:480–488PubMedGoogle Scholar
  390. Plaumann L (1983) Die Hannover-Marburg-Stuttgart-Studie: Ergebnisse der multizentrischen Studie über die Therapie unvorbehandelter Non-Hodgkin-Lymphome hoher Malignität. Symposium der Arbeitsgemeinschaften für Internistische und Radiotherapeutische Onkologie der Deutschen Krebsgesellschaft e.V., Hahnenklee/Harz, 10.–12. 2. 1983Google Scholar
  391. Portlock CS (1980) Management of the indolent non-Hodgkin’s lymphomas. Semin Oncol 7:292–301PubMedGoogle Scholar
  392. Portlock CS (1983) „Good risk“ Non-Hodgkin-Lymphomas: Approaches to management. Semin Hematol 20:25–34PubMedGoogle Scholar
  393. Portlock C et al (1986) Pulse chlorambucil and the value of gallium scanning in advanced low grade non-Hodgkin’s lymphomas. Proc ASCO 5:198 (Abstr 777)Google Scholar
  394. Porzsolt F (1986) Primary treatment of hairy cell leukemia: Should IFN-therapy replace splenectomy? Blut 52:265–272PubMedGoogle Scholar
  395. Quesada JR et al (1984) Treatment of hairy cell leukemia with alpha-interferon. Proc ASCO 3:207 C-806Google Scholar
  396. Rai KR (1975) Clinical staging of chronic lymphocytic leukemia. Blood 46:219–234PubMedGoogle Scholar
  397. Ratain MJ et al (1985) Treatment of hairy cell leukemia with recombinant alpha interferon. Blood 65:644–648PubMedGoogle Scholar
  398. Reiss HE et al (1975) Die primär-extranodale Magenmanifestation der Lympho- und Retikulosarkome. Z Krebsforsch 83:105 ffGoogle Scholar
  399. Riddel S et al (1986) Response of Waldenstrom’s macroglobulineamia to pentostatin (2’-desoxycoformycin). Cancer Treat Rep 70:546–548Google Scholar
  400. Rosenberg SA (1985) The low grade non-Hodgkin’s lymphomas: Challenges and opportunities. J Clin Oncol 3:299–310PubMedGoogle Scholar
  401. Roth S et al (1984) Primär extranodale Non-Hodgkin-Lymphome. Eine retrospektive Untersuchung von 529 Einzelkasuistiken aus Köln und aus der Literatur. In: Diehl V, Sack H (Hrsg) Diagnostik und Therapie der Non-Hodgkin-Lymphome. Zuckschwerdt, München Bern Wien. Aktuelle Onkologie Bd 12:138–177Google Scholar
  402. Rühl U (1980) Die Strahlentherapie der Non-Hodgkin-Lymphome. MMW 44:1533 ffGoogle Scholar
  403. Sawitsky A et al (1977) Comparison of daily versus intermittend chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. Blood 50:1049–1059PubMedGoogle Scholar
  404. Schwarze EW (1984) Primär extranodale Non-Hodgkin-Lymphome. Ihre bevorzugte Lokalisation, Histopathologic und Pathogenese. In: Diehl V, Sack H (Hrsg) Diagnostik und Therapie der Non-Hodgkin-Lymphome. Zuckschwerdt, München Bern Wien. Aktuelle Onkologie 12:131–138Google Scholar
  405. Sheridan WP et al (1985) Non-Hodgkin’s lymphoma of the stomach: A prospective pilot study of surgery plus chemotherapy in early and advanced disease. J Clin Oncol 3:495–500PubMedGoogle Scholar
  406. Shipp M et al (1985) M-BACOD and m-BACOD in the treatment of unfavorable prognosis lymphoma: Analysis of prognostic variables. Proc ASCO 4:205 (Abstr C-799)Google Scholar
  407. Shipp MA et al (1986) Long-term survival of large cell lymphoma patients treated with m- or M-BACOD: Identification of major prognostic subgroups. Proc ASCO 5:193 (Abstr 758)Google Scholar
  408. Shipp MA et al (1986) Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med 104:757–765PubMedGoogle Scholar
  409. Sibbald R, Catowsky D (1979) Complete remission in prolymphocytic leukaemia with the combination chemotherapy CHOP. Br J Haematol 42:488–490PubMedGoogle Scholar
  410. Siegert W et al (1982) Treatment of non-Hodgkin’s lymphoma of low-grade malignancy with human fibroblast interferon. Anticancer Res 2:193–198PubMedGoogle Scholar
  411. Siegert W et al (1985) Non-Hodgkin’s lymphomas presenting with gastrointestinal involvement. Klin Wochenschr 63:55–61Google Scholar
  412. Skarin AT (1977) High dose methotrexate with folic acid in the treatment of advanced Non-Hodgkin-Lymphomas including CNS-involvement. Blood 50:1039–1047PubMedGoogle Scholar
  413. Slater DE et al (1986) Lymphoblastic lymphoma in adults. J Clin Oncol 4:57–67PubMedGoogle Scholar
  414. Spitzer G et al (1984) High-dose chemotherapy with autologous bone marrow transplantation. Cancer 54:1216–1225PubMedGoogle Scholar
  415. Stacher A, Häcker (Hrsg) (1979) Lymphknotentumoren. Urban & Schwar-zenberg, München Wien BaltimoreGoogle Scholar
  416. Sullivan MP, Ramirez J (1985) Curability of Burkitt’s lymphoma with high-dose cyclophosphamide-high dose methotrexate therapy and intrathecal chemoprophylaxis. J Clin Oncol 3:627–636PubMedGoogle Scholar
  417. Sutcliffe SB et al (1985) Role of radiation therapy in localized non-Hodgkin’s lymphoma. Radiation Oncology 4:211–223Google Scholar
  418. Sweet et al (1980) Cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabin (COMLA) combination sequential chemotherapy for advanced diffuse histiocytic lymphoma. Ann Intern Med 92:785–790PubMedGoogle Scholar
  419. Takvorian T et al (1985) Autologous bone marrow transplantation (ABMTx) in B-cell malignancy: anti-B1 monoclonal antibody treated autologous bone marrow. Proc ASCO 4:204 (Abstr C-795)Google Scholar
  420. Theml H (1985) Maligne Non-Hodgkin-Lymphome. Klinische Hämatologie 3. Aufl. (Begemann H, Rastetter J, Hrsg.) Thieme Stuttgart-New York 678–755Google Scholar
  421. Theml H, Ziegler-Heitbrock HWL (1984) Management of CLL and allied disorders with reference to their immunology and proliferation kinetics. In: Leukemia. Recent developments in diagnosis and therapy. Thiel E, Thierfelder S (Hrsg.). Recent results in cancer research, Vol XCIII, Springer, Berlin, pp 240–258Google Scholar
  422. The Non-Hodgkin’s Lymphoma Pathologic Classification Project (1982) National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas: Summary and description of a working formulation for clinical usage. Cancer 49:2112–2135Google Scholar
  423. Thompson JA et al (1985) Recombinant alpha-2 interferon in the treatment of hairy cell leukemia. Cancer Treat Rep 69:791–793PubMedGoogle Scholar
  424. Tirelli U et al (1984) A pilot study with VP-16 and prednimustine in elderly patients with non-Hodgkin’s lymphoma (NHL): Preliminary results. 2nd Inter Conf on Malignant Lymphoma, June 13–16, 1984, Lugano, Switzerland, Abstr T94, p24Google Scholar
  425. Todd MB et al (1986) Prognostic indicators in diffuse large-cell (histiocytic) lymphoma. Int J Radiat Oncol Biol Phys 12:593–601PubMedGoogle Scholar
  426. Tubiana M et al (1986) Prognostic factors in non-Hodgkin’s lymphoma. Int J Radiation Oncology Biol Phys 12:503–514Google Scholar
  427. Urba WJ, Longo DL (1985) Cytologic, immunologic, and clinical diversity in non-Hodgkin’s lymphoma: Therapeutic implications. Semin Oncol 12:250–267PubMedGoogle Scholar
  428. Wannenmacher M, E Pfannmüller (1986) Radiotherapie der Non-Hodgkin-Lymphome. Internist 27:498–505PubMedGoogle Scholar
  429. Warrell RP Jr et al (1983) Isoretinoid in cutaneous T-cell lymphoma. Lancet 2:629 ffPubMedGoogle Scholar
  430. Weick J et al (1985) Radiation therapy with and without chemotherapy in limited stage (I, IE, II, IIE) non-Hodgkin’s lymphoma (NHL): A Southwest Oncology Group study. Proc ASCO 4:206 (Abstr C-804)Google Scholar
  431. Winkler CHF et al (1986) Combined modality treatment of cutaneous T cell lymphoma: results of a 6 year follow-up. J Clin Oncol 4:1094–1100PubMedGoogle Scholar
  432. Wintrobe et al (1974) Clinical hematology. 7th ed., Lea & Febinger, Philadelphia, p 1529Google Scholar
  433. Worman CP et al (1985) Treatment of hairy-cell leukaemia (HCL) with alpha interferon: British results. Blut 51:231Google Scholar
  434. Ziegler JL et al (1978) Combined modality treatment of Burkitt’s lymphoma. Cancer Treatm Rep 62:2031–2034Google Scholar
  435. Bamberg M et al (1979) Malignant progression of angioimmunoblastic lymphadenopathy. J Cancer Res Clin Oncol 93:255–264PubMedGoogle Scholar
  436. Bergholz C et al (1979) Angioimmunoblastic lymphadenopathy and persistent virus infection? Discussion of immunohistological findings in 2 cases. Klin Wochenschr 57:1317–1321PubMedGoogle Scholar
  437. Blumenfeld W et al (1983) AILD in homosexual men with acquired immune definciency syndrome. Arch Pathol Lab Med 107:567–569PubMedGoogle Scholar
  438. Bluming AZ (1979) AILD, a pathogenic link between physiologic lymphoid proliferation and malignant lymphoma. Am J Med 67:421–428PubMedGoogle Scholar
  439. Donhuijsen K et al (1980) Angioimmunoblastische Lymphadenopathie mit Entwicklung eines malignen Lymphoms. Zbl allg Pathol u pathol Arch 124:314–324Google Scholar
  440. Dorfmann RF, Warnke R (1975) Hum Pathol 5:519–550Google Scholar
  441. Ershler WB et al (1983) Immunoblastic lymphadenopathy: failure of, rather than lack of immunoregulation. J Med 14:81–94PubMedGoogle Scholar
  442. Frizzera G et al (1974) Angio-immunoblastic lymphadenopathy with dysproteinemia. Lancet 1:1070–1073PubMedGoogle Scholar
  443. Garam T et al (1981) Angioimmunoblastic lymphadenopathy: a study of lymphocyte populations. Cancer 47:2850–2855PubMedGoogle Scholar
  444. Klajman A et al (1981) AILD: a T- and B-cell disorder. Cancer 48:2433–2437PubMedGoogle Scholar
  445. Krüger GRF et al (1979) Rubella virus antigen in lymphocytes of patients with Angioimmunoblastic lymphadenopathy. J Cancer Res Clin Onc 95:87–91Google Scholar
  446. Lennert K, Knecht H (1981) Dtsch Ärztebl 13:601–605Google Scholar
  447. Lukes RJ, Tindle N (1975) Immunoblastic lymphadenopathy. A hyperimmune entity resembling Hodgkin’s disease. N Engl J Med 292:1–3PubMedGoogle Scholar
  448. Nathwani BN et al (1978) Malignant lymphoma arising in angioimmunoblastic lymphadenopathy. Cancer 41:578–606PubMedGoogle Scholar
  449. Sohrt J, Römeling R von, Schmoll HJ, Peter HH, Freund M, Vykoupil H, Poliwoda H (1985) Angioimmunoblastic lymphadenopathy: Clinical course, immunological characteristics and treatment results in 24 patients. Proc Second Int Conference on Malignant Lymphoma, Lugano, Abstract No 99, p 68Google Scholar
  450. Radaszkiewicz T, Lennert K (1975) Lymphogranulomatosis X. Dtsch Med Wschr 100:1157–1163PubMedGoogle Scholar
  451. Yatanagas X, Papadimitriou C, (1977) Angioimmunoblastic lymphadenopathy terminating as Hodgkin’s disease. Cancer 39:2183–2189Google Scholar
  452. Ahre A, Björkholm M et al (1984) Human leucocyte interferon and intermittent high-dose melphalan-prednisone administration in the treatment of multiple myeloma: A randomised clinical trial from the myeloma group of central Sweden. Cancer Treat Rep 68:1331–1338PubMedGoogle Scholar
  453. Alberts DS, Balcerzak SP, Bonnet JD, Stephens RL (1985) Phase II Trial of Mitoxantrone in Multiple Myeloma: A Southwest Oncology Group Study. Cancer Treat Rep 69:1321–1323PubMedGoogle Scholar
  454. Alberts DS, Chang SY, Chen HSG, Evans TL, Moon TE (1979) Oral melphalan kinetics. Clin Pharmacol Ther 26:737–745PubMedGoogle Scholar
  455. Alexanian R, Dreicer R (1984) Chemotherapy for multiple myeloma. Cancer 53:583–588PubMedGoogle Scholar
  456. Alexanian R, Barlogie B, Dixon D (1986) Update of VAD for resistant multiple myeloma. Proc Am Soc Clin Oncol 5:653Google Scholar
  457. Alexanian R, Haut A et al (1969) Treatment for multiple myeloma-combination chemotherapy with different melphalan dose regimes. JAMA 208:1680–1685PubMedGoogle Scholar
  458. Alexanian R, Salmon S et al (1981) Chemoimmunotherapy for multiple myeloma. Cancer 47:1923–1929PubMedGoogle Scholar
  459. Barlogie B, Smith L, Alexanian R (1984) Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 310:1353–1356PubMedGoogle Scholar
  460. Barlogie B, Alexanian R, Dicke KA, Spitzer G, Zander A (1986) High dose melphalan and autologous bone marrow transplantation for refractory myeloma. Proc Am Soc Clin Oncol: 650Google Scholar
  461. Bataille R, Durie BGM, Grenier J, Sany J (1986) Prognostic factors and staging in multiple myeloma: A reappraisal. J Clin Oncol 4:80–87PubMedGoogle Scholar
  462. Belch A, White D, Bergsagel D, Wilson K, Shelley W (1984) The role of maintenance chemotherapy for multiple myeloma. Proc Am Soc Clin Oncol: C-1050Google Scholar
  463. Bergsagel DE (1985) Controversies in the treatment of plasma cell myeloma. Postgrad Med J 61:109–116PubMedGoogle Scholar
  464. Berinstein N, Blend R, Huthcheon M, Bergsagel D (1984) Pulmonary complications in multiple myeloma. Proc Am Soc Clin Oncol: C-386Google Scholar
  465. Björkholm M (1982) Daily low dose interferon versus intermittent high dose melphalane/prednisone treatment in multiple myeloma. Proc ASCO 1: 242Google Scholar
  466. Bonnet J, Alexanian R, Salmon S, Bottomley R, Amare M, Haut A, Dixon D (1982) Vincristine, BCNU, Doxorubicin and Prednisone (VBAP) combination in treatment of relapsing or resistant multiple myeloma: a southwest oncology group study. Cancer Treat Rep 66:1267–1271PubMedGoogle Scholar
  467. Bosanquet AG, Silby (1984) Effect of Food on Melphalan Absorption. Cancer Chemother Pharmacol 12:183–186PubMedGoogle Scholar
  468. Brandes LJ, Israels LG (1982) Treatment of advanced plasma cell myeloma with weekly cyclophosphamide and alternate-day prednisone. Cancer Treat Rep 66:1413–1415PubMedGoogle Scholar
  469. Case DC, Lee BJ, Clarkson BD (1977) Improved survival in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, and BCNU. Am J Med 63:897–906PubMedGoogle Scholar
  470. Case DC, Sonneborn HL, Pausi SD, Hayes DM, Dorsk BM, Carroll RJ, Bove L (1985) Combination chemotherapy for multiple myeloma with BCNU, Cyclophosphamide, Vincristin, Melphalan and Prednisone (M-2 Protocol). Oncology 42:137–140PubMedGoogle Scholar
  471. Chak, Boswick DG, Creger WP (1984) Clinical history of patients with solitary plasmacytoma of bone (SPB). Proc Am Soc Clin Oncol 3: C-1054Google Scholar
  472. Christen C, Gregory SA, Knospe WH (1984) Anaplastic extramedullary myeloma. Proc Am Soc Clin Oncol 3: C-1051Google Scholar
  473. Christopherson WM, Miller AJ (1950) A re-evaluation of solitary plasmaceli myeloma of bone. Cancer 3:240–252Google Scholar
  474. Cohen HJ, Bartolucci A (1985) Age and the treatment of multiple myeloma. Am J Med 79:316–324PubMedGoogle Scholar
  475. Cohen HJ, Bartolucci A, et al (1986) Consolidation and Maintenance Therapy in Multipe Myeloma: Randomised Comparison of a New Approach. J Clin Oncol 4:888–899PubMedGoogle Scholar
  476. Cornwell GG, III, Pajak TF, McIntire OR, Knochwa S, Dosik H (1982) Influence of renal failure on myelosuppressive effects of melphalan: cancer and leukemia group B experience. Cancer Treat Rep 66:475–481PubMedGoogle Scholar
  477. Durie B, Salmon SE (1975) A clinical staging system for multiple myeloma. Cancer 36:842–854PubMedGoogle Scholar
  478. Durie GM et al (1986) Improved Survival Duration With Combination Chemotherapy Induction for Multiple Myeloma: A Southwest Oncology Group Study. J Clin Oncol 4:1227–1237PubMedGoogle Scholar
  479. Fish V, Rabinowitz L (1983) Solitary plasma cell tumors of bone and soft tissue. Natural history and response to therapy. Proc ASCO 2:243Google Scholar
  480. Garewal H et al (1984) Serum beta2-microglobulin in the initial staging and subsequent monitoring of monoclonal plasma cell disorders. J Clin Oncol 2:51–57PubMedGoogle Scholar
  481. Gupta V, Rajaraman S, Thomson BB, Costanzi JJ: (1986) Establishment and characterization of serially transplantable human myeloma cells in nude mice. Proc Am Soc Clin Oncol 5:88Google Scholar
  482. Gockermann JP et al (1986) Phase II Evaluation of Etoposide in Refractory Multiple Myeloma: A Southeastern Study Group Trial. Cancer Treat Rep 70, 6:801–802Google Scholar
  483. Harlex JB, Pajak TF, McIntyre OR (1979) Improved survival of increased risk myeloma patients on combined triple-alkylating agent therapy: A study of the CALGB. Blood 54:13–22Google Scholar
  484. Ho AD, Wittkam S, Theml H, Keilholz U, Hunstein W (1986) Ergebnisse mit dem M2-Protokoll beim Plasmozytom. Dtsch med Wschr 111:858–861PubMedGoogle Scholar
  485. Illiger HJ, Hartlapp H, Schmidt RE (1984) Ergebnisse der oralen und intravenösen Melphalantherapie bei Patienten mit multiplem Myelom. Tumor-Diagnostik & Therapie 5:182–185Google Scholar
  486. Jackson DV, Case LD, Pope EK, et al (1985) Single agent vincristine by infusion in refractory multiple myeloma. J Clin Oncol 3:1508–1512PubMedGoogle Scholar
  487. Kyle RA (1984) Treatment of multiple myeloma. N Engl J Med 1382–1383Google Scholar
  488. Lee BJ, Sahakion G, Clarkson BD et al (1974) Proceedings: Combination chemotherapy of multiple myeloma with alkeran, Cytoxan, vincristine, prednisone, and BCNU. Cancer 33:533–538PubMedGoogle Scholar
  489. Leile van der H, Monasche ED, Pegels HG, Albert EG, Borne von dem KR (1986) Vindesine in refractory multiple myeloma. Cancer 57:226–229Google Scholar
  490. Lenhard RE, Oken MM, Barness JM, Humphrey RL, Glick JH, Silverstein MN (1984) High dose cyclophosphamide. An effective treatment for advanced refractory multiple myeloma. Cancer 53:1456–1460PubMedGoogle Scholar
  491. Lewis JP, MacKenzie MR (1984) Multiple Myeloma is associated with nonrandom chromosomal abnormalities. Proc Am Soc Clin Oncol 3: C-36Google Scholar
  492. McIntire OR, Paja TF, Kyle RA, Cornwell GG, Leone L: (1985) Response rate and survival in myeloma patients receiving prednisone alone. Med and Ped Oncol 13:239–243Google Scholar
  493. Medical research council’s working party on leukaemia in adults (1980) Treatment comparisons in the third MRC myelomatosis trial. Brit J Cancer 42:823–830Google Scholar
  494. Mellstedt J, Björkholm M, Joannsson B et al (1979) Interferon therapy in myelomatosis. Lancet 1:245–248PubMedGoogle Scholar
  495. Morstyn G, Geraldine P et al (1984) Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: Heterogeneity of tumor responsiveness. Cancer Treat Rep 68:1439–1446PubMedGoogle Scholar
  496. Niell HB, Palmierie GMA, Sebes JI, Neely CL, West SK (1984) The postabsorptive hydroxyproline in the long term follow up of patients with multiple myeloma. Proc Am Soc Clin Oncol 3: C-9Google Scholar
  497. Ohno R et al (1985) Treatment of plasma cell neoplasm with recombinant leucocyte A interferon and human lymphoblastoid interferon. Cancer Chemother Pharmacol 14:34–37PubMedGoogle Scholar
  498. Oken MM, Kyle RA et al (1985) A phase II trial of interferon Alpha2 (rIFNaa) in the treatment of resistant multiple myeloma. Proc ASCO 4:215Google Scholar
  499. Oken MM, Tsiatis A, Abramson N, Glick J (1984) Comparison of standard (MP) with intensive (VBMCP) therapy for the treatment of multiple myeloma (MM). Proc Am Soc Clin Oncol 3: C-1055Google Scholar
  500. Osborn C, Perrotta A (1986) Results with the M-2 Protocol (Vincristine, Cyclophosphamide, Melphalan, BCNU and Prednisone) (VCMBP) in multiple Myeloma: Impact of renal failure on response and survival. Proc Am Soc Clin Oncol 5:584Google Scholar
  501. Pavlovsky S, Saslavsky J, Pinto MT et al (1984) A randomized trial of melphalan and prednisone versus melphalan, prednisone, cyclophosphamide, MeCCNU and vincristine in untreated multiple myeloma. J Clin Oncol 2:836–840PubMedGoogle Scholar
  502. Peest D, Schmoll HJ, Schedel I, Deicher H, Boll J, Essers U, Gamm H, Glück S, et al (1986) Current Results of a Multicenter Trial in Multiple Myeloma. Onkologie 3:168–169Google Scholar
  503. Perren TJ, Selby PJ, Mbidde EK, Malpas JS, McElwain TJ (1986) High dose chemotherapy of multiple myeloma (MM) with Melphalan (HDM) and with methyl prednisone (HDMP). Proc Am Soc Clin Oncol 5:619Google Scholar
  504. Salmon SE, Haut A, Bonnet JD, Amare M, Weick JK, Durie BGM, Dixon DO (1983) Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 1:453–461PubMedGoogle Scholar
  505. Sayegh A, Al-Mondhiry H, Bartholomew M (1986) Comparison of two combination chemotherapy regimens in advanced multiple myeloma. Proc Am Soc Clin Oncol 5:644Google Scholar
  506. Schedel I (1986) Application of immunoglobulin preparations in multiple myeloma. In: Clinical Use of Immunoglobulins, Nydegger E, Barrandun S (ED), Accamedic Press, London, pp 123–132Google Scholar
  507. Skoryna SC, Prchal JF (1984) Rationale for adjuvant stable strontium therapy for bone lesions associated with multiple myeloma. Proc Am Soc Clin Oncol 3: C-1045Google Scholar
  508. Smith J, Alghren J, Ferraresi R et al (1984) Treatment of multiple solitary plasmocytomas with alpha-2-IFN recombinant DNA (Intron). Proc ASCO 3:270Google Scholar
  509. Smith L, Hall R, Pershous M, Alexanian R, Barlogie B (1984) Quiescent cells in S Phase-A cytokinetic sanctuary in myeloma. Proc Am Soc Clin Oncol 3: C-41Google Scholar
  510. Tobias JS, Richards JDM, Blackman GM, Joannides T, Trask CWL, Nathan JI (1985) Hemibody irradiation in multiple myelome. Radiother. Oncol 3:11–16Google Scholar
  511. Tsiatis A, Abramson N, Gleik J (1984) Comparison of standard (MP) with intensive (VBMCP) therapy for the treatment of multiple myeloma. Proc ASCO 3:270Google Scholar
  512. Uhm K, Camacho FJ, Bennett JM, Glick JH, Oken MM (1984) Phase II trial of vindesine (VDS) in patients with previously treated multiple myeloma. Proc Am Soc Clin Oncol 3: C-1048Google Scholar
  513. Wasserman TH, Trenker D, Scharnhorst K, Holland J (1986) Solitary plasmocytomas (SP): Response to radiation (XRT) and progression to multiple myeloma (MM). Proc Am Soc Clin Oncol 5:587Google Scholar
  514. American Joint Committee on Cancer (1983) Manual for staging of cancer J. B. Lippincott Comp. Philadelphia. Sec. ed.Google Scholar
  515. Armand JP et al (1984) Phase III chemotherapy comparing F AC vs FEC in advanced breast cancer. Preliminary results. Proc ASCO 3:118, C-460Google Scholar
  516. Ashford RFU et al (1984) Conservative excision and radiotherapy for early breast cancer — an acceptable alternative? Clin Oncol 10:45–58PubMedGoogle Scholar
  517. Australian and New Zealand Cancer Trials Group, Clinical Oncological Society of Australia (1986) A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially as in combination. J Clin Oncol 4:186–195Google Scholar
  518. Baral E, Ogenstach S, Wallgren A (1985) The effect of adjuvant radiotherapy on the time of occurence and prognosis of local recurrence in primary operable breast cancer. Cancer 56:2779–2782PubMedGoogle Scholar
  519. Bennett JM et al (1985) A randomized multicenter trial of cyclophosphamide, novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, adriamycin, 5-fluorouracil (CAF) in patients with metastatic breast cancer. Proc ASCO 4:26, C-493Google Scholar
  520. Blumenschein GR (1984) The role of progestins in the treatment of cancer. Semin Oncol [Suppl 4] 10:7–10Google Scholar
  521. Bonadonna G, Valagussa P (1985) Adjuvant systemic therapy of resectable breast cancer. J Clin Oncol 3:259–275PubMedGoogle Scholar
  522. Bonadonna G et al (1986) Adjuvant CMF in node negative breast cancer (Abstr. 290) Proc ASCO 5:74Google Scholar
  523. Brambilla C et al (1976) Response and survival in advanced breast cancer. Br Med J 1:801–804PubMedGoogle Scholar
  524. Brambilla C et al (1986) Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treat Rep 70:261–266PubMedGoogle Scholar
  525. Bruning PF et al (1985) Low dose aminoglutethimide without hydrocortisone in advanced postmenopausal breast cancer. Proc 3rd Eur Conf on Clin Oncol Stockholm, June 16–20 Abstr 611Google Scholar
  526. Brunner KW (1983) Stand der Chemotherapie beim metastasierenden Mammakarzinom. In: Kubli, Nagel, Kadach, Kaufmann (Hrsg) Neue Wege in der Brustkrebserkrankung. Zuckschwerdt, München. Aktuelle Onkologie Bd 8: 197–216Google Scholar
  527. Buchanan RB et al (1985) Tamoxifen versus surgical oophorectomy in premenopausal women with advanced breast cancer. Proc ASCO 4:59, C-227Google Scholar
  528. Cancer Research Campaign Working Party (King’s Cambridge) (1980) Trial of early breast cancer. A detailed update at the tenth year. Lancet II: 55–60Google Scholar
  529. Canellos GP et al (1974) Cyclical combination chemotherapy for advanced breast carcinoma. Br Med J 1:218–220PubMedGoogle Scholar
  530. Cavalli F et al (1983) Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer: Report of the Swiss group for Clinical Cancer Research. Br Med J 286: 5ff.Google Scholar
  531. Cobleigh MA et al (1981) Phase II study of vindesine in patients with metastatic breast cancer. Cancer Treat Rep 65: 659–663PubMedGoogle Scholar
  532. De Jager R et al (1982): Phase-II clinical trial of mitoxantrone in solid tumours and lymphomas. Proc ASCO 1:89Google Scholar
  533. Durand JC et al (1984) Wide excision of the tumor, axillary dissection and postoperative radiotherapy as treatment of small breast cancer. Cancer 53:2439–2443PubMedGoogle Scholar
  534. Ege GN, Elhakim T (1984) The relevance of internal mammary lymphoscintigraphy in the management of breast carcinoma. J Clin Oncol 2:774–781PubMedGoogle Scholar
  535. Ehninger G et al (1984) Mitoxantrone and cyclophosphamide in patients with advanced breast cancer. Cancer Treat Rep 68:1283–1284PubMedGoogle Scholar
  536. Ehrlichman C et al (1984) Male breast cancer: A 13 year review of 89 patients. J Clin Oncol 2:903–909Google Scholar
  537. Estevez RA et al (1985) Teniposide (VM 26) plus mitomycin C (C) in multitreated breast cancer adriamycin resistent patients. Proc ASCO 4:75, C-287Google Scholar
  538. Fisher ER et al (1975) The pathology of breast cancer: A syllabus derived from findings of the National Surgical Adjuvant Breast Project (Protocol 4). Cancer 36:1–85PubMedGoogle Scholar
  539. Fisher B et al (1985 a) Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 312:665–673PubMedGoogle Scholar
  540. Fisher B et al (1985 b) Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 312:674–681PubMedGoogle Scholar
  541. Fisher B et al (1986) Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project trial. J Clin Oncol 4: 459–471PubMedGoogle Scholar
  542. Fisher B et al (1986) Ten-year results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trial evaluating the use of L-phenylalanine nustard (L-PAM) in the management of primary breast cancer. J Clin Oncol 4: 929–941PubMedGoogle Scholar
  543. Goldhirsch A (Ludwig Breast Cancer Study Group) (1985): Randomized trial of chemo-endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis. Lancet I: 1256–1260Google Scholar
  544. Gutterman JU et al (1976) Chemoimmunotherapy of advanced breast cancer: Prolongation of remission and survival with BCG. Br Med J 11:1222–1225Google Scholar
  545. Harris JR, Hellman S, Kinne DW (1985), Limited surgery and radiotherapy for early breast cancer. N Engl J Med 313:1365–1368PubMedGoogle Scholar
  546. Harris AL et al (1985) Low dose aminoglutethimide (AG) (125 mg 2 × daily) plus replacement dose hydrocortisone (HC) in advanced postmenopausal breast cancer. Proc 3rd Eur Conf on Clin Oncol Stockholm, June 16–20 1985 (Abstr 612)Google Scholar
  547. Henderson JC (1984) Chemotherapy for advanced breast cancer. In: Bonadonna G (ed) Breast cancer: Diagnosis and management. Wiley & Sons, Chichester, pp 247–280Google Scholar
  548. Henderson JC (1985) Adjuvant chemotherapy of breast cancer: A promising experience or standard practice? J Clin Oncol 3:140–143PubMedGoogle Scholar
  549. Höffken K (1986) Aktuelle Aspekte der Hormontherapie des Mammakarzinoms. Ergebnisse der Internistischen Onkologie 1 (Höffken K, CG Schmidt; Hrgb.) Enke StuttgartGoogle Scholar
  550. Höffken K et al (1986) Low dose aminoglutethimide (AG) in the treatment of postmenopausal patients with advanced breast cancer (Abstr. 215). Proc ASCO 5:56Google Scholar
  551. Høost H, Brennhovd JO Loeb M (1986) Postoperative radiotherapy in breast cancer-Long-term results from the Oslo study. Int J Radiation Oncol Biol Phys 12:727–732Google Scholar
  552. Hortobagyi GN (1985) Mitomycin-C in breast cancer. Semin Oncol 12 (Suppl 6): 65–70PubMedGoogle Scholar
  553. Ingle JN et al (1986) Randomized trial of bilateral Ophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 4:178–185PubMedGoogle Scholar
  554. Ingle IN et al (1986) Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer. J Clin Oncol 4:958–964PubMedGoogle Scholar
  555. Kurtz JM et al (1984) Radiation therapy after breast-conserving surgery for stage I and II mammary carcinoma. Results of the Marseille experience 1961–1976. Strahlentherapie 160:239–243PubMedGoogle Scholar
  556. Lenaz L (1985) Mitomycin C in advanced breast cancer. Cancer Treat Rev 12:235–249PubMedGoogle Scholar
  557. Lippman ME (1984) Antiestrogen therapy of breast cancer. Semin Oncol [Suppl 4] 10:11–19Google Scholar
  558. Margreiter R, Wiegele J (1984) Tamoxifen (Nolvadex) for premenopausal patients with advanced breast cancer. Breast Cancer Res Treatm 4:45–48Google Scholar
  559. Mattson W et al (1982). A weekly schedule of low dose doxorubicin in the treatment of advanced breast cancer. Clinical Therap 5:193–203Google Scholar
  560. Mortimer J et al (1985) Aggressive adriamycin-containing regimen (PM-FAC) in estrogen receptor-negative disseminated breast cancer. Cancer 56:2376–2380PubMedGoogle Scholar
  561. Mouridsen HT (1986) Prednimustine in advanced breast cancer: a review. Semin Oncol 13 (Suppl 1): 27–31PubMedGoogle Scholar
  562. Neidhardt JA et al (1986) A comparison of mitoxantrone and doxorubicine in breast cancer. J Clin Oncol 4:672–677Google Scholar
  563. Osborne MP et al (1984) Breast conservation in the treatment of early breast cancer. A 20-year follow up. Cancer 53:349–355PubMedGoogle Scholar
  564. Pasterz RB et al (1985) Mitomycin in metastatic breast cancer refractory to hormonal and combination chemotherapy. Cancer 56:2381–2384PubMedGoogle Scholar
  565. Patel JK et al (1986) Does more intense palliative treatment improve overall survival in metastatic breast cancer patients? Cancer 57:567–570PubMedGoogle Scholar
  566. Patey DH et al (1948) The prognosis of carcinoma of the breast in relation of the type of operation performed. Br J Cancer 2:7–13PubMedGoogle Scholar
  567. Planting AST, Alexieva-Figusch J et al (1985) Tamoxifen therapy in premenopausal women with metastatic breast cancer. Cancer Treat Rep 69:363–368PubMedGoogle Scholar
  568. Powles TJ (1984) The role of aromatase inhibitors in breast cancer. Semin Oncol [Suppl 4] 10:20–24Google Scholar
  569. Pritchard K et al (1985) The role and mechanism of action of tamoxifen in premenopausal women with metastatic carcinoma of the breast: an update. Proc ASCO 4:54, C-206Google Scholar
  570. Ribeiro G et al (1983) Adjuvant tamoxifen for operable carcinoma of the breast: report of clinical trial by the Christie Hospital and Holt Radium Institute. Br Med J 286:827Google Scholar
  571. Rose C et al (1985) Beneficial treatment of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet 1:16–19PubMedGoogle Scholar
  572. Rose C et al (1986) Combined endocrine treatment of postmenopausal patients with advanced breast cancer (Abstr. 247). Proc ASCO 5:64Google Scholar
  573. Rosner D, Nemoto T (1986) Investigation for a second and third line rescue chemotherapy in metastatic breast cancer. (Abstr. 222) Proc ASCO: 5–57Google Scholar
  574. Rossi A et al (1981) Multimodal therapy in the operable breast cancer: Five-years results of the CMF-programme. Br Med J 282:1427–1431Google Scholar
  575. Rubens RD, Knight RK (1985) The contribution of prednisolone (P) to primary endocrine therapy (PET) in advanced breast cancer. Proc ASCO 4: C-202Google Scholar
  576. Sarrazin D et al (1984) Conservative treatment versus mastectomy in breast cancer tumors with macroscopic diameter 20 mm or less. The experience of the Institute Gustave-Roussy. Cancer 53:1209–1213PubMedGoogle Scholar
  577. Savka CA et al (1986) Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma. Cancer Research 46:3152–3156Google Scholar
  578. Seeber S (1985) Chemotherapieresistenz beim Mammakarzinom. Beitr Onkol 22:102–111Google Scholar
  579. Senn HF et al (1978) Adjuvant chemoimmuno-therapy with LMF + BCG in node-negative and node-positive breast cancer patients. Application of cancer chemotherapy. Antibiotics Chemother. 24:213–228Google Scholar
  580. Senn HJ (ed) 1984 Adjuvant chemotherapy of breast cancer. Recent Results in Cancer Research, Springer, Berlin Heidelberg New York Tokyo Vol 96Google Scholar
  581. Smith IE et al (1978) Vindesine: A phase II study in the treatment of breast carcinoma, malignant melanoma and other tumors. Cancer Treat Rep 62:1427–1433PubMedGoogle Scholar
  582. Swenerton KD et al (1979) Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 39:1552 ffPubMedGoogle Scholar
  583. Tormey DC et al (1982) A comparison of induction chemotherapies for metastatic breast cancer. Cancer 50:1235–1244PubMedGoogle Scholar
  584. Tancini G et al (1983) Adjuvant CMF in breast cancer: Comparable five years results of 12 versus 6 cycles. J Clin Oncol 1:2 ffPubMedGoogle Scholar
  585. Taylor SG et al (1986) Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women. Ann Intern Med 104:455–461PubMedGoogle Scholar
  586. Urban JA (1986) Breast cancer 1985: What have we learned? Cancer 57: 637–643Google Scholar
  587. Veronesi U (1984) Current status of primary surgery in the management of breast cancer. In: Breast cancer: Diagnosis and management. Bonadonna G (ed) Wiley & Sons, Chichester New York Brisbane Toronto Singapore, pp 169–204Google Scholar
  588. Vorherr H (1984) Adjuvant chemotherapy of breast cancer. Hope-reality-hazard. Klin Wochenschr 62:149–161PubMedGoogle Scholar
  589. Veronesi U, Zucali R, Luini A (1986) Local control and survival in early breast cancer: the Milan trial. Int. J. Radiat Oncol Biol Phys 12:717–720PubMedGoogle Scholar
  590. Wagstaff J et al (1985) Rotating oral cyclosphamide, methotrexate and fluorouracil (oral CMF) for patients with advanced carcinoma of the breast. Proc 3rd Eur Conf on Clin Oncol, Stockholm June 16–20 (Abstr. 639)Google Scholar
  591. Wander HE et al (1985) Megestrolazetat in verschiedenen Dosierungen bei der Behandlung des metastasierenden Mammakarzinoms — Klinische und endokrinologische Untersuchungen. Klin Wochenschr 63:312–318PubMedGoogle Scholar
  592. Wang DM et al (1986) Serum prolactin levels in women with breast cancer and their relationship to survival. Eur J Cancer Clin Oncol 22:487–492PubMedGoogle Scholar
  593. Yap HY et al (1981) Vindesine in the treatment of refractory breast cancer: Improvement in therapeutic index with continuous 5-day infusion. Cancer Treatment Reports 65:775–779PubMedGoogle Scholar
  594. Yau JC et al (1985) A comparative randomized trial of vinca alkaloids in patients with metastatic breast cancer. Cancer 55:337–340PubMedGoogle Scholar
  595. Abrams J (1986) Present optimal therapy in ovarian cancer. Eur J Cancer Clin Oncol 22:9–12PubMedGoogle Scholar
  596. Barker GH, Wiltshaw E (1981) Use of high dose cis-dichloro-diammine platinum (II) following failure of previous chemotherapy for advanced carcinoma of the ovary. Br J Obstet Gynaecol 88:1192–1199PubMedGoogle Scholar
  597. Belinson JL et al (1984) Treatment of advanced and recurrent ovarian carcinoma with cyclophosphamide, doxorubicin, and cisplatin. Cancer 54:1983–1990PubMedGoogle Scholar
  598. Beller U, Speyer J (1985) Current issues in the evaluation and treatment of epithelial carcinoma of the ovary. In: Experimental and clinical progress in cancer chemotherapy. Muggia FM (ed) M Nijhoff Publ Boston, pp235–262Google Scholar
  599. Berek JS et al (1985) Intraperitoneal recombinant α2 interferon for ‘salvage’ immunotherapy in persistent epithelial ovarian cancer. Cancer Treatm Rev 12 (Suppl B): 23–32Google Scholar
  600. Berek J et al (1986) Correlation of Ca 12–5 serum levels and second-look operations among ovarian cancer patients (Abstr. 434) Proc ASCO 5:434Google Scholar
  601. Bruckner HW et al (1978) Combination chemotherapy for ovarian carcinoma with cyclophosphamide, adriamycin, and cis-diammineplatinum (II) after failure of initial chemotherapy. Cancer Treat Rep 62:1021–1025PubMedGoogle Scholar
  602. Bruckner HW et al (1981) High-dose platinum for the treatment of refractory ovarian cancer. Gynecol Oncol 12:64–67PubMedGoogle Scholar
  603. Bruckner HW et al (1982) Ovarian cancer: Schedule modification and dosage intensification of cyclophosphamide, hexamethylmelamine, adriamycin and cisplatinum regimen (CHAP II). Proc ASCO 1:107Google Scholar
  604. Brunner KW et al (1985) Die Chemotherapie als Primärtherapie beim nicht radikal operierten Ovarialkarzinom. Onkologie 8:347–355PubMedGoogle Scholar
  605. Bruntsch U, Gallmeier WM (1983) Chemotherapie der epithelialen Ovarial-karzinome. Münch Med Wochenschr 125:993–995Google Scholar
  606. Buchsbaum JJ, Lifshitz S (1984) Staging and surgical evaluation of ovarian cancer. Semin Oncol 11:227–237PubMedGoogle Scholar
  607. Cangir A et al (1978) Improved prognosis in children with ovarian cancers following modified VAC (vincristine, dactinomycin and cyclophosphamide) chemotherapy. Cancer 42:1234 ff.PubMedGoogle Scholar
  608. Carlson RW et al (1983) Combination cisplatin, vinblastine, and bleomycin chemotherapy (PVB) for malignant germ-cell tumors of the ovary. J Clin Oncol 1:645–651PubMedGoogle Scholar
  609. Cohen CJ et al (1983) Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO stages III and IV) as measured by surgical endstaging (second-look operation). Am J Obstet Gynecol 145:955–967PubMedGoogle Scholar
  610. Dauplat J et al (1986) Second look laparatomy in managing epithelial ovarian carcinoma. Cancer 57:1627–1631PubMedGoogle Scholar
  611. Decker DG et al (1982) Cyclophosphamide plus cisplatinum in combination. Treatment program for stage III or IV ovarian carcinoma. Obstet Gynecol 60:481 ff.PubMedGoogle Scholar
  612. Dembo AJ (1984) Radiotherapeutic management of ovarian cancer. Semin Oncol 11:238–250PubMedGoogle Scholar
  613. Dembo AJ (1985) The sequential multiple modality treatment of ovarian cancer. Radiotherapy Oncol 3:187–197Google Scholar
  614. Dembo AJ et al (1982) Choice of postoperative therapy based on prognostic factores. Int J Radiat Oncol Biol Phys 8:893–898PubMedGoogle Scholar
  615. Dembo AJ et al (1986) Prognostic factors in stage I epithelial ovarian carcinoma (Abstr 483) Proc ASCO 5:124Google Scholar
  616. Dougherty J et al (1985) Recurrence pattern of advanced ovarian carcinoma after negative laparotomy (Abstr C-474). Proc ASCO 4:122Google Scholar
  617. Edmonson JH et al (1984) Comparison of cyclophosphamide and cisplatin (CP) vs. a combination of hexamethylmelamine, cyclophosphamide, doxorubicin and cisplatin (HCAP) as primary chemotherapy for stage III and IV ovarian carcinoma (Abstr C-660). Proc ASCO 3:169Google Scholar
  618. Fuks Z et al (1982) The multimodal approach to the treatment of stage III ovarian carcinoma. Int J Radiat Oncol Biol Phys 8:903–908PubMedGoogle Scholar
  619. Geisler HE (1983) Megestrolacetate for the palliation of advanced ovarian cancer. Obstet Gynecol 61:95–98PubMedGoogle Scholar
  620. Gershenson DM et al (1985) Prognosis of surgically determined complete responders in advanced ovarian cancer. Cancer 55:1129–1135PubMedGoogle Scholar
  621. Gershenson DM et al (1985) Treatment of malignant nondysgerminomatous germ cell tumors of the ovary with vincristine, dactinomycin, and cyclophosphamide. Cancer 56:2756–2761PubMedGoogle Scholar
  622. Granowska M et al (1986) A prospective study of 123J-labelled monoclonal antibody imaging in ovavian cancer. J Clin Oncol 4:730–736PubMedGoogle Scholar
  623. Greco FA et al (1981) Advanced ovarian cancer: Brief intensive combination chemotherapy and second-look operation. Obstet Gynecol 58:199–205PubMedGoogle Scholar
  624. Greiner R et al (1984) Whole-abdomen radiation in patients with advanced ovarian carcinoma after surgery, chemotherapy and second-look laparotomy. J Cancer Res Clin Oncol 107:94–98PubMedGoogle Scholar
  625. Greten H, Klapdor R (Hrsg) (1985) Neue tumorassoziierte Antigene. Zwei Jahre klinische Erfahrung mit monoklonalen Antikörpern. Thieme, StuttgartGoogle Scholar
  626. Hacker NF et al (1985) Whole abdominal radiation as salvage therapy for epithelial ovarian cancer. Obstet Gynecol 65:60–66PubMedGoogle Scholar
  627. Hainsworth JD et al (1983) Advanced minimal residual ovarian cancer: abdominopelvic radiation therapy following combination chemotherapy. Obstet Gynecol 61:619PubMedGoogle Scholar
  628. Hoskins WJ et al (1985) Whole abdominal and pelvic irradiation in patients with minimal disease at second-look surgical reassessment for ovarian carcinoma. Gynecol Oncol 20:271–280PubMedGoogle Scholar
  629. Howell SB (1985) Intraperitoneal chemotherapy: the use of concurrent systemic neutralizing agents. Semin Oncol 12 (Suppl 4): 17–22PubMedGoogle Scholar
  630. Jones RB et al (1978) High volume intraperitoneal chemotherapy („Belly Bath“) for ovarian cancer. Cancer Chem Pharmacol 1:161–166Google Scholar
  631. Kühnle H et al (1984) Krankheitsorientierte Phase-II-Studie mit Etoposid (NSC 141540) bei Cisplatin-refraktären Ovarialkarzinomen. Tumor Diagn Ther 5:152–155Google Scholar
  632. Kühnle H et al (1986) A phase II study of etoposide in advanced ovarian cancer with primary and secondary resistance to high dose cisplatin (Abstr 761) Proc AACR 27:192Google Scholar
  633. Ladner HA (1984) Strahlentherapie des Ovarialkarzinoms. Onkologie 7 (Suppl 2): 36–40PubMedGoogle Scholar
  634. Malcolm AW et al (1983) Advanced minimal residual ovarian carcinoma: Abdominopelvic irradiation following combination chemotherapy. (Abstr C-588) Proc ASCO 2:151Google Scholar
  635. Markman M et al (1984) Combination intraperitoneal chemotherapy with cisplatin, cytarabine, and doxorubicin for refractory ovarian carcinomas and other malignancies principally confined to the peritoneal cavity. J Clin Oncol 2:1321–1326PubMedGoogle Scholar
  636. Markman M et al (1984) Intraperitoneal chemotherapy with high dose cisplatin and cytarabine in patients with refractory ovarian carcinoma and other malignancies confined to the abdominal cavity (Abstr C-643). Proc ASCO 3:165Google Scholar
  637. Markman M et al (1986) Survival following cisplatin (DDP)-based intraperitoneal chemotherapy for refractory ovarian carcinoma (Abstr. 438) Proc ASCO 5:113Google Scholar
  638. McVie JG et al (1985) Intraperitoneal chemotherapy in minimal residual ovarian cancer with cisplatin and i.v. sodium thiosulfate protection (Abstr C-485) Proc ASCO 4:125Google Scholar
  639. Meerpohl HG (1984) Chemotherapie fortgeschrittener epithelialer Ovarialkarzinome. Onkologie 7 (Suppl 2): 22–24PubMedGoogle Scholar
  640. Miller DS et al (1986) A critical reassement of second-look laparatomy in epithelial ovarian carcinoma. Cancer 57:530–535PubMedGoogle Scholar
  641. Myers C (1984) The use of intraperitoneal chemotherapy in the treatment of ovarian cancer. Semin Oncol 11:275–284PubMedGoogle Scholar
  642. Myers M et al (1981) Advanced ovarian carcinoma: Response to antiestrogen therapy. Cancer 48:2368–2370PubMedGoogle Scholar
  643. Neijt JP et al (1985) Combination chemotherapy with CHAP-5 and CP in advanced ovarian carcinoma: A randomized trial of the Netherland Joint Study Group for ovarian cancer (Abstr C-442). Proc ASCO 4:114Google Scholar
  644. Ozols RF (1985) The case for combination chemotherapy in the treatment of advanced ovarian cancer. J Clin Oncol 3:1445–1447PubMedGoogle Scholar
  645. Ozols R (1985) Intraperitoneal chemotherapy in the management of ovarian cancer. Semin Oncol 12 (Suppl 14): 75–80PubMedGoogle Scholar
  646. Ozols RF, Young RC (1985) High-dose cisplatin therapy in ovarian cancer. Semin Oncol 12 (Suppl 6): 21–30PubMedGoogle Scholar
  647. Ozols RF et al (1982) Phase I and pharmacologic studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res 41:4165 ff.Google Scholar
  648. Ozols RF et al (1984) High dose cisplatin in hypertonic saline. Ann Intern Med 100:19–24PubMedGoogle Scholar
  649. Ozols RF et al (1985) High dose cisplatin in hypertonic saline in refractory ovarian cancer. J Clin Oncol 3:1246–1250PubMedGoogle Scholar
  650. Ozols RF et al (1985) High dose (HD) cisplatin (P) (40 mg/m2 qd × 5) and HD carboplatinum (CBDCA) (400 mg/m2 qd × 2) in refractory ovarian cancer: Active salvage drugs with different toxicities (Abstr C-462). Proc ASCO 4:119Google Scholar
  651. Ozols RF et al (1986) High-dose (HD) (800 mg/m2) carboplatin (CBDCA) in ovarian cancer (OC): potential for replacing HD cisplatin in the combination chemotherapy of OC (Abstr. 461) Proc ASCO 5:118Google Scholar
  652. Parker LM et al (1983) Advanced ovarian carcinoma: Interaction of surgical treatment and chemotherapy with cyclophosphamide, adriamycin, and cisdiamminedichloroplatinum. Proc ASCO 2:153Google Scholar
  653. Pecorelli S et al (1983) Radiotherapy following second look laparotomy in stage III and IV epithelial cancer of the ovary treated by chemotherapy: cisplatinum (P) versus cyclophosphamide and cis-platinum (CP) versus cyclophosphamide, adriamycin and cis-platinum (CAP). Gynecol Oncol 15:138Google Scholar
  654. Pfleiderer A (1984) Chemotherapie der Ovarialkarzinome. Verh Dtsch Krebsges 5:711–719Google Scholar
  655. Piccart M et al (1985) Advanced epithelial ovarian cancer (OV-CA): update with impressive survival utilizing cisplatin (DDP) (100 mg/m2/cycle) and cyclophosphamide (CTX) (Abstr C-455). Proc ASCO 4:117Google Scholar
  656. Piver MS (1981) Effective weekly cis-dichlorodiammine platinum (DDP) as third line chemotherapy in ovarian cancer (Abstr C-526). Proc ASCO 22:467Google Scholar
  657. Preusser P et al (1985) Cisplatin. Arzneimitteltherapie 3:50–65Google Scholar
  658. Richardson GS et al (1985a) Common epithelial cancer of the ovary (First of two parts). N Engl J Med 312:415–425PubMedGoogle Scholar
  659. Richardson GS et al (1985b) Common epithelial cancer of the ovary (Second of two parts). N Engl J Med 312:474–483PubMedGoogle Scholar
  660. Rizel S et al (1985) Combined modality treatment for stage III ovarian carcinoma. Radiotherapy Oncol 2:237–244Google Scholar
  661. Schmidt-Matthiesen H, Bastert G (1984) Gynäkologische Onkologie. 2. Aufl, Schattauer Verlag, StuttgartGoogle Scholar
  662. Schray M et al (1984) Advanced epithelial ovarian cancer: preliminary results of whole abdominal irradiation for patients with recurrent or persistent disease after chemotherapy (Abstr 120). Int J Radiat Oncol Biol Phys 10 (Suppl 2): 139Google Scholar
  663. Schröck R et al (1986) Tumorassoziierte Antigene und Fibrinderivate als Reaktionsprodukte des Ovarialkarzinoms. Geburtsh. u. Frauenheilk. 46:1–10Google Scholar
  664. Schwartz P et al (1982) Tamoxifen therapy for advanced ovarian cancer. Obstet Gynecol 59:583–588PubMedGoogle Scholar
  665. Seltzer V et al (1984) High overall and complete remission rates of substantial value in retreatment of advanced ovarian cancer with dichloroplatinum-based combination chemotherapy after relapse from complete remission (Abstr C-657). Proc ASCO 3:168Google Scholar
  666. Sikíc BJ et al (1986) Activity of high-dose Megestrol acetate in patients with epithelial ovarian cancers refractory to chemotherapy. A phase II study of the Northern California Oncology Group. Proc ASCO 5:122 (Abstr. 477)Google Scholar
  667. Slayton RE (1984) Management of germ cell and stromal tumors of the ovary. Semin Oncol 11:299–313PubMedGoogle Scholar
  668. Speyer JL et al (1980) Phase I and pharmacologic studies of 5-fluorouracil administered intraperitoneally. Cancer Res 40:567 ffGoogle Scholar
  669. Thigpen JT et al (1984) New drugs and experimental approaches in ovarian cancer treatment. Semin Oncol 11:314–326PubMedGoogle Scholar
  670. Vogl SE et al (1979) The CHAD and HAD regimen in advanced ovarian cancer: Combination chemotherapy including cyclophosphamide, hexamethylmelamine, adriamycin and cisdichlorodiammine platinum (II). Cancer Treat Rep 63:311 ffGoogle Scholar
  671. Vogl SE et al (1981) Cyclophosphamide, hexamethylmelamine, adriamycin, and diamminedichloroplatinum (CHAD) versus melphalan for advanced ovarian cancer (Abstr). Proc ASCO 22:473Google Scholar
  672. Vogl SE et al (1983) Cis-platin based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burden. Cancer 51:2024–2030PubMedGoogle Scholar
  673. Vogl SE et al (1984) „Second-effort“surgical resection for bulky ovarian cancer. Cancer 54:2220–2225PubMedGoogle Scholar
  674. Wiltshaw E et al (1983) JM8, successor to cisplatin in advanced ovarian carcinoma? Lancet I: 1110ffGoogle Scholar
  675. Wiltshaw E et al (1985) Phase III randomized trial cisplatin versus JM8 (carboplatin) in 112 ovarian cancer patients, stages III and IV (Abstr C-471). Proc ASCO 4:121Google Scholar
  676. Young JA et al (1984) Alternating combination chemotherapy for stages III and IV ovarian carcinoma. J Clin Oncol 2:1317–1320PubMedGoogle Scholar
  677. Young RC (1984) Ovarian cancer treatment: Progress or paralysis? Sem Oncol 11:327–329Google Scholar
  678. Young RC et al (1974) The chemotherapy of ovarian carcinoma. Cancer Treat Rep 1:99–110Google Scholar
  679. Arsenau JC, Hatch K et al (1985) Phase II study of carboplatin in advanced squamous cell carcinoma of the cervix. Proc Am Soc Clin Oncol 4:468Google Scholar
  680. Baltzer J, Köpcke W et al (1984) Die operative Behandlung des Zervixkarzinoms. Geburtsh. u. Frauenheilk. 44:279–285Google Scholar
  681. Baltzer J, Lohe KJ et al (1984) Surgical treatment of cervix cancer. Treatment results and data on the postoperative course over a minimum of 5 years following uniform surgery and standardized histological examination of the histological material of 1092 patients at 4 university gynecology clinics. Geburtsh Frauenheilk 44:279–285PubMedGoogle Scholar
  682. Bonomi P, Bruckner HW, Cohen C, Marshall R, Blessing J, Slayton R (1982) A randomized trial of three cis-platin regimens in squamous cell carcinoma of the cervix. Proc ASCO 1:110Google Scholar
  683. Edmonson JH, Johnson PS et al (1986) Comparison of Bleomycin, Cyclophosphamide, Adriamycin and Cisplatin (BCAP) vs. Bleomycin and Cisplatin (BP) in advanced cervical carcinoma. Proc Am Soc Clin Oncol 5:474Google Scholar
  684. Einhorn MD, Patek MD, Sjöberg B (1985) Outcome of different treatment modalities in cervix carcinoma stage IB and IIA. Cancer 55:949–955PubMedGoogle Scholar
  685. George M, Haie C et al (1986) Combination of radiotherapy (RT) and chemotherapy (CT) in the primary treatment of advanced uterine cervix carcinoma (CxCa). Three-year results. Proc Am Soc Clin Oncol 5:440Google Scholar
  686. Goldhirsch A, Greiner R, et al (1986) Combination of chemotherapy with methotrexate, bleomycin, and cis-platinum, and radiation therapy for locally advanced carcinoma of the cervix. Am J Clin Oncol 9:12–14PubMedGoogle Scholar
  687. Inoue T, Okumura M (1984) Prognostic significance of parametrial extension in patients with cervical carcinoma stages IB, IIA, and IIB. Cancer 54:1714–1719PubMedGoogle Scholar
  688. Jungi WF (1983) Chemo- und Hormontherapie des Zervix- und Korpuskarzinoms. Münch Med Wochenschr 125:788–790Google Scholar
  689. Kavanagh J, Gershenson D et al (1986) Fluorouracil, Doxorubicin, and Cisplatin (FAP) for the treatment of recurrent or metastatic adenocarcinomas of the cervix. Proc Am Soc Clin Oncol 5:445Google Scholar
  690. Kavanagh J, Saul PB et al (1985) Continous-infusion-vindesine in refractory carcinoma of the cervix: A phase II trial. Cancer Treat Rep 69, No. 1: 139–140PubMedGoogle Scholar
  691. Leibel S, Bauer M, Philipps T et al (1985) Radiotherapy with or without Misonidazole in patients with stage IIIB or IVB squamous cell carcinoma of the uterine cervix. Proc ASCO C-482Google Scholar
  692. Matsuyama T et al (1984) Stage Ib, IIa, and IIb cervix cancer, postsurgical staging, and prognosis. Cancer 54:3072–3077PubMedGoogle Scholar
  693. Moberg PJ, Einhorn N et al (1986) Adenocarcinoma of the uterine cervix. Cancer 57:407–410PubMedGoogle Scholar
  694. Montana GS et al (1985) Analysis of results of radiation therapy for stage II carcinoma of the cervix. Cancer 55:956–962PubMedGoogle Scholar
  695. Muggia FM, Lira-Puerto V et al (1985) Potential for platinum analogs in the treatment of cancer of the uterine cervix. Cancer Treatment Rev 12:93–99Google Scholar
  696. Muscato MS, Perry MC, Yarbro JW (1982) Chemotherapie of cervical carcinoma. Semin Oncol 9:373–387PubMedGoogle Scholar
  697. O’Reilly SE, Swenerton KD et al (1986) Concomitant Cisplatin (DDP) and radiotherapy (RT) in advanced cervical squamous cell carcinoma (SSC). Proc Am Soc Clin Oncol 5:448Google Scholar
  698. Picozzi VJ, Sikic BI et al (1985) Bleomycin, Mitomycin, and Cisplatin therapy for advanced squamous carcinoma of the uterine cervix: A phase II study of the northern california oncology group. Cancer Treat Rep 69:903–905PubMedGoogle Scholar
  699. Rhomberg WU, Mesche E (1981) Vindesine in the Treatment of Advanced Solid Tumors. Experience with a Twice Weekly Schedule. In: Brade W, Nagel GA, Seeber S (Hrsg) Proceedings of the International Vinca Alkaloid Symposium-Vindesin. Karger, Berlin (Contributions to oncology, vol 6) pp 222–226Google Scholar
  700. Seltzer V, Vogl SE, Davis TE, Camacho F (1985) Chemotherapy of cervical cancer with cisplatinum, bleomycin and standard dose methotrexate with leucovorin rescue — a safe program with limited activity. Proc ASCO C-478Google Scholar
  701. Sorbe B, Frankendahl B (1984) Bleomycin-adriamycin-cisplatin combination chemotherapy in the treatment of primary advanced and recurrent cervical carcinoma. Obstet Gynecol 63:167–170PubMedGoogle Scholar
  702. Thar T, Million RR, Dary JW (1982) Radiation treatment of carcinoma of the cervix. Semin Oncol 9:299–311PubMedGoogle Scholar
  703. Thigpen T et al (1981) Cis-Platinum in the treatment of advanced or recurrent squamous cell carcinoma of the cervix. Cancer 48:899–903PubMedGoogle Scholar
  704. Umbach GE et al (1986) Die Chemotherapie des fortgeschrittenen Zervixkar-zinoms. Tumordiagnostik & Therapie 7:89–98Google Scholar
  705. Wallace HJ, Hreschchyshyn MM et al (1978) Comparison of the therapeutic effects of adriamycin alone versus adriamycin plus vincristine versus adriamycin plus cyclophosphamide in the treatment of advanced carcinoma of the cervix. Cancer Treat Rep 62:1435–1441PubMedGoogle Scholar
  706. Wertheim MS, Hakes TB et al (1985) A pilot study of adjuvant therapy in patients with cervical cancer at high risk of recurrence after radical hysterectomy and pelvic lymphadenectomy. J Clin Oncol Vol 3:912–916PubMedGoogle Scholar
  707. Belinson JL, Spirou M et al (1983) Stage I carcinoma of the endometrium: A 5-year experience utilizing preoperative cesium. Gynecologic Oncol 20:325–335Google Scholar
  708. De Oliveira, CF et al (1986) Phase II study of Cyclophosphamide (C), Adriamycin (A), Cisplatin (P) in recurrent or advanced endometrial cancer. Proc Am Soc Clin Oncol 5:480Google Scholar
  709. De Palo G, Merson M, Del Vecchio M, Magnioni C et al (1985) A controlled clinical study of adjuvant medroxyprogesterone acetate therapy in pathologic stage I endometrial carcinoma with myometrial invasion. Proc Am Soc Clin Oncol 4: C-470Google Scholar
  710. Durant JR 1982 Hormonal therapy of gynecologic cancers. Semin Oncol 10:29–33Google Scholar
  711. Hilgers RD, von Hoff DD et al (1985) Mitoxantrone in adenocarcinoma of the endometrium: A southwest oncology group study. Cancer Treat Rep 11:1329 ffGoogle Scholar
  712. Horton J, Elson P, Gordon P, Hahn R, Creech R (1982) Combination Chemotherapie for advanced endometrial cancer. An evaluation of three regimens. Cancer 49:2441–2445PubMedGoogle Scholar
  713. Mackillop WJ et al (1985) Stage III Endometrial Carcinoma. Cancer 56:2519–2523PubMedGoogle Scholar
  714. Malkasian GD (1983) Endometrial carcinoma — common but curable. Geriatrics 3:107–112Google Scholar
  715. Pasmantier MW et al (1985) Treatment of advanced endometrial carcinoma with doxorubicin and cisplatin: — Effects on both untreated and previously treated patients. Cancer Treat Rep 69:539–542PubMedGoogle Scholar
  716. Saigo PE, Cain JM et al (1986) Prognostic factors in adenocarcinoma of the uterine cervix. Cancer 57:1584–1593PubMedGoogle Scholar
  717. Thigpen T, Blessing J, DiSaia P, Ehrlich C (1985) A randomized comparison of adriamycin with or without cyclophosphamide in the treatment of recurrent endometrial carcinoma. Proc Am Soc Clin Oncol 1: C-448Google Scholar
  718. Thigpen JT, Buchsbaum HJ, Mangan C 1979 Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group Study. Cancer Treat Rep 63:21–27PubMedGoogle Scholar
  719. Turbow MM, Ballon SC et al (1985) Cisplatin, doxorubicin and cyclophosphamide chemotherapy for advanced endometrial carcinoma. Cancer Treat Rep 69:465–467PubMedGoogle Scholar
  720. Ballon SC et al (1977) Obstet Gynecol Surg 32:405Google Scholar
  721. Begent RHJ, Bagshawe KD (1982) The management of high-risk choriocarcinoma. Semin Oncol 9:198–203PubMedGoogle Scholar
  722. Berkowitz DP, Goldstein, Jones MA, Marean AR, Bernstein MR (1980) Methotrexat with citrovorum factor rescue. Cancer 45:423–426PubMedGoogle Scholar
  723. Goldstein DP, Berkowitz RS (1982) Nonmetastatic and low-risk metastatic gestational trophoblastic neoplasms. Semin Oncol 9:191–187PubMedGoogle Scholar
  724. Hammond CB et al (1973) Treatment of metastatic trophoblastic disease; good and poor prognosis. Am J Obstet Gynecol: 115:451 ffGoogle Scholar
  725. Newlands ES (1979) The activity of the epipodophyllin derivative VP 16–213 and cisplatinum in combination in drug resistent choriocarcinoma. Int Symp Gestational Trophobl Tumors; London (Abstract)Google Scholar
  726. Newlands ES (1985) VP 16 in combinations for first line treatment of germ cell tumors and gestational choriocarcinoma. Semin Oncol 12 (Suppl 2): 37–40PubMedGoogle Scholar
  727. Newlands ES (1982) New Chemotherapeutic Agents in the Management of Gestational Trophoblastic Disease. Semin Oncol 9:239–243PubMedGoogle Scholar
  728. Newlands ES et al (1986) Weekly EMA/CO chemotherapy for high risk gestational trophoblastic tumors (GTTs). Proc Am Soc Clin Oncol 5:112Google Scholar
  729. Surwit EA (1982) The management of poor prognosis throphoblastic disease. Semin Oncol 9:204–207PubMedGoogle Scholar
  730. Weed JC, Jr et al (1982) Choriocarcinoma metastatic to the brain: therapy and prognosis. Semin Oncol 9:208 ffGoogle Scholar
  731. Amin R et al (1985) Successful response of extragonadal retroperitoneal seminoma to chemotherapy. Brit J Radiother 58:377–379Google Scholar
  732. Bosl GJ, Geller NL et al (1983) Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 43:3403–3407PubMedGoogle Scholar
  733. Bosl GJ, Yagoda A et al (1985) Role of etoposide-based chemotherapy in the treatment of patients with refractory or relapsing germ cell tumors. Am J Med 78:423–428PubMedGoogle Scholar
  734. Bosl GJ, Bajorin D et al (1986) A randomized trial of etoposide (E) + Cisplatin (P) and VAB-6 in the treatment (Rx) of „Good Risk“patients (pts) with germ cell tumors (GCT). Proc Am Soc Clin Oncol 5: Abstr. 405Google Scholar
  735. Cavalli F, Monfardini S et al (1980) Report on the international workshop on staging and treatment of testicular cancer. Eur J Cancer 16:1367–1372PubMedGoogle Scholar
  736. Chong C, Logothetis C, et al (1986) The successful management of pure endodermal sinus tumors (EST) of adult males. Proc Am Soc Clin Oncol 5: Abstr. 379Google Scholar
  737. Daniels JR (1985) Chemotherapy in seminoma: When is it appropriate initial treatment. J Clin Oncol 3:1294–1295PubMedGoogle Scholar
  738. Daugaard G, Roerth M (1986) High-dose cisplatin and VP-16 with bleomycin in the management of advanced germ cell tumors. Eur J Cancer Clin Oncol 22:477–485PubMedGoogle Scholar
  739. DeWys WD, Green SB et al (1984) Adjuvant therapy of testicular cancer. In: Salmon, Jones (eds) Adjuvant therapy of cancer IV. Grune & Stratton, New York, pp 529–538Google Scholar
  740. Einhorn LH, Donohue J (1977) Cis-diamminedichloroplatinum, vinblastine, bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87:293–298PubMedGoogle Scholar
  741. Einhorn LH, Williams SD (1980) Chemotherapy of disseminated testicular cancer: A randomized prospective study. Cancer 46:1339–1344PubMedGoogle Scholar
  742. Einhorn LH, Williams SD, Mandelbaum I, Donohue JP (1981) Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction. Cancer 48:904–908PubMedGoogle Scholar
  743. Evensen JF, Fossa SD et al (1985) Testicular seminoma: Analysis of treatment failure for stage II disease. Radiotherapy Oncology 4:55–61Google Scholar
  744. Fossa SD, Ous S et al (1985) Post-treatment fertility in patients with testicular cancer. Brit J Urology 57:210–214Google Scholar
  745. Friedman EL, Garnick MB et al (1985) Therapeutic guidelines and results in advanced seminoma. J Clin Oncol 3:1325–1332PubMedGoogle Scholar
  746. Greist A, Einhorn LH et al (1984) Pathologic findings at orchiectomy following chemotherapy for disseminated testicular cancer. J Clin Oncol 2:1025 ffGoogle Scholar
  747. Hainsworth JP et al (1985) Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin: Results of a Southeastern Cancer Study Group Trial. J Clin Oncol 3:666–671PubMedGoogle Scholar
  748. Imhoff GW, Sleijfer DT et al (1986) Acute nonlymphocytic leukemia 5 years after treatment with cisplatin, vinblastine, and bleomycin for disseminated testicular cancer. Cancer 57:984–987PubMedGoogle Scholar
  749. Jaeger N, Weissbach L et al (1983) Primary lymphadenectomy or primary chemotherapy in advanced metastatic testicular tumor? Eur J Urol 9:329–333Google Scholar
  750. Javadpour N, Jeffrey MD (1985) Alternative to retroperitoneal lymphadenectomy with preservation of ejaculation and fertility in stage I nonseminomatous testicular cancer. Cancer 55:1604–1606PubMedGoogle Scholar
  751. Lester SG, Morphis II JG et al (1985) Testicular seminoma: Analysis of treatment results and failures. Int J Radiation Oncol Biol Phys 12:353–358Google Scholar
  752. Lester SG, Morphis II JG et al (1984) Brain metastases and testicular tumors: Need for aggressive therapy. J Clin Oncol 2:1397–1403PubMedGoogle Scholar
  753. Levi J, Raghavan D et al (1986) Deletion of bleomycin from therapy for good prognosis advanced testicular cancer: A prospective randomized study. Proc Am Soc Clin Oncol 5: Abstr. 374Google Scholar
  754. Loehrer PJ, Einhorn SL et al (1986) VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer. J Clin Oncol 4:528–536PubMedGoogle Scholar
  755. Loehrer PJ, Birch R et al (1986) Cisplatin combination chemotherapy in metastatic seminoma: The southeastern cancer study group (SEG) experience. Proc Am Soc Clin Oncol 5: Abstr. 410Google Scholar
  756. Logothetis CJ et al (1985) Improved survival with cyclic chemotherapy for nonseminomatous germ cell tumors of the testis. J Clin Oncol 3:326–335PubMedGoogle Scholar
  757. Motzer RJ, Bosl GJ et al (1986) Residual mass: An indication for surgery in patients (pts) with advanced seminoma following systemic chemotherapy. Proc Am Soc Clin Oncol 5: Abstr. 404Google Scholar
  758. Newlands ES, Bagshawe KD et al (1986) Current optimum management of anaplastic germ cell tumors of the testis and other sites. Brit J Urol 58:307–314PubMedGoogle Scholar
  759. Oliver RT (1983) Cis-Platinum in combination or as single agent for metastatic seminoma of the testis or dysgerminoma of the ovary. Proc ASCO 2: C-564Google Scholar
  760. Oliver RTD, Hope-Stone HF, Blandy JP (1983) Justification of the use of surveillance in the management of stage I germ cell tumors of the testis. Brit J Urol 55:760–763PubMedGoogle Scholar
  761. Peckham MJ, Barrett A et al (1983) The treatment of metastatic germ cell testicular tumours with bleomycin, etoposide and cis-platin (BEP). Br J Cancer 47:613–619PubMedGoogle Scholar
  762. Peckham MJ, Horwich A, Blackmore C, Hendry WF (1985) Etoposide and cisplatin with or without bleomycin as first-line chemotherapy for patients with small-volume metastases of testicular nonseminoma. Cancer Treat Rep 69, 5:483–487PubMedGoogle Scholar
  763. Peckham MJ, Barrett A, et al (1983) Orchiectomy alone for stage I testicular non-seminoma. Brit J Urol 55:754–759PubMedGoogle Scholar
  764. Pizzocaro G, Zanoni F et al (1986) Orchiectomy alone in clinical stage I nonseminomatous testis cancer: A critical appraisal. J Clin Oncol 4:35–40PubMedGoogle Scholar
  765. Pizzocaro G, Salvioni, R et al (1986) Successful treatment of good-risk disseminated testicular cancer with cisplatin, bleomycin and reduced-dose vinblastine. Cancer 57:2114–2118Google Scholar
  766. Reed E, Sanger WG et al (1986) Results of semen cryopreservation in young men with testicular carcinoma and lymphoma. J Clin Oncol 4:537–539PubMedGoogle Scholar
  767. Report from the Medical Research Council Working Party on Testicular Tumours (1985) Lancet 1:8–11Google Scholar
  768. Reynoso E, Yau J et al (1986) Acute leukaemia and mediastinal teratocarcinoma. Proc Am Soc Clin Oncol 5: Abstr. 377Google Scholar
  769. Samson MK, Crawford ED et al (1986) A randomized comparison of cisplatin, vinblastine (VLB) plus either bleomycin (PVB) or VP-16 (VPV) in patients with advanced testicular cancer. Proc Am Soc Clin Oncol 5: Abstr. 373Google Scholar
  770. Samuels ML, Johnson DE and Holoye PY (1975) Continuous intravenous bleomycin (NSC-125066) therapy with vinblastine (NSC-49842) in stage III testicular neoplasia. Cancer Chemother Rep 59:563–570PubMedGoogle Scholar
  771. Samuels ML, Johnson DE et al (1979) Velban plus continuous infusion bleomycin (VB-3) in stage III advanced testicular cancer: Results in 99 patients with a note on high dose velban and sequential cisplatinum. In: Johnson DE, Samuels ME (eds) Cancer of the genitourinary tract. Raven, New York, pp 159–172Google Scholar
  772. Scheulen ME, Niederle N, Höffken K et al (1985) Ifosfamide/Mesna (IF/M) alone or in combination with etoposide (IF/M + E): Salvage therapy for patients with metastasized nonseminomatous testicular cancer (NSTC) Proc ASCO C-379Google Scholar
  773. Schmoll H-J, Waegner W (1984) Adjuvant therapy in resectable stage II nonseminomatous testicular cancer. In: Salmon, Jones (eds) Adjuvant therapy of cancer IV. Grune & Stratton, New York, pp 539–548Google Scholar
  774. Schmoll H-J et al (1981) VP-16 Mono- und Kombinationschemotherapie beim therapierefraktären Hodenkarzinom. In: Seeber S, Nagel G, et al (Hrsg) Etoposid, derzeitiger Stand und neue Entwicklungen in der Chemotherapie maligner Neoplasien. Zuckschwerdt, München, pp 178–190Google Scholar
  775. Schmoll H-J, Diehl V, Hartlapp J, Illiger J (1984 a) Results of a prospective randomized trial: Platinum, vinblastine, bleomycin ± ifosfamide in advanced testicular cancer. In Denis, Murphy, Prout, Schröder (eds) Controlled clinical trials in urologic oncology. Raven, New York, pp 29–38Google Scholar
  776. Schmoll HJ (1984 b) Aktuelle Aspekte zur Seminomtherapie. Onkologisches Forum für Chemotherapie 3:11–17Google Scholar
  777. Schmoll HJ, Arnold A, Bergmann L, Illiger J, Preiß J, Pfreundschuh M, Fink, U (1986) Effective chemotherapy in testicular cancer with bulky disease: Platinum ultra high dose/VP 16/Bleomycin. Proc Am Soc Clin Oncol 5:Abstr. 396Google Scholar
  778. Schmoll HJ, Knoblauch T, Bading I (1986) Salvage Chemotherapie bei disseminiertem Hodenkarzinom: Ergebnisse abhängig von der Qualität der ersten Remission und der ersten Chemotherapie. J Canc Res Clin Oncol 111 (Suppl): 144Google Scholar
  779. Schuette J, Niederle N et al (1985) Chemotherapy of metastatic seminoma. Brit J Cancer 51:467–472PubMedGoogle Scholar
  780. Sleijfer Dt, DeVries EGE et al (1986) Ablative chemotherapy followed by autologous bone marrow transplantation for the treatment of germ cell tumors. Proc Am Soc Clin Oncol 5: Abstr. 375Google Scholar
  781. Smalley SR, Evans RG et al (1985) Radiotherapy as initial treatment for bulky stage II testicular seminomas. J Clin Oncol 3:1333–1338PubMedGoogle Scholar
  782. Stanton GF, Bosl GJ et al (1985) VAB-6 as initial treatment of patients with advanced seminoma. J Clin Oncol 3:336–339PubMedGoogle Scholar
  783. Stomper PC, Jochelson MS et al (1985) Residual abdominal masses after chemotherapy for nonseminomatous testicular cancer: Correlation of CT and histology. Am J Radiol 145:743–746Google Scholar
  784. Swartz DA, Johnson DE, Hussey DH (1983) Should an elevated human chorionic gonadotropin titer alter therapy for seminoma? J Urol 131:63–65Google Scholar
  785. Tiffany P, Morse MJ et al (1986) Sequential excision of residual thoracic and retroperitoneal masses after chemotherapy for stage III germ cell tumors. Cancer 57:978–983PubMedGoogle Scholar
  786. Trump DL, Horvet L (1985) Etoposide and very high dose cisplatin: Salvage therapy for patients with advanced germ cell neoplasms. Cancer Treat Rep 69:259–261PubMedGoogle Scholar
  787. Vaeth M, Schultz HP et al (1984) Prognostic factors in testicular germ cell tumours. Acta Radiol Oncol 23:271–285PubMedGoogle Scholar
  788. Vugrin D, Herr HW, Whitmore WF Jr, Sogani PC, Golbey RB (1981) VAB-6-combination chemotherapy in disseminated cancer of the testis. Ann Intern Med 95:59–61PubMedGoogle Scholar
  789. Vugrin D et al (1985) The role of chemotherapy and surgery in the treatment of retroperitoneal metastases in advanced nonseminomatous testis cancer. Cancer 55:1874–1878PubMedGoogle Scholar
  790. Weiss RB, Stablein DM et al (1986) Toxicity of chemotherapy as adjuvant or salvage treatment in early stage non-seminomatous testicular cancer (NSTC). Proc Am Soc Clin Oncol 5: Abstr. 384Google Scholar
  791. Weißbach L, Boedefeld EA et al (1984) Therapy in stage I nonseminomatous testicular cancer. Eur J Urol 10:1–9Google Scholar
  792. Williams S, Einhorn L et al (1985) Disseminated germ cell tumors: A comparison of cisplatin plus bleomycin plus either vinblastine (PVB) or VP-16 (BEP). Proc ASCO 4: C-390Google Scholar
  793. Williams S, Muggia, F et al (1986) Resected stage II testicular cancer: Immediate adjuvant chemotherapy versus observation. Proc Am Soc Clin Oncol 5: Abstr. 380Google Scholar
  794. Ahmann FR, Tucson AZ et al (1986) Zoladex: A monthly depot LH-RH analog for prostate cancer. Proc Am Soc Clin Oncol 5:412Google Scholar
  795. Bauer HW, Altwein JE: Palliative Therapie des Prostatakarzinoms. Kombination von Androgenentzug und Antiandrogenen. Palliative Therapie des Prostatakarzinoms. Klinische und Experimentelle Urologie Band 10, W. Zuckschwerdt Verlag München, Bern, Wien, 1985Google Scholar
  796. Bagshaw MA (1980) External radiation therapy of carcinoma of the prostate. Cancer [Suppl] 45:1912 ffGoogle Scholar
  797. Bruce AW et al (1981) The significance of prostatic acid phosphate in adenocarcinoma of the prostate. J Urol 126:357 ffGoogle Scholar
  798. Byar DP, Administration Cooperative Urological Research Group (1972) Survival of patients with incidentally found microscopic cancer of the prostate: Result of clinical trial of conservative treatment. J Urol 108:908 ffPubMedGoogle Scholar
  799. Chen, JJ et al (1986) Low dose aminoglutethimide treatment of metastatic prostate cancer (Stage D2) after failure of testicular androgen blockade. Proc Am Soc Clin Oncol 5:389Google Scholar
  800. de Riese W, Drimalla GH, Sürig T, Aeikens S, Schindler E (1986) Indikation, Komplikationen, Früh- und Spätergebnisse nach radikaler Prostatektomie. Tumor Diagnostik & Therapie 7:33–36Google Scholar
  801. Drago JR et al (1984) Clinical effect of aminoglutethimide, medical adrenalectomy, in treatment of 43 patients with advanced prostatic carcinoma. Cancer 53:1447–1450PubMedGoogle Scholar
  802. Eisenberger MA, Simon R et al (1985) A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 3:827–837PubMedGoogle Scholar
  803. Elder JS, Gibbons RP et al (1985) Efficacy of radical prostatectomy for stage A2 carcinoma of the prostate. Cancer 56:2151–2154PubMedGoogle Scholar
  804. Fossa SD, Miller A (1976) Treatment of advanced carcinoma of the prostate with estramustine phosphate. J Urol 115:406–408PubMedGoogle Scholar
  805. Gagnon JD et al (1979) Pre-estrogen breast irradiation for patients with carcinoma of the prostate: A critical review. J Urol 122:182–184Google Scholar
  806. Garnick MB (1985) Long-term efficacy of the GnRH-Analogue, Leuprolide [(Lupron) (LEU)] in metastatic prostate cancer. An Update: Part I. Proc ASCO 4: C-382Google Scholar
  807. Geller J et al (1983) Comparison of various hormonal therapies for prostatic carcinoma. Semin Oncol 10 [Suppl 4] 4:34–41Google Scholar
  808. Gleason DF Jr et al (1974) Prediction of prognosis for prostatic adenocarcinoma by combined histologic grading and clinical staging. J Urol 111: 58 ffPubMedGoogle Scholar
  809. Gropp, Burk K (1985) Was ist gesichert in der Therapie des fortgeschrittenen Prostatacarcinoms? Internist 26:765–770PubMedGoogle Scholar
  810. Guinan P, Sharifi R et al (1986) LH-RH agonists and the management of stage D-2 prostate cancer. Proc Am Soc Clin Oncol 5:429Google Scholar
  811. Hanks GE, Leibel SA, Krall JM, Kramer S (1985) Patterns of care studies: Dose-response observations for local control of adenocarcinoma of the prostate. Int J Radiation Oncology Biol Phys Vol 11:153–157Google Scholar
  812. Jewett HJ (1975) The present status of radical prostatectomy for stage A and B prostatic cancer. Urol Clin North Am 2:105–124PubMedGoogle Scholar
  813. Kasimis BS et al (1985) Cyclophosphamide versus 5-fluoro-uracil, doxorubicin and Mitomycin-C (FAM) in the treatment of hormonresistant metastatic carcinoma of the prostate: A preliminary report of a randomized trial. J Clin Oncol 3:385–392PubMedGoogle Scholar
  814. Keller J, White JM, Browder H, Lauper D (1986) A phase III randomized trial of megestrol acetate vs diethylstilbestrol in stage D2 prostate cancer. Preliminary results. Proc Am Soc Clin Oncol 5:421Google Scholar
  815. Klein LA (1979) Medical progress: Prostatic carcinoma. N Eng J Med 300:824–833Google Scholar
  816. Labrie F, Dupont A, Belanger A (1985) Complete androgen blockade for the treatment of prostate cancer. In: DeVita, Hellman, Rosenberg (eds) Important Advances in Oncology. Lippincott, Philadelphia, pp 193–217Google Scholar
  817. Leistenschneider W (1985) Die Behandlung des fortgeschrittenenen Prostatakarzinoms. Die Berliner Ärztekammer 7:361–368Google Scholar
  818. Loening SA, Breckley S et al (1983) Comparison of estramustine phosphate, methotrexate and cis-platinum in patients with advanced, hormone refractory prostate cancer. J Urol 129:1001–1006PubMedGoogle Scholar
  819. Marion A et al (1983) Weitere Indikationen zur Behandlung mit hochdosiertem Medroxprogesteronacetat (MAP). In Nagel, Robustell: Della Cuma, Lauius (Hrsg.) Medroxprogesteronacetat in der Therapie hormonsensibler Tumoren, pp 191–206Google Scholar
  820. Mills SE, Fowler JE (1986) Gleason Histologic Grading of Prostatic Carcinoma. Correlations Between Biopsy and Prostatectomy Specimens. Cancer 57:346–349PubMedGoogle Scholar
  821. Muss HB et al (1981) Cyclophosphamide versus cyclophosphamide, methotrexate and 5-fluorouracil in advanced prostatic cancer: A randomized trial. Cancer 47:1949–1953PubMedGoogle Scholar
  822. Paulson DF et al (1982) Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J Urol 128:502PubMedGoogle Scholar
  823. Poyet P, Labrie F (1985) Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate. Molecular and Cellular Endocrinology: 42, 283–288PubMedGoogle Scholar
  824. Presant CA, Soloway MS et al (1985) Buserelin as Primary Therapy in Advanced Prostatic Carcinoma. Cancer 56:2416–2419PubMedGoogle Scholar
  825. Presant CA, Soloway M et al (1986) Duration of response and improved quality of life (QL) in buserelin-treated prostate carcinoma: Long-term results. Proc Am Soc Clin Oncol 5:398Google Scholar
  826. Robinson MRG (1980) Aminoglutethimide: Medical adrenalectomy in the management of carcinoma of the prostate. A review after 6 years. Br J Urol 52:328–329PubMedGoogle Scholar
  827. Scott W, Johnson DE, Schmidt JE et al (1976) Chemotherapy of advanced prostatic carcinoma with cyclophosphamide or 5-fluorouracil: Results of first national randomized study. J Urol 114:909–911Google Scholar
  828. Smith JA, Glode LM et al (1985) Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of prostate. Urology, Vol. 25:106–114PubMedGoogle Scholar
  829. Sogani PC, Israel A et al (1985) Gleason grading of prostate cancer: A predictor of survival. Urology, Vol 25:223–227PubMedGoogle Scholar
  830. Sotz de M (1985) Long-term toxicity of the GnRH Analogue, Leuprolide (Lupron, LEU) vs Diethylstilbestrol (DES) in metastatic prostate cancer — An Update: Part II. Proc ASCO 4: C-383Google Scholar
  831. Taylor WJ et al (1979) Radiation therapy for localized prostate cancer. Cancer 43:1123 ffPubMedGoogle Scholar
  832. Tannock IF (1985) Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J Clin Oncol 3:1013–1021PubMedGoogle Scholar
  833. Torti F, Aston D, Lum BL et al (1983) Weekly doxorubicin in endocrine refractory carcinoma of the prostate. J Clin Oncol 1:477–482PubMedGoogle Scholar
  834. Torti FM et al (1984) Tamoxifen in advanced prostatic carcinoma. Cancer 54:739–745PubMedGoogle Scholar
  835. Walsh PC (1980) Radical prostatectomy for the treatment of localized prostatic carcinoma. Urol Clin North Am 7:583 ffPubMedGoogle Scholar
  836. Whitmore WF Jr (1956) Hormone therapy in prostatic cancer. Am J Med 21:697–713PubMedGoogle Scholar
  837. Whitmore WF Jr (1963) The rationale and results of ablative surgery for prostatic cancer. Cancer 16:1119–1132PubMedGoogle Scholar
  838. Zincke H et al (1981) Radical retropubic prostatectomy and pelvic lymphadenectomy for high-stage cancer of the prostate. Cancer 47:1901–1910PubMedGoogle Scholar
  839. Ahmed T, Sklaroff R, Yagoda A (1984) Sequential trials of methotrexate, cisplatin and bleomycin for penile cancer. J Urol 132:465 ffPubMedGoogle Scholar
  840. Ahmed T, Sklaroff R, Yagoda A (1984) An appraisal of the efficacy of bleomycin in epidermoid carcinoma of the penis. Anticancer Res 4:289 ffPubMedGoogle Scholar
  841. Folke E (1976) Combined treatment with bleomycin in penile carcinomas. GANN Monogr Cancer 19:231–233Google Scholar
  842. Fraley EF et al (1985) Cancer of the penis. Cancer 55:1618–1624PubMedGoogle Scholar
  843. Garnick MB, Skarin AT, Steele GA (1979) Metastatic carcinoma of the penis: complete remission after high dose methotrexate chemotherapy. J Urol 122:265–266PubMedGoogle Scholar
  844. Grabstald H (1980) Controversies concerning lymph node dissection for cancer of the penis. Urol Clin North Am 7:793–799PubMedGoogle Scholar
  845. Haile K, Delclos L (1980) The place of radiation therapy in the treatment of carcinoma of the distal end of the penis. Cancer 45:1980–1984PubMedGoogle Scholar
  846. Hardner GJ et al (1972) Carcinoma of the penis: Analysis of therapy in 100 consecutive cases. J Urol 108:428 ffPubMedGoogle Scholar
  847. Ichikawa T (1977) Chemotherapy of penis carcinoma. In: Grundmann E, Vahlensieck W (Hrgb.) Tumors of the male genital system. Springer, Berlin Heidelberg New York, Recent Results in Cancer Research, Vol 60, pp 140–156Google Scholar
  848. Jackson SM (1966) The treatment of carcinoma of the penis. Br J Surg 53:33–35PubMedGoogle Scholar
  849. Merrin CE (1980) Cancer of the penis. Cancer 45:1973 ffGoogle Scholar
  850. Meyers FJ (1983) Penile cancer chemotherapy. Recent Results Cancer Res 85:143 ffPubMedGoogle Scholar
  851. Yagoda A (1979) Phase II trials with cis-dichlorodiammineplatinum (II) in the treatment of urothelial cancer. Cancer Treat Rep 63:1565 ffPubMedGoogle Scholar
  852. Baumgartner G, Heinz R, Arbers H, Semhofer R, Pridum N, Schaller J (1980) Methotrexate + Citrovorum-factor used alone and in combination chemotherapy. Cancer Treat Rep 64:41–46PubMedGoogle Scholar
  853. Bell DR, Aronay RS, Fisher RJ, Levi JJ (1984) High dose methotrexate with leucovorin rescue, vinblastine and bleomycin with or without tamoxifen in metastatic renal cell carcinoma. Cancer Treat Rep 68:587–590PubMedGoogle Scholar
  854. Carter SK (1984) Perusing the ASCO-abstracts with a focus on interferons in malignant melanoma and renal cell carcinoma. Cancer Chemother Pharmacol 13:153–156PubMedGoogle Scholar
  855. Cetto GL, Franceschi T, Bassetto MA, Bellini A, Molino AM, Capelli C (1986) Phase I/II trial of recombinant alpha-2 Interferon (IFN) and Vinblastine (VBL) in metastatic renal cell cancer (MRCC). Proc Am Soc Clin Oncol 427Google Scholar
  856. Decker D et al (1984) Brain metastases in patients with renal cell carcinoma. Prognosis and treatment. J Clin Oncol 2 3:169–173PubMedGoogle Scholar
  857. Decker DA et al (1984) Brain Metastases in Patients with Renal-Cell Carcinoma: Prognosis and Treatment. J Clin Oncol 2:169–172PubMedGoogle Scholar
  858. Dernevik L et al (1985) Surgical Removal of Pulmonary Metastasis from Renal-Cell Carcinoma. Scand J Urol Nephrol 19:133–137PubMedGoogle Scholar
  859. Diedrich H, Schmoll H-J, Wussow v. P, Anagnou J (1987) Phase II-study of a combination therapy with HuIFN-alpha, vinblastine, tamoxifen in advanced renal cell carcinom. A. Georgii (Hrsgb.) Verhdl Deutsche Krebsgesellschaft, Fischer, Stuttgart (in Druck)Google Scholar
  860. Finney R (1973) An evaluation of postoperative radiotherapy in hypernephroma — a clinical trial. Cancer 32:1332–1340Google Scholar
  861. Figlin RA, de Kernion JB, Maldazys J, Sarna G (1985) Treatment of Renal-Cell Carcinoma with a (Human Leucocyte) Interferon and Vinblastine in combination: A Phase I–II Trial. Cancer Treat Rep 69:263–267PubMedGoogle Scholar
  862. Harris DT (1983) Hormonal therapy and chemotherapy of renal-cell carcinoma. Semin Oncol 10:422–430PubMedGoogle Scholar
  863. Kaufmann GW, Zohrbach R, Richter G, Rußweiler R, Sommerkamp M (1984) Nierentumorembolisation. Urologe A 23:109 ffGoogle Scholar
  864. Krown SE (1985) Therapeutic Options in Renal-Cell Carcinoma. Semin Oncol 12:13–17PubMedGoogle Scholar
  865. Marshall ME, Mendelsohn L, Butler K, Metcalfe M, Harvey J, Cantrell J, Flanigan R, Macdonald JS (1986) Treatment of metastatic renal carcinoma with coumarin and Cimetidine. Proc Am Soc Clin Oncol 5: 399Google Scholar
  866. Torti FM (1983) Treatment of metastatic renal cell carcinoma. Recent results in cancer research, Springer, Berlin, pp 123 ffGoogle Scholar
  867. Wagner H, Possinger K, Wilmans W (1984) Therapie des metastasierenden Nierenzell-Karzinoms. ZAC 2:5–13Google Scholar
  868. Ahmed T, Yagoda A, Needles B, Scher HI, Watson RC, Geller N (1985) Vinblastine and Methotrexate for Advanced Bladder Cancer. J Urol 133:602–604PubMedGoogle Scholar
  869. Blandy JP, Tiptaft RC, Paris AMI, Oliver RTD, Hope-Stone HF (1985) The case for definitive radiotherapy and salvage cystectomy in localized bladder carcinoma. World J Urol 3:94–97Google Scholar
  870. Blumenreich MS, Yagoda A, Natale RB, Watson RC (1982) Phase II trial of vinblastine sulfate for metastatic urothelial tract tumors. Cancer 50:435 ffPubMedGoogle Scholar
  871. Cant JD, Brausi M, Soloway MS (1985) Adjuvant chemotherapy for locally advanced bladder cancer. World J Urol 3:115–120Google Scholar
  872. Christopher J, Logothetis, Melvin L et al (1985) Cyclophosphamide, Doxorubicin und Cisplatin chemotherapy for patients with locally advanced urothelial tumors with or without nodal metastases. J Urol 134:460–464Google Scholar
  873. Coppin C, Brown E, and the GU Tumour Group (1986) Concurrent cisplatin with radiation for locally advanced bladder cancer: A pilot study suggesting improved survival. Proc Am Soc Clin Oncol 5:382Google Scholar
  874. Creekmore SP, Waters WB, Vogelzang NJ et al (1986) Antitumor activity of 24-hour CBDCA infusions in metastatic transitional cell carcinoma. Proc Am Soc Clin Oncol 5:393Google Scholar
  875. de Kernion JB (1977) The chemotherapy of advanced bladder cancer. Cancer Res 37:2771 ffGoogle Scholar
  876. Droller, MJ (1985) The natural history of invasive bladder cancer and the cause against definitive radiation therapy. World J Urol 3:86–93Google Scholar
  877. Harker WG, Meyers FJ, Freiha FS, Palmer JM, Shortliffe LD, Hannigan JF, McWhirter KM, Torti FM (1985) Cisplatin, Methotrexate, and Vinblastine (CMV): An effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group Study. J Clin Oncol 3:1463–1470PubMedGoogle Scholar
  878. Hillcoat BL and Raghavan D (1986) A randomized comparison of cisplatinum (C) versus cisplatinum and methotrexate (C+M) in advanced bladder cancer. Proc Am Soc Clin Oncol 5:426Google Scholar
  879. Jakse G, Fritsch E, Frommhold H (1985) Combination of chemotherapy and irradiation for non-resectable bladder carcinoma. World J Urol 3:121–125Google Scholar
  880. Khandekar JD, Elson PJ, De Wys WD (1983) Improved activity and toxicity of cyclophosphamide (CTX), adriamycin (ADR), and cisdiamminedichlo-roplatinum (DDP) combination (CAD) as compared to DDP in dissemina-ted transitional cell carinomas of the urinary tract (DTCUT). Proc Am Soc Clin Oncol 3:143Google Scholar
  881. Lum BL (1983) Intravesical chemotherapy of superficial bladder cancer. In: Torti FM (ed) Urologic cancer. Springer, Berlin Heidelberg New York, Recent results in cancer research, Vol 85, pp 3–36Google Scholar
  882. Natale RB, Yagoda A, Watson RC, Whitmore WF, Blumenreich M, Braun DW (1981) Methotrexate: an active drug in bladder cancer. Cancer 47:1246–1250PubMedGoogle Scholar
  883. Prout GR, Kopp J (1981) Evaluation and management of patients with primary bladder carcinoma; protocols of the National Bladder Cancer Collaborative Group A. In: Denis, Murphy, Prout, Schröder (eds) Controlled clinical trials in urologic oncology. Raven, New York, p 221 ffGoogle Scholar
  884. Sternberg C, Yagoda A et al (1985) Methotrexat (mx), vinblastin (vlb), adriamycin (adm) and cisplatin (ddp) (M-VAC) for transitional cell carcinoma (TCC) of the urothelium. J Urol 133:403–407PubMedGoogle Scholar
  885. Sternberg CN, Yagoda A, Scher HI, Whitmore WF et al (1986) Surgical staging and long term survival in patients with advanced transitional cell carcinoma (TCC) of the urothelium treated with M-VAC. Proc Am Soc Clin Oncol 5:390Google Scholar
  886. Stoter G (1985) Chemotherapy for metastatic bladder cancer. World J Urol 3:110–114Google Scholar
  887. Torti FM, Phillips TL, Lum BL et al (1986) Effect of preoperative cisplatin (CDDP) and radiation therapy (XRT) on downstaging of invasive bladder cancer: A NCOG study. Proc Am Soc Clin Oncol 5:401Google Scholar
  888. Torti FM, Shortliffe LD, Williams RD, Spoulding GT, Hannigan GF (1984) Superficial bladder cancers are responsive to alpha 2 interferon administered intravesically. Proc Am Soc Clin Oncol 3:160Google Scholar
  889. Turner AG, Hendry WF, Williams GB, Bloom HJG (1977) The treatment of advanced bladder cancer with methotrexate. Br J Urol 46:673 ffGoogle Scholar
  890. Yagoda A (1979) Phase II trials with cisdiamminedichloro-platinum II in the treatment of urothelial cancers. Cancer Treat Rep 63:1565–1572PubMedGoogle Scholar
  891. Aisner J et al (1982) Combination chemotherapy for small cell carcinoma of the lung: Continuous versus alternating non-cross-resistant combinations. Cancer Treat Rep 66:221–230PubMedGoogle Scholar
  892. Aisner J et al (1983) Role of chemotherapy in small cell lung cancer. A consensus report of the IASLC Lung Cancer Workshop. Cancer Treat Rep 67:37–44PubMedGoogle Scholar
  893. Aisner J, et al (1984) Cyclophosphamide, doxorubicin and etoposide (CAE) for the treatment of small cell lung cancer. In: Issel BF, Muggia FM, Carter SK (eds): Etoposide (VP-16). Current status and new developments. Academic Press, pp 171–182Google Scholar
  894. Allan SG et al (1984) Phase II trial of vindesine and VP16 in the palliation of poor-prognosis patients and elderly patients with small cell lung cancer. Cancer Chemother Pharmacol 13:106–108PubMedGoogle Scholar
  895. Aroney RS et al (1983) Value of prophylactic cranial irradiation given at complete remission in small cell lung cancer. Cancer Treat Rep 67:675–682PubMedGoogle Scholar
  896. Batist G et al (1983) Small-cell carcinoma of the lung: Reinduction therapy after late relapse. Ann Intern Med 98:472–474PubMedGoogle Scholar
  897. Baudrexl A et al (1984) Surgical treatment of small-cell bronchial carcinoma. Arch Geschwulstforsch 54:61PubMedGoogle Scholar
  898. Bork E, et al (1985) VM-26: The most active agent in small cell lung cancer? IVth World Conf Lung Cancer, Toronto, Abstr. 561Google Scholar
  899. Byhardt RW, Lox ID (1983) Is chest radiotherapy necessary in any or all patients with small cell carcinoma of the lung? Yes. Cancer Treat Rep 67:209–215Google Scholar
  900. Chahinian AP et al (1984) Evaluation of anticoagulation with warfarin and of alternating chemotherapy in extensive small cell cancer of the lung. Proc ASCO C-879Google Scholar
  901. Cohen EA et al (1985) Phase II studies in small cell lung cancer (SCLC): An analysis of 97 trials. Proc ASCO 4:191, C-744Google Scholar
  902. Cohen MH (1983) Is thoracic radiation therapy necessary for patients with limited-stage small cell lung cancer? No. Cancer Treat Rep 67:217–221PubMedGoogle Scholar
  903. Cohen MH et al (1977) Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep 61:349–354PubMedGoogle Scholar
  904. Comis RL (1983) The potential role of surgery in the contempory combined modality management of small cell anaplastic lung cancer. In: Greco FA (ed) Biology and management of lung cancer. Nijhoff, Boston, pp 171–189Google Scholar
  905. Craig JB et al (1984) Prospective evaluation of changes in computed cranial tomography in patients with small cell lung carcinoma treated with chemotherapy and prophylactic cranial irradiation. J Clin Oncol 2:1151–1156PubMedGoogle Scholar
  906. Cullen M et al (1986) Maintenance chemotherapy for anaplastic small cell carcinoma of the bronchus: a randomized, controlled trial. Cancer Chemother Pharmacol 17:157–160PubMedGoogle Scholar
  907. Daniels IR et al (1984) Chemotherapy of small-cell carcinoma of lung: A randomized comparison of alternating and sequential combination chemotherapy programs. J Clin Oncol 2:1192–1199PubMedGoogle Scholar
  908. Drings P et al (1985) EPICO in der Chemotherapie des kleinzelligen Bronchialkarzinoms. In: AIO Symposium: Farmorubicin. Klinische Erfahrungen. Nagel, Wannenmacher (Hrsg.), Zuckschwerdt, München Bern Wien, Aktuelle Onkologie, Bd 16:141–147Google Scholar
  909. Einhorn LH et al (1984) Platinum (P) + VP16 chemotherapy for refractory small cell lung cancer (RSCLC) (Abstr.) Proc Am Assoc Cancer Res 25:174Google Scholar
  910. Elliot IA et al (1984) Cyclic alternating „non-cross-resistant“chemotherapy in the management of small cell anaplastic carcinoma. Cancer Treat Rev 11:103–113Google Scholar
  911. Ettinger DS et al (1985) Prospective evaluation of the role of surgery in limited disease (LD) small cell lung cancer (SCLC). An ECOG pilot study. Proc ASCO 4:180, C-704Google Scholar
  912. Evans WK et al (1984) VP 16 and cisplatin for small cell lung cancer (SCLC) after failure of induction chemotherapy. Proc ASCO 3:C-222Google Scholar
  913. Evans BD et al (1985) Carboplatin (JM8) and VP16 combination chemotherapy for untreated small cell lung carcinoma (SCLC): A phase II study. Proc ASCO 4:188, C-734Google Scholar
  914. Evans WK et al (1984) VP 16 alone and in combination with cisplatin in previously treated patients with small cell lung cancer. Cancer 54:1461–1466Google Scholar
  915. Evans WK et al (1986): Canadian multicenter randomized trial comparing standard (SD) and alternating (A) combination chemotherapy in extensive small cell lung cancer (SCLC). Proc ASCO 5:169 (Abstr. 662)Google Scholar
  916. Farha P et al (1983) High-dose chemotherapy and autologous bone marrow transplantation for the treatment of small cell lung carcinoma. Cancer 52:1351–1355PubMedGoogle Scholar
  917. Feld R et al (1984) Combined modality induction therapy without maintenance chemotherapy for small cell carcinoma of the lung. J Clin Oncol 2:294–304PubMedGoogle Scholar
  918. Ginsberg SI et al (1979) Long-term survivorship in small cell anaplastic lung cancer. Cancer Treat Rep 63:13–19Google Scholar
  919. Gore ME et al (1986) High dose carboplatin (JM8) in patients with lung cancer: A phase I study. Proc ASCO 5:179 (Abstr. 701)Google Scholar
  920. Greco FA et al (1985) High-dose etoposide (VP-16) in small cell lung cancer. Semin Oncology 12 (Suppl 2): 42–44Google Scholar
  921. Greschuchna D, Maaßen W (1981) Pro-Contra: Kleinzelliges Bronchialkarzinom — Operation oder Chemotherapie als primäre Behandlung. Argumente für eine selektive primäre Resektionsbehandlung. Internist (Berlin) 22:656–659Google Scholar
  922. Hansen HH et al (1978) Chemotherapy of advanced small cell anaplastic carcinoma: Superiority in a randomized trial of a 4 drug combination to a 3 drug combination. Ann Intern Med 89:177–181PubMedGoogle Scholar
  923. Harms V et al (1983) A randomized multicenter trial comparing sequential versus alternating polychemotherapy in small cell lung cancer. XIII. Internat Congress on Chemotherapy, Wien (Abstr.)Google Scholar
  924. Havemann K et al (1984) Randomized trial comparing sequential combination chemotherapy with cyclic alternating chemotherapy in small cell lung cancer. Proc ASCO 3: C-908Google Scholar
  925. Herskovic AM, Orton CG (1986) Elective brain irradiation for small cell anaplastic lung cancer (Editorial). Int J Radiation Oncology Biol Phys 12:427–429Google Scholar
  926. Lichter AS et al (1985) The role of radiation therapy in the treatment of small cell lung cancer. Cancer 55:2163–2175PubMedGoogle Scholar
  927. Liesenfeld A et al (1984) Drei multizentrische Phase-II-Studien in der Behandlung des kleinzelligen Bronchialkarzinoms (incl. AIO-Studien BI + BII). Onkologie 7:145–151PubMedGoogle Scholar
  928. Livingstone RB et al (1984) Combined modality treatment of extensive small cell lung cancer: A Southwest Oncology Group Study. J Clin Oncol 2:585–590Google Scholar
  929. Lucas CF et al (1986) Morbidity of cranial relapse in small cell lung cancer and the impact of radiation therapy. Cancer Treat Rep 70:565–570PubMedGoogle Scholar
  930. McCracken JD et al (1985) Concurrent chemoradiotherapy for limited small cell carcinoma of the lung (SCCL). Proc ASCO 4:175, C-683Google Scholar
  931. Meyer IA et al (1979) Selective surgical resection in small cell carcinoma of the lung. J Thorac Cardiovasc Surg 77:243–248PubMedGoogle Scholar
  932. Morstyn G et al (1984) Small cell lung cancer. 1973–1983. Early progress and recent obstacles. Int J Radiat Oncol Biol Phys 10:515–539PubMedGoogle Scholar
  933. Morgan DAL et al (1985) Vincristine and etoposide chemotherapy for advanced small cell lung cancer (SCLC). 3rd Europ Conf Clin Oncol, Stockholm, Abstr. 369Google Scholar
  934. Murray N et al (1984) Alternating chemotherapy and thoracic radiotherapy with concurrent cisplatin for limited stage small cell carcinoma. Proc ASCO 3: C-835Google Scholar
  935. Natale RB, Wittes RE (1981) Combination cisplatinum and VP 16 in small cell lung cancer. In: Seeber S, Nagel GA, Achterrath W, Schmidt CG, Raettich R (Hrsg.) Etoposid — Derzeitiger Stand und neue Entwicklungen in der Chemotherapie maligner Neoplasien. Zuckschwerdt, München, pp 59–62Google Scholar
  936. Niederle N et al (1982) Untersuchungen zur kurzzeitigen Induktions- und zyklischen Erhaltungstherapie beim inoperablen kleinzelligen Bronchialkarzinom. Klin Wochenschr 60:829–838PubMedGoogle Scholar
  937. Niederle N et al (1984) Treatment of recurrent small cell lung carcinoma with vindesine and cisplatin. Cancer Treat Rep 68:791–792PubMedGoogle Scholar
  938. Niederle N et al (1985) Erste Ergebnisse einer alternierenden Kombinationschemotherapie von Epirubicin, Cyclophosphamid und Vincristin (EPICO) im Vergleich zum ACO-Protokoll beim kleinzelligen Bronchialkarzinom. In: AIO-Symposium: Farmorubicin. Klinische Erfahrungen. Zuckschwerdt, München Bern Wien. Aktuelle Onkologie 16:133–140Google Scholar
  939. Ochs JJ et al (1983) „Salvage“ radiation therapy for intrathoracic small cell carcinoma of the lung progressing on combination chemotherapy. Cancer Treat Rep 67:1123–1126PubMedGoogle Scholar
  940. Perry MC et al (1986) Chemotherapy (CT) with or without radiation therapy (RT) in limited small cell cancer of the lung (SCLC). Proc ASCO 5:173 (Abstr. 678)Google Scholar
  941. Powel B et al (1985) Sequential hemibody radiation (SHB) integrated into a conventional chemotherapy — local radiotherapy program for limited disease (LD) small cell lung cancer (SCLC). Proc ASCO 4:193, C-756Google Scholar
  942. Preusser P et al (1985) Cisplatin. Arzneimitteltherapie 3:50–65Google Scholar
  943. Rosenmann J, Choi N (1982) Improved quality of life of patients with small cell carcinoma of the lung by elective irradiation of the brain. Int J Radiat Oncol Biol Phys 8:1041–1043Google Scholar
  944. Schilcher RB, Seeber S, Scheulen ME, Schmidt GS (1982) Etoposide and Ifosfamide in combination for inoperable carcinoma of the bronchus. Canc Treatm Rev 9 (Supp A): 107–110Google Scholar
  945. Schütte J et al (1985) Small cell lung cancer (SCLC): Sequential combination chemotherapy with adriamycin/cyclophosphamide/vincristin and etoposide/cisplatin +/- consolidating thoracic irradiation. 3rd Europ Conf Clin Oncol, Stockholm Abstr. 375Google Scholar
  946. Seeber S et al (1977) Integrale Behandlung (Chemo- + Radiotherapie) des inoperablen Bronchialkarzinoms. Vorläufige Ergebnisse bei 50 Patienten. Dtsch Med Wochenschr 102:147–152PubMedGoogle Scholar
  947. Seeber S et al (1980) Adriamycin, Cyclophosphamid und Vincristin („ACO“) beim kleinzelligen Bronchialkarzinom. Verlaufsanalyse und Langzeitergebnisse. Onkologie 3:5–11PubMedGoogle Scholar
  948. Seeber S et al (1983) Sequential combination chemotherapy with etoposidecisplatin and vincristin-adriamycin-cyclophosphamide in inoperable small cell bronchogenic carcinoma. XIII. Internat. Congress on Chemotherapy, Wien (Abstr)Google Scholar
  949. Sierocki JS et al (1979) Cis-Dichlorodiamminoplatinum (II) and VP-16–213: An active induction regimen for small cell carcinoma. Cancer Treat Rep 63:1593–1597PubMedGoogle Scholar
  950. Slevin ML et al (1986) Randomized trial to evaluate the effect of schedule on the activity of etoposide. Proc ASCO 5:175 (Abstr 685)Google Scholar
  951. Smith IE et al (1985) Carboplatin: A very active new cisplatin analog in the treatment of small cell lung cancer. Cancer Treat Rep 1:43–46Google Scholar
  952. Souhami RL et al (1984) A controlled trial of radiotherapy in small cell lung cancer treated by combination chemotherapy. Br Med J 288:1643–1646Google Scholar
  953. Spiro SG (1985) Chemotherapy of small cell lung cancer. Clin Oncol 4:105–120Google Scholar
  954. Stanley KE (1985): Prognostic factors in lung cancer. In: Aisner J (ed) Lung cancer. Churchill Livingstone, New York, Edinburgh, London, Melbourne, pp 41–66Google Scholar
  955. Stuart-Harris R et al (1986) Carboplatin (CBDCA, JM8), VP-16–213 in previously untreated patients with small cell lung cancer (SCLC). Proc ASCO 5:187 (Abstr 732)Google Scholar
  956. Thatcher N, et al (1985) Three month’s treatment with cyclophosphamide, VP-16–213 followed by methotrexate and thoracic radiotherapy for small cell lung cancer. Cancer 56:1332–1336PubMedGoogle Scholar
  957. Tobias JS (1985) The role of radiotherapy in small cell lung cancer. Clin Oncol 4:121–140Google Scholar
  958. Umlshine IH et al (1984) Diagnosis and significance of liver metastases in small cell carcinoma of the lung. J Clin Oncol 2:733–741Google Scholar
  959. Volk SA et al (1984) Morbidity of long-term survivors of small cell carcinoma of the lung. Cancer 54:25–27PubMedGoogle Scholar
  960. Walker RW et al (1985) Neuropsychological abnormalities in long term survivors of small cell lung cancer receiving prophylactic cranial irradiation. Proc ASCO 4:187, C-732Google Scholar
  961. Wilke H et al (1986) Etoposide and split dose cisplatin in small cell lung cancer (SCLC): Improved results. Proc ASCO 5:179 (Abstr. 702)Google Scholar
  962. WHO (1982) Histologic typing of lung tumors. Neoplasma 29:211.Google Scholar
  963. Yesner R, Sobin LH (1981) Histologic typing of lung tumors. International histologic classification of tumors, 2nd edn. World Health Organization, GenevaGoogle Scholar
  964. Anderson G, Payne H (1985) Response rate and toxicity of etoposide (VP-16) in squamous carcinoma of the lung: report from the lung cancer treatment study group. Semin Oncol 12 (Suppl 2) 21–22PubMedGoogle Scholar
  965. Arcangeli G et al (1985) Pilot study of multiple-fraction daily radiotherapy alternating with chemotherapy in patients with stage IV non-oat cell lung cancer. Cancer Treat Rep 69: 25–31PubMedGoogle Scholar
  966. Blum RH et al (1986) Cisplatin and vinblastine chemotherapy for metastatic non-small cell carcinoma followed by irradiation in patients with regional disease. Cancer Treat Rep 70: 333–337PubMedGoogle Scholar
  967. Carmichael J et al (1985) Cisplatinum and vindesine in combination in treatment of non-small cell lung cancer. Eur J Cancer Clin Oncol 7: 811–814Google Scholar
  968. Cohen MH (1983) Is immediate radiation therapy indicated for patients with unresectable non-small cell lung cancer? No. Cancer Treat Rep 67: 333–336PubMedGoogle Scholar
  969. Collaborative study (1975) Preoperative radiation of lung cancer: Final report of a therapeutic trial. Cancer 36: 914–925Google Scholar
  970. Coughlin CT et al (1986) Cisplatin and radiation therapy for locally advanced squamous cell carcinoma of the lung. Cancer Treat Rep 70: 643–645PubMedGoogle Scholar
  971. Cox JD et al (1983) Is immediate radiotherapy obligatory for any or all patients with limited stage non-small cell carcinoma of the lung? Yes. Cancer Treat Rep 67: 327–331PubMedGoogle Scholar
  972. Dhingra HM et al (1985) Randomized trial of three combinations of cisplatin with vindesine and or VP 16–123 in the treatment of advanced non-small cell lung cancer. J Clin Oncol 3: 176–183PubMedGoogle Scholar
  973. Dombernowsky P et al (1985) A randomized study of vindesine (VDS) vs. CCNU, cyclophosphamide (CTX) and methotrexate (MTX) vs. all 4 drugs in adenocarcinoma of the lung (ACL). Proc ASCO 4: 188, C-735Google Scholar
  974. Drings P, Manke HG (1985) Die Behandlung des nichtkleinzelligen Bronchialkarzinoms mit Cisplatin, Ifosfamid, Vindesin und VP 16. Strahlentherapie 161: 131–133PubMedGoogle Scholar
  975. Drings P et al (1985) Chemotherapie des fortgeschrittenen nichtkleinzelligen Bronchialkarzinoms mit Ifosfamid und Etoposid. Prax klin Pneumol 39: 833–834Google Scholar
  976. Drings P et al (1985) Lungentumoren. Empfehlungen zur standardisierten Tumortherapie. Dtsch Ärztebl 82: 3449–3454Google Scholar
  977. Einhorn LH et al (1985) Phase III random prospective study of vindesine (V) versus V + high dose (120 mg/m2) platinum (VP) in non-small cell lung cancer (NSCLC). Proc ASCO 4: 176, C-685Google Scholar
  978. Elliot JA (1986) Is there standard chemotherapy for non-small cell lung cancer? Eur J Cancer Clin Oncol 22: 369–371Google Scholar
  979. Elliot JA et al (1984) Vindesine and cisplatin combination chemotherapy compared with vindesine as a single agent in the management of non-small cell lung cancer: A randomized study. Eur J Cancer Clin Oncol 20: 1025–1032Google Scholar
  980. Emslander P et al (1985) Endobronchiale Laser- und Afterloading-Behandlung. Laser 1: 143–146Google Scholar
  981. Finkelstein DM, Ettinger DS, Ruckdeschel JC (1986) Long-term survivors in metastatic non-small-cell lung cancer: an ECOG study. J Clin Oncol 4: 702–709PubMedGoogle Scholar
  982. Fram R et al (1985) Combination chemotherapy followed by radiation therapy in patients with regional stage III unresectable non-small cell lung cancer. Cancer Treat Rep 69: 587–590PubMedGoogle Scholar
  983. Gandara D et al (1986) High dose cisplatin (200 mg/m2) in non-small lung cancer: reduced toxicity of a modified dose schedule. Proc ASCO 5: 173 (Abstr 679)Google Scholar
  984. Gatzemeier U et al (1986) Combination chemotherapy with mitomycin C, ifosfamide and vindesine in the treatment of NSCLC. J Cancer Res Clin Oncol 111 (Suppl) 37 Abstr Ifo 35Google Scholar
  985. Gralla RJ et al (1979) Phase II evaluation of vindesine in patients with non-small cell carcinoma of the lung. Cancer Treat. Rep. 63:1343–1346PubMedGoogle Scholar
  986. Gralla RJ et al (1981) Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules. Ann Intern Med 95: 414–420PubMedGoogle Scholar
  987. Gralla RJ et al (1986) The influence of the addition of mitomycin C to vindesine plus cisplatin. Proc ASCO 5: 182 (Abstr 714)Google Scholar
  988. Hainsworth JD et al (1986) Combination chemotherapy with vindesine, etoposide, and cisplatin in non-small cell lung cancer: a pilot study of the South Eastern Cancer Study Group. Cancer Treat Rep 70: 339–341PubMedGoogle Scholar
  989. Hilaris BS, Nori D, Martini N (1986) Results of radiation therapy in stage I and II unresectable non-small-cell lung cancer. Endocurie, Hypertherm Oncol 2: 15–21Google Scholar
  990. Holmes EC, Gail M for the lung cancer study group (1986) Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma. J Clin Oncol 4: 710–715Google Scholar
  991. Joss RA et al (1984) Combination chemotherapy for non-small lung cancer with doxorubicine, mitomycin or cisplatin and etoposide. Cancer Treat Rep 68: 1079–1084PubMedGoogle Scholar
  992. Klastersky J, Sculier JPC (1985) Chemotherapy of non-small-cell lung cancer. Semin Oncol 12 (Suppl 6): 38–48PubMedGoogle Scholar
  993. Longeval E et al (1982) Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma. Cancer 50: 2751–2756PubMedGoogle Scholar
  994. Luedke DW et al (1986) Vindesine and mitomycin in the treatment of advanced non-small cell lung cancer: A Southeastern Cancer Study Group trial. Cancer Treat Rep 70: 651:653Google Scholar
  995. Macha HN et al (1986) Neue Wege der Strahlentherapie des Bronchialkarzinoms. Die endobronchiale Kleinraumbestrahlung mit der Iridium-High-Dose-Afterloading-Technik in Kombination mit dem Neodym-YAG-Laser. Dtsch med Wschr 111: 687–681PubMedGoogle Scholar
  996. Madey PJ et al (1984) Combined modality therapy for stage III non-small lung cancer. Cancer 54: 5–12Google Scholar
  997. Miller TP et al (1986) Effect of alternating combination chemotherapy on survival of ambulatory patients with metastatic large-cell and adenocarcinoma of the lung: a SWOG study. J Clin Oncol 4: 502–508PubMedGoogle Scholar
  998. Morgan LR et al (1981) Ifosfamide: A weekly dose fractionated schedule in bronchogenic carcinoma. Cancer Treat Rep 65: 693–695PubMedGoogle Scholar
  999. Niederle N et al (1985) Vindesine/cisplatin chemotherapy in patients with advanced non-small-cell carcinoma of the lung. IV World Conf on Lung Cancer Toronto (August 25–30) Abstr 465Google Scholar
  1000. Niederle N et al (1985) High-dose etoposide in patients (pts) with extensive disease non-small-cell lung cancer (NSCLS). Proc ASCO 4: 181 (Abstr C-706)Google Scholar
  1001. Pedersen AG, Hansen HH (1986) Chemotherapie beim nicht-kleinzelligen Lungenkarzinom. Münch Med Wschr 128: 151–154Google Scholar
  1002. Perez CA et al (1986) Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int J Radiat Oncol Biol Phys 12: 539–547PubMedGoogle Scholar
  1003. Ruckdeschel JC et al (1985) Chemotherapy for metastatic non-small-cell bronchogenic carcinoma: EST 2575 generation — A randomized comparison of four cisplatin-containing regimens. J Clin Oncol 3: 72–79PubMedGoogle Scholar
  1004. Ruckdeschel JC et al (1986) A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol 4: 14–22PubMedGoogle Scholar
  1005. Salazar OM et al (1986) A prospective randomized trial comparing once-a-week vs daily radiation therapy for locally-advanced, non-metastatic lung cancer: a preliminary report. Int J Radiation Oncology Biol Phys 12: 779–787Google Scholar
  1006. Schaake-Konig C et al (1986) Radiotherapy and cis-diammine-dichloroplatinum (II) as a combined treatment modality for inoperable non-small cell lung cancer. A dose finding study. Int J Radiat Oncol Biol Phys 12: 379–383Google Scholar
  1007. Schray MF et al (1985) Malignant airway obstruction: management with temporary intraluminal brachytherapy and laser treatment. Endocurie, Hypertherm Oncol 1: 237–245Google Scholar
  1008. Sculier KP, Klastersky S (1984) Progress in chemotherapy of non-small lung cancer. Eur J Cancer Clin Oncol 20: 1329–1333PubMedGoogle Scholar
  1009. Seagren S, Harrell J (1985) High dose rate endobronchial palliative radiotherapy. Proc ASCO 4: 175, C-681Google Scholar
  1010. Seagren StL (1986) Endobronchial irradiation: a review. Endocurie Hypertherm Oncol 2: 87–91Google Scholar
  1011. Shields TW (1972) Preoperative radiation therapy in the management of bronchial cancer. Cancer 30: 1388–1394PubMedGoogle Scholar
  1012. Simes J (1985) Risk-benefit relationships in cancer clinical trials: The ECOG experience in non-small-cell lung cancer. J Clin Oncol 4: 462–472Google Scholar
  1013. Strauss G et al (1986) Combined modality therapy for regionally advanced stage III non-small-cell carcinoma of the lung (NSCLC) employing neoadjuvant chemotherapy (CT), radiotherapy (RT), and surgery (s). Proc ASCO 5: 172 (Abstr 675)Google Scholar
  1014. Thatcher N et al (1985) Ifosfamide bolus therapy for advanced non-small cell lung cancer. IV World Conf on Lung Cancer Toronto (August 25–30) 106 Abstr 201Google Scholar
  1015. Trybula M et al (1985) Preoperative simultaneous cisplatin/5-fluorouracil and radiotherapy in clinical stage III, non-small cell bronchogenic carcinoma. Proc ASCO 4: 182, C-710Google Scholar
  1016. Van Houtte P et al (1984) Radiotherapy in non-small cell lung cancer: Present progress and future perspections. Eur J Cancer Clin Oncol 20: 997–1006PubMedGoogle Scholar
  1017. Wilke H et al (1985) A phase II study of etoposide and splitted doses of CDDP for the treatmet of non-small lung cancer. IV World Conf on Lung Cancer Toronto (August 25–30) Abstr 481Google Scholar
  1018. Wils JA (1984) Phase II randomized trial of radiotherapy alone versus the sequential use of chemotherapy and radiotherapy in stage II non-small cell lung cancer. Phase II-trial of chemotherapy alone in stage IV non-small cell lung cancer. Eur J Cancer Clin Oncol 20: 911–914PubMedGoogle Scholar
  1019. Woods RL et al (1985) Non-small cell lung cancer: A randomized comparison of chemotherapy with no chemotherapy. Proc ASCO 4: 177, C-691Google Scholar
  1020. Bader M et al (1986) Palliative treatment of malignant stenoses of the upper gastrointestinal tract using a combination of laser and afterloading therapy. Endoscopy 18 (Suppl 1):27–31PubMedGoogle Scholar
  1021. Bezwoda WR et al (1984) Treatment of esophageal cancer with vindesine: an open trial. Cancer Treat Rep 68:783 ff.PubMedGoogle Scholar
  1022. Carey RW et al (1986) Squamous esophageal cancer: survival update of cohort treated with adjuvant fluorouracil/cisplatinum. Proc ASCO 5:92 (Abstr 360)Google Scholar
  1023. Carey RW et al (1986) Preoperative chemotherapy followed by surgery with possible postoperative radiotherapy in squamous cell carcinomas of the esophagus: evaluation of the chemotherapy component. J Clin Oncol 4: 697–701PubMedGoogle Scholar
  1024. De Besi P et al (1984) Cisplatin, bleomycin and methotrexate in the treatment of advanced esophageal cancer. Eur J Cancer Clin Oncol 20:743–747PubMedGoogle Scholar
  1025. De Besi P et al (1986) Cisplatin and fluorouracil infusion chemotherapy for advanced squamous esophageal cancer. Proc ASCO 5:148 (Abstr 578)Google Scholar
  1026. Dinwoodie WR et al (1986) Phase II evaluation of cisplatin, bleomycin, vindesine in advanced squamous cell carcinoma of the esophagus: A Southeast Cancer Study Group trial. Cancer Treat Rep 70:267–270PubMedGoogle Scholar
  1027. Gisselbrecht C et al (1986) Chemotherapy-radiotherapy versus control group in advanced esophageal carcinoma. Proc ASCO 5:86 (Abstr 335)Google Scholar
  1028. Hellman S (1984) Cancer of the esophagus: A brighter future? J Clin Oncol 2:73–74PubMedGoogle Scholar
  1029. Keane TJ et al (1985) Radical radiation therapy with 5-fluorouracil infusion and mitomycin C for esophageal squamous carcinoma. Radiother Oncol 4:205–210PubMedGoogle Scholar
  1030. Kelsen D (1984) Chemotherapy of esophageal cancer. Semin Oncol 11:159–169PubMedGoogle Scholar
  1031. Kelsen D (1985) Chemotherapy of esophageal cancer. Eur J Cancer Clin Oncol 21:5–7PubMedGoogle Scholar
  1032. Kelsen D et al (1982) Combined chemotherapy of esophageal carcinoma using cisplatin, vindesine and bleomycin. Cancer 49:1174–1177PubMedGoogle Scholar
  1033. Kelsen D et al (1984) Combined modality therapy of esophageal cancer. Semin Oncol 11:169–177PubMedGoogle Scholar
  1034. Leichman L et al (1984) Preoperative chemotherapy and radiation therapy for patients with cancer of the esophagus: A potentially curative approach. J Clin Oncol 2:75–79PubMedGoogle Scholar
  1035. Lux G, Groitl H, Ell CH (1986) Tumor stenoses of the upper gastrointestinal tract — therapeutic alternatives to laser therapy. Endoscopy 18 (Suppl 1): 37–43PubMedGoogle Scholar
  1036. Moertel CG (1982) The Esophagus. In: Holland, Frei (eds) Cancer Medicine. Lea & Fibiger, Philadelphia, pp 1753–1760Google Scholar
  1037. Poplin E et al (1986) SWOG 8037: Combined therapy for squamous cell carcinoma of the esophagus. Proc ASCO 5:80 (Abstr 311)Google Scholar
  1038. Resbeut M et al (1985) Squamous cell carcinoma of the esophagus. Treatment by combined vincristin-methotrexate plus folinic acid rescue and cisplatin before radiotherapy. Cancer 56:1246–1250PubMedGoogle Scholar
  1039. Siewert JR, Ries G, Fink U (1984) Palliative Behandlung des Ösophagus-Karzinoms. Münch med Wschr 126:438–443Google Scholar
  1040. Siewert JR et al (1986) Ösophaguskarzinom: Transthorakale Ösophagektomie mit regionaler Lymphadenektomie und Rekonstruktion mit aufgeschobener Dringlichkeit. Dtsch med Wschr 111:647–651PubMedGoogle Scholar
  1041. Abe M, Yabumoto E, Takahashi M et al (1980) Intra-operative radiotherapy of gastric cancer. Cancer 45:40–44PubMedGoogle Scholar
  1042. Bedikian JLT et al (1984) The natural history of gastric cancer and prognostic factors influencing survival. J Clin Oncol 2: 305–310PubMedGoogle Scholar
  1043. Beer M, Cocconi G et al (1983) A phase II study of cisplatin in advanced gastric cancer. Eur J Cancer Clin Oncol 19:717–720PubMedGoogle Scholar
  1044. Cullinan S, Moertel C, Fleming T et al (1984) A randomized comparison of 5-FU alone (F), 5-FU + adriamycin (FA) and 5-FU + adriamycin + mitomycin C (FAM) in gastric and pancreatic cancer. Proc ASCO 3:137Google Scholar
  1045. Della Cuna CR, Pavesi L, Preti P, Ganzina (1983) Clinical evaluation of 4-epi-doxorubicin in advanced solid tumors. Invest New Drugs 1:349 ffGoogle Scholar
  1046. Douglass HO, Lavin et al (1984a) An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, adriamycin and 5-fluorouracil in advanced measurable gastric cancer (EST 2577). J Clin Oncol 2:1372–1381PubMedGoogle Scholar
  1047. Douglass HO et al (1984b) Controlled trial of adjuvant chemotherapy following curative resection of gastric cancer. In: Salmon SE, Jones SE (eds) Adjuvant therapy of cancer IV. Grune & Stratton, New York, pp 456–463Google Scholar
  1048. Dupont JB Jr et al (1978) Adenocarcinoma of the stomach: Review of 1497 cases. Cancer 41:941 ffPubMedGoogle Scholar
  1049. Gastrointestinal tumor study group (1982) Randomized study of combination chemotherapy in unresectable gastric cancer. Cancer 53:13–17Google Scholar
  1050. Heim ME, Flechtner H, Queißer W (1985) Die Therapie des fortgeschrittenen Magenkarzinoms mit 5-Fluorouracil. Epirubicin und Mitomycin C. In: Nagel, Wannemacher (eds) Farmorubicin. Klinische Erfahrungen. Aktuelle Onkologie, Bd. 15, Zuckschwerdt, München, pp 186–193Google Scholar
  1051. Herrmann R, Fritze D et al (1984) Chemotherapie des Magenkarzinoms (Leserzuschrift). Dtsch Med Wschr 109:1463Google Scholar
  1052. Klein HO et al (1986) 5-Fluorouracil (5-FU), Adriamycin (ADM) and Methotrexat (MTX) — A combination protocol (FAMTX) for treatment of metastasized stomach cancer. Proc ASCO 84:325Google Scholar
  1053. Kolaric K (1984) Studies with epirubicin in gastric cancer. In: Bonadonna G (ed) Advances in antracycline chemotherapy: Epirubicin. Masson, Milano, pp 111–118Google Scholar
  1054. Kolaric K, Potrebica V et al (1983) Phase II clinical trial of 4-epi-doxorubicin in metastatic solid tumors. J Cancer Res Clin Oncol 106:148–152PubMedGoogle Scholar
  1055. Köster R, Scherer E (1984) Gegenwärtiger Stand und Möglichkeiten der Strahlentherapie bei der interdisziplinären Behandlung der Malignome des Magens, des Pankreas und der Gallenwege. Strahlentherapie 160:224–235PubMedGoogle Scholar
  1056. McDonald JS et al (1980) 5-Fluorouracil, doxorubicin, mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 93:533 ffGoogle Scholar
  1057. McDonald JS et al (1982) National conference on gastrointestinal cancer. Cancer 50, 11:2582–2596Google Scholar
  1058. Meyer HJ et al (1984) Diagnostik und Therapie beim Magenfrühkarzinom. Med Klin 79:428–432Google Scholar
  1059. Moertel CG, Childs DS et al (1984) Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. J Clin Oncol 2:1249–1254PubMedGoogle Scholar
  1060. Panettiere FJ et al (1984) Drug combinations in the treatment of gastric adenocarcinoma: A randomized Southwest Oncology Group study. J Clin Oncol 2:420–424PubMedGoogle Scholar
  1061. Paul F, Engstrom MD, Philip T, Lavin PD (1984) Adjuvant fluorouracil plus methyl-CCNU for resected gastric cancer: EST 3275. In: Salmon SE, Jones SE (eds) Adjuvant therapy of cancer IV. Grune & Stratton, New York, pp 449–456Google Scholar
  1062. Preusser P, Wilke H et al (1986) Pilot study and phase II study in advanced gastric cancer with Etoposide (E)/Adriamycin (A)/Cisplatin (P) (EAP). Proc AACR Abstr 704, p 178Google Scholar
  1063. Queißer W, Schnitzler G, Heim ME et al (1984) Prospektive randomisierte Studie beim forgeschrittenen Magenkarzinom. Dtsch med Wochschr 109:976–980Google Scholar
  1064. Takahashi T (1964) Studies on preoperative and postoperative telecobalt therapy in gastric cancer. Nippon Acta Radiol 24:129 ffPubMedGoogle Scholar
  1065. Vogl SE et al (1984) Phase II trial of cisplatin in advanced gastric cancer. Cancer Treat Rep 68, 12:1497–1498PubMedGoogle Scholar
  1066. Wadler S, Green M, Muggia F (1985) The role of anthracyclines in the treatment of gastric cancer. Cancer Treatm Rev 12:105–132Google Scholar
  1067. Wieland C, Hymmen U (1970) Megavoltage therapy for malignant gastric tumors. Strahlentherapie 140:20 ffPubMedGoogle Scholar
  1068. Wils J, Bleiberg H et al (1986) An EORTC gastrointestinal (GI) group phase II evaluation of sequential high dose Methotrexate (MTX) and 5-Fluorouracil (F) combined with Adriamycin (A) (FAMTX) in advanced gastric cancer. Proc ASCO 5: Abstr 302Google Scholar
  1069. Bitrann JD, Desser RK, Kozloff MF et al, (1979) Treatment of metastatic adenocarcinoma of the pancreas with 5-fluorouracil, adriamycin and mitomycin-C (FAM). Cancer Treat Rep 63:2049–2051Google Scholar
  1070. Bonmann PC et al (1986) Pancreatic cancer: palliative treatment of obstructive jaundice. Lancet I:69–71Google Scholar
  1071. Bukowski RM, Abderhalten RT, Hewlett JS et al (1980) Phase II trial of streptozotocin, mitomycin-C and 5-fluorouracil in adenocarcinoma of the pancreas. Cancer Clin Trials 3:321ffPubMedGoogle Scholar
  1072. Bukowski RM, Schacter LP, Groppe CW, Hewlett JS et al (1982) Phase II trial of 5-fluorouracil, adriamycin, mitomycin C, and streptozotocin (FAM-S) in pancreatic carcinoma. Cancer 50:197–200PubMedGoogle Scholar
  1073. Cullinan SA, Moertel CG et al (1985) A comparison of three chemotherapeutic regimes in the treatment of advanced pancreatic and gastric carcinoma. JAMA 253: 2061–2067PubMedGoogle Scholar
  1074. Di Magno EP et al (1977) A prospective comparison of current diagnostic tests for pancreatic cancer. N Engl J Med 297:737ffGoogle Scholar
  1075. Fitzgerald PJ et al (1978) The value of diagnostic aids in detecting pancreas cancer. Cancer 41: 868ffPubMedGoogle Scholar
  1076. Harada H et al (1977) Assessment of endoscopic aspiration cytology and endoscopic retrograde cholangiopancreatography (ERCP) in patients with cancer of the pancreas Part I. Gastroenterol Jpn 12: 52ffPubMedGoogle Scholar
  1077. Horton J, Gelber RD et al (1981) Trials of single-agent and combination chemotherapy for advanced cancer of the pancreas. Cancer Treat Rep 65:65–68PubMedGoogle Scholar
  1078. Kalser MH, Ellenberg SS (1985) Pancreatic cancer: Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. Vol 120:899–903PubMedGoogle Scholar
  1079. Klassen DJ, et al (1985) Treatment of locally unresectable cancer of the stomach and pancreas: A randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil. An Eastern Cooperative Oncology Group study. J Clin Oncol 3:373–378Google Scholar
  1080. Kupchik HZ (1982) National pancreatic cancer project workshop on pancreatic tumor markers. Dig Dis Sci 27:65ffPubMedGoogle Scholar
  1081. Lee Y-TN (1982) Tissue diagnosis for carcinoma of the pancreas and periampullary structures. Cancer 49:1035ffPubMedGoogle Scholar
  1082. Loehrer PJ et al (1985) Ifosfamide: An active drug in the treatment of adenocarcinoma of the pancreas. J Clin Oncol 3/3:367–372PubMedGoogle Scholar
  1083. Mallinson CN et al (1980) Chemotherapy in pancreatic cancer: results of a controlled, prospective, multicenter trial. Br Med J 281:1589–1591PubMedGoogle Scholar
  1084. Malt RA (1983) Treatment of pancreatic cancer. JAMA 250:1433ffPubMedGoogle Scholar
  1085. Moertel CG et al (1979) Treatment of advanced adenocarcinoma of the pancreas with combinations of streptozotocin plus 5-fluorouracil and streptozotocin plus cyclophosphamide. Cancer 40:605–608Google Scholar
  1086. Moertel CG et al (1969) Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet II: 865ffGoogle Scholar
  1087. Moertel CG, Frytak S, Hahn RG et al (1981) Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads), radiation alone, moderate dose radiation (4000 rads + 5 fluorouracil) and high dose radiation (6000 rads) + 5-fluorouracil. Cancer 48:1705ffPubMedGoogle Scholar
  1088. Nishimura MD et al (1984) Intraoperative radiotherapy for advanced carcinoma of the pancreas. Cancer 54:2375–2384.PubMedGoogle Scholar
  1089. O’Connell MJ (1985) Current status of chemotherapy for advanced pancreatic and gastric cancer. J Clin Oncol, Vol 3:1032–1039PubMedGoogle Scholar
  1090. Oster MW, Gray R et al (1986) Chemotherapy for advanced pancreatic cancer. A Comparison of 5-Fluorouracil, Adriamycin and Mitomycin (FAM) with 5-Fluorouracil, Streptozotocin, and Mitomycin (FSM). Cancer 57:29–33PubMedGoogle Scholar
  1091. Sanfey H et al (1983) Solid and papillary neoplasm of the pancreas — A potentially curable surgical lesion. Ann Surg 197:272ffPubMedGoogle Scholar
  1092. Sarr MG, Cameron JL (1982) Surgical managemant of unresectable carcinoma of the pancreas — clinical review. Surgery 91:123ffPubMedGoogle Scholar
  1093. Schein PS, Smith FP, Dritschillo A et al (1983) Phase I–II trial of combined modality FAM (5-fluorouracil, adriamycin and mitomycin-C) plus split course radiation (FAM-RT-FAM) for locally advanced gastric (LAG) and pancreatic (LAP) cancer: A mid-atlantic oncology program study. Proc ASCO 2:491Google Scholar
  1094. Schein PS (1985) The role of chemotherapy in the management of gastric and pancreatic carcinomas. Semin Oncol, Vol 12 (Suppl 4) 49–60PubMedGoogle Scholar
  1095. Schnitzler G, Queißer W et al (1986) Prospektiv randomisierte Prüfung von 5-Fluorouracil, Adriamycin, BCNU (FAB) versus Beobachtung beim meta-stasierten Pankreas-Karzinom. Tumor Diagnostik & Therapie 7 (135–138)Google Scholar
  1096. Shiu MH (1982) Resection of pancreas without production of fistula. Surg Gynecol Obstet 154:497ffPubMedGoogle Scholar
  1097. Smith FP, Noble S et al (1986) A pilot study of streptozotozin, mitomycin-C, 5-fluorouracil (SMF) plus irradiation: SMF-RT-SMF for locally advanced pancreatic cancer (LAP). A mid atlantic onocology program study. Proc Am Soc Clin Oncol, Vol 5:359Google Scholar
  1098. Smith FP et al (1980) 5-fluorouracil, adriamycin and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas. Cancer 46:2014–2018PubMedGoogle Scholar
  1099. Smith FP, Stäblein DM, Korsmeyer S et al (1983) Combination chemotherapy for locally advanced pancreatic cancer: Equivalence to external beam irradiation and implication for future management. J Clin Oncol 1:413–415PubMedGoogle Scholar
  1100. Stolinsky DC, Pugh RP, Bateman JR (1975) 5-fluorouracil (NSC-19893) therapy for pancreatic carcinoma: Comparison of oral and intravenous routes. Cancer Chemother Rep 59:1031–1033PubMedGoogle Scholar
  1101. Wiggans RG et al (1978) Phase II trial of streptozotocin, mitomycin C and 5-fluorouracil in the treatment of advanced pancreatic cancer. Cancer 41:387–391PubMedGoogle Scholar
  1102. Wils J et al (1985) Phase II study of epirubicin in advanced adenocarcinoma of the pancreas. Eur J Cancer Clin Oncol 21:191–194PubMedGoogle Scholar
  1103. Zimmerman SE et al (1981) Chemotherapy of pancreatic carcinoma. Cancer 47:1724ffPubMedGoogle Scholar
  1104. Brennan MF (1985) Cancer of the endocrine system. In: De Vita VT, Hellman S, Rosenberg SA (eds) Cancer. Principles and practice of oncology. Lippincott, Philadelphia, pp 1206–1223Google Scholar
  1105. Broder LE, Carter SK (1973) Pancreatic islet cell carcinoma II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med 79:108 ffPubMedGoogle Scholar
  1106. Fujita J et al (1986) A functional study of a case of Glucagonoma exhibiting typical Glucagonoma Syndrome. Cancer 57:860–865PubMedGoogle Scholar
  1107. Jensen RT et al (1983) Zollinger-Ellison syndrome: Current concepts and management. Ann Intern Med 98:59 ffGoogle Scholar
  1108. Kümmerle F, Rückert K (1982) Chirurgie des endokrinen Pankreas. Thieme, Stuttgart New YorkGoogle Scholar
  1109. Marbet UA, Kraenzlin M, Gyr K, Stalder G-A (1986) Endokrin aktive Magen-Darm-Tumoren: gibt es neue therapeutische Möglichkeiten? Dtsch. med. Wschr. 111:1120–1123Google Scholar
  1110. Moertel CG, Hanley JA, Johnson LA (1980) A randomized comparison of streptozotocin alone vs. streptozotocin plus 5-fluorouracil in the treatment of metastatic islet cell carcinoma. Proc ASCO 21:415Google Scholar
  1111. Moertel CG et al (1980) Streptozotocin alone compared with Streptozotocin plus fluorouracil in the treatment of advanced islet cell Carcinoma. N Engl J Med 303:1189ffPubMedGoogle Scholar
  1112. Moertel CG et al (1982) Phase II trial of doxorubicin therapy for advanced islet cell carcinoma. Cancer Treat Rep 66:1567–1569PubMedGoogle Scholar
  1113. Weil C (1985) Gastroenteropancreatic endocrine tumors. Klin Wochenschr 63:433 ffPubMedGoogle Scholar
  1114. Wienbeck M, Erkenbrecht J (1982) The control of gastrointestinal motility by Gl-hormones. Clin Gastroenterol 11:523 ffPubMedGoogle Scholar
  1115. Zollinger RM, Ellison EH (1955) Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 142:709 ffPubMedGoogle Scholar
  1116. Aigner KR (1985) Regionale Chemotherapie der Leber. Isolierte Perfusion, intraarterielle Infusion und Resektion. Beitr Onkol 21, Karger, BaselGoogle Scholar
  1117. American Joint Committee on Cancer (1983) Manual staging of cancer; 2nd edn. Beahrs OH, Tiyers MH (eds) Lippincott, Philadelphia p 81Google Scholar
  1118. Chlebowski RT et al (1984) Hepatocellular carcinoma. Diagnostic and prognostic features in North American patients. Cancer 53:2701–2706PubMedGoogle Scholar
  1119. Christ MM, Balch CH (1984) Intraarterial chemotherapy for hepatoma using adriamycin via an implantable constant infusion pump. Proc ASCO 3:148Google Scholar
  1120. Falkson G et al (1984) Phase II trial of mitoxantrone in patients with primary liver cancer. Cancer Treat Rep 68:1311–1312PubMedGoogle Scholar
  1121. Falkson G et al (1984) Primary liver cancer, an Eastern Cooperative Oncology Group trial. Cancer 54:970–977PubMedGoogle Scholar
  1122. Falkson G, Coetzer BJ (1986) Application and results of different chemotherapy regimens in primary liver malignancies. Recent Results in Cancer Research 100:103–111PubMedGoogle Scholar
  1123. Friedmann MA et al (1979) Therapy of hepatocellular cancer with intrahepatic arterial adriamycin and 5-fluorouracil combined with whole liver irradiation: A Northern California Oncology Group study. Cancer Treat Rep 63:1885–1888Google Scholar
  1124. Fugimoto S et al (1985) Biodegradable mitomycin C microspheres given intraarterially for inoperable hepatic cancer with particular reference to a comparison with continuous infusion of mitomycin C and 5-fluorouracil. Cancer 56:2404–2410Google Scholar
  1125. Hasogawa Y et al (1986) Specific diagnosis of hepatocellular carcinoma by delayed hepatobiliary imaging. Cancer 57:230–236Google Scholar
  1126. Hochster HS et al (1985) 4-Epidoxorubicin (Epirubicin): Activity in hepatocellular carcinoma. J Clin Oncol 3:1535–1540PubMedGoogle Scholar
  1127. Ihde DC et al (1985) Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Identification of two groups of patients with prospects for prolonged survival. Am J Med 78:399–406PubMedGoogle Scholar
  1128. Lai ECS et al (1986) Treatment of unresectable hepatocellular carcinoma: results of a randomized controlled trial. World J Surg 10:1–9Google Scholar
  1129. Lee VW et al (1985) The specific diagnosis of hepatocellular carcinoma by scintigraphy. Multiple tracer approach. Cancer 56:25–36PubMedGoogle Scholar
  1130. Melia WM et al (1983) Induction of remission in hepatocellular carcinoma. A comparison of VP16 with adriamycin. Cancer 51:206–210PubMedGoogle Scholar
  1131. Moertel CG (1982) The liver. in: Cancer Medicine. Holland JF, Frei E III (eds) 2nd ed Lea & Febinger, Philadelphia pp 1774–1781Google Scholar
  1132. Nasague N et al (1986) Estrogen receptors in hepatocellular carcinoma. Cancer 57:87–91Google Scholar
  1133. Okazaki N et al (1985) Bone metastasis in hepatocellular carcinoma. Cancer 55:1991–1994PubMedGoogle Scholar
  1134. Order SE (1985) Iodine 131 antiferritin, a new treatment modality in hepatoma: A Radiation Therapy Oncology Group study. J Clin Oncol 3:1573–1582PubMedGoogle Scholar
  1135. Philipps R, Murikami K (1960) Primary neoplasms of the liver: results of radiation therapy. Cancer 13:714Google Scholar
  1136. Ramming KP (1983) The effectiveness of hepatic artery infusion in treatment of primary hepatobiliary tumors. Semin Oncol 10:119–205